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Abstract 
The transcriptional response to hypoxia is critically dependent on the Hypoxia Inducible 
Factors HIF-1 and HIF-2, which have roles not only in development and cellular 
adaptation to low oxygen levels, but also in diseases such as cancer. Although many HIF 
target genes have been well-characterised, there is strong evidence that the complete set of 
HIF responsive genes have not been described. This thesis describes the characterisation 
of a novel hypoxia responsive gene, Rgs4, found by a previous microarray study. Rgs4 
encodes the Regulator of G-protein Signalling 4 (RGS4 protein), which directly inhibits 
signalling from various G-protein coupled receptors. Hypoxic regulation of Rgs4 mRNA 
is observed in neuroblastoma and pheochromocytoma cells derived from rat, mouse and 
human samples. This response is found to be mimicked by HIF pathway activating 
chemicals, and occurs in a manner consistent with direct HIF regulation of Rgs4 
transcription. However, hypoxic regulation of this gene is not observed in all cell types 
that Rgs4 is expressed in. Reporter gene assays testing 32.9kb of the locus encompassing 
the Rgs4 gene failed to detect a hypoxia responsive element, though bioinformatics 
analysis indicates that Rgs4 is under the control of distant enhancers outside of the region 
tested. Further characterisation of the Rgs4 hypoxic response could help to explain 
functions of HIF that are currently poorly characterised, such as its effect on 
catecholamine release and signalling, while the atypical nature of Rgs4 regulation by HIF 
may provide a model to discover other as-yet unknown HIF interacting proteins and cell 
type specific HIF target genes. 
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1. Introduction 10   
1.1. The Hypoxia Inducible Factors 
1.1.1. Hypoxia and the Hypoxia Inducible 
Factors 
Oxygen is critical for the survival of metazoan cells due to its central role in metabolism. 
The mitochondria of these cells use diatomic oxygen as the final electron acceptor of the 
electron transfer chain, where oxidative phosphorylation produces ATP from the proton 
gradient across the inner mitochondrial membrane which is generated by oxidation of 
NADH from the Krebs cycle. If cellular oxygen demand outweighs supply (hypoxia), the 
efficient conversion of carbon energy sources to ATP will be disrupted. In this situation 
cells are well-adapted to counter with a variety of hypoxic response pathways, which are 
utilised in both adaptation to hypoxia and organism development, as well as dysregulated 
in some disease states. 
Cells can respond to hypoxia by modulating metabolism, in order to conserve and make 
more efficient use of the oxygen that is available. Furthermore, the efficiency of oxygen 
delivery can be increased, such as through the activation of angiogenic and erythropoietic 
pathways. Hypoxia also serves as an important developmental signal, such that disruption 
of hypoxia signalling pathways causes severe developmental phenotypes (Iyer et al., 1998; 
Tian et al., 1998). In addition, acute and chronic hypoxia are sensed and responded to in 
differing ways. For instance, the carotid body acts as an acute hypoxia sensor through use 
of O2-regulated K
+ channels (reviewed by Lopez-Barneo et al., 2009). These channels 
signal for a hyperventilatory response, which improves the delivery of oxygen to all 
tissues. However, almost all mammalian cells respond to chronic hypoxia through 
activation of the Hypoxia Inducible Factor (HIF) pathway. HIF is a heterodimeric 
transcription factor which binds at over 100 genomic sites to activate transcription of 
specific genes which allow cellular response and adaptation to hypoxia (Wenger et al., 
2005). This pathway has been the focus of much research due to its involvement in 
adaptation, development and pathogenesis, in particular oncogenesis. 
HIF is a heterodimer comprised of two basic-Helix-Loop-Helix/Per-Arnt-Sim domain 
(bHLH/PAS) proteins, known as HIF- and HIF- (Wang and Semenza, 1995), which 11   
dimerise in the nucleus to activate transcription (Konietzny et al., 2009). The N-terminal 
bHLH domains of HIF- and - allow for DNA binding and primary dimerisation, while 
the PAS domains provide secondary dimerisation. HIF- also contains two transactivation 
domains, known as the N-terminal Transactivation Domain (N-TAD) and the C-Terminal 
Transactivation Domain (C-TAD), the latter of which binds coactivators CBP or p300 to 
promote target gene transcription (Arany et al., 1996; Ebert and Bunn, 1998). HIF-, 
alternatively known as the Aryl Hydrocarbon Receptor Nuclear Translocator (ARNT), is 
constitutively expressed and unresponsive to hypoxia. HIF- also acts as a general partner 
factor for other dimeric bHLH/PAS transcription factors such as NPAS4 (Ooe et al., 
2004), SIM-1, SIM-2 and the Aryl Hydrocarbon Receptor (AhR) (Swanson et al., 1995). 
These heterodimers respond to different stimuli, such as membrane depolarisation for 
NPAS4, but bind very similar genomic DNA sequences, all with a core CGTG consensus. 
In this way, crosstalk between some members of the bHLH/PAS family at genomic 
binding sites has been demonstrated previously (Farrall and Whitelaw, 2009; Ooe et al., 
2004). The HIF- subunits are the only members of the bHLH/PAS family of proteins to 
be regulated at the level of stability and activity by oxygen concentration.  
There are three genes encoding HIF- subunits: Hif1a, which encodes HIF-1 protein; 
Epas1, which encodes HIF-2 protein, also known as HIF-Like Factor (HLF) or 
Endothelial Per-ARNT-Sim protein-1 (EPAS1); and Hif3a, which encodes various splice 
variants of HIF-3 protein. HIF-1 and -2 bind to HIF- in order to form active HIF 
transcription factors HIF-1 or HIF-2, respectively. When compared to HIF-1 and HIF-
2, HIF-3 variants lack transactivation domains, and therefore are thought to have only 
an inhibitory or dominant-negative role on the transcriptional role of HIF (Hara et al., 
2001; Makino et al., 2001; Makino et al., 2002). There are also two genes encoding HIF- 
subunits, Arnt1 and Arnt2, both of which encode proteins capable of partnering HIF-
1(Drutel et al., 2000; Stolze et al., 2002). Many of the features of HIF-1 and HIF-2 
regulation and function are similar, and therefore the term HIF- is used here to refer to 
these two subunits collectively. 
1.1.2. Post-Translational HIF Regulation 
Both HIF- proteins are sensitive to oxygen availability as a result of hydroxylation 
reactions in two of their domains. Normal oxygen levels, known as normoxia, enable 12   
proline residues (P402 and P564 in human HIF-1) to be hydroxylated by the HIF Prolyl 
Hydroxylase Domain proteins (PHD1, PHD2 and PHD3) (Jaakkola et al., 2001). These 
hydroxylated prolines are located in a domain named the Oxygen Dependent Degradation 
domain (ODD), which overlaps with the N-TAD (Huang et al., 1998). Hydroxylation of 
these prolines leads to recognition by an E3 ubiquitin ligase (Von-Hippel Lindau protein, 
pVHL) (Jaakkola et al., 2001), ubiquitylation of HIF-, and subsequent rapid turnover of 
the protein via the ubiquitin-proteasome degradation pathway (Huang et al., 1998; Salceda 
and Caro, 1997). Generally, this results in no detectable HIF- protein in well-oxygenated 
mammalian cells. In addition, interaction between HIF- and transcriptional coactivators 
p300 or CBP is inhibited during normoxia by hydroxylation of an asparagine residue 
(N803 in human HIF-1) in the HIF- C-TAD by Factor Inhibiting HIF (FIH) (Hewitson 
et al., 2002; Lando et al., 2002a; Lando et al., 2002b). Consequently, hydroxylation at this 
residue prevents transcriptional activation from the HIF- C-TAD. In contrast, hypoxic 
conditions prevent hydroxylation and lead to HIF- stabilisation and subsequent 
dimerisation with HIF- to constitute the HIF transcription factor, which is then 
transcriptionally active (Figure 1.1).  
The hydroxylation activity of the PHD and FIH enzymes requires diatomic oxygen, 2-
oxoglutarate and an appropriate peptide substrate, producing a hydroxylation modification 
on the peptide substrate, and CO2 and succinate as byproducts. Fe-II is also required by 
these enzymes for catalysis (Aravind and Koonin, 2001; Epstein et al., 2001). The best 
characterised substrates of these enzymes are HIF-1 and HIF-2, but other substrates are 
known. For example, the Notch-1, -2 and -3 Intracellular Domains (ICD) can be 
hydroxylated by FIH (Coleman et al., 2007; Zheng et al., 2008). As this hydroxylation 
reaction directly requires O2, and hypoxia therefore inhibits hydroxylation of HIF, the 
PHD and FIH enzymes are thought to be the primary oxygen sensors of this the HIF 
pathway (Epstein et al., 2001). 
Post-translational modifications other than the hydroxylation pathway can also affect HIF 
activity. Increased levels of HIF-1 protein and activity have been observed following 
insulin, IGFI, IGFII, EGF (Feldser et al., 1999; Jiang et al., 2001), angiotensin-II, 
thrombin, FGF2 and PDGF (Richard et al., 1999), lipopolysaccharide (Blouin et al., 2004)  13   
 
Figure 1.1. The domain structure of HIF- (either HIF-1 or HIF-2, shown at top) and canonical 
post-translational regulatory pathway. Hypoxic conditions (left) prevent HIF- degradation and 
allow interaction with coactivators to promote target gene transcription. Normoxic conditions 
(right) allow PHD and FIH hydroxylation of HIF-, promoting degradation and inhibiting 


























































N14   
or TNF (Sandau et al., 2001) treatment of certain cell culture lines. Many of these 
signalling pathways result in phosphorylation of HIF-1 by kinases such as the p42 and 
p44 MAPKs (Richard et al., 2000) and PI3K (Jiang et al., 2001), resulting in increased 
HIF activity. However, it should be noted that some of these treatments also affect 
transcription of the HIF- encoding genes. There is also evidence that reactive oxygen 
species (ROS) (Chandel et al., 2000) and nitric oxide (Sandau et al., 2001) can signal to 
activate the HIF pathway. Furthermore, the activity of HIF-1 can be modified by post-
translational modifications other than those mentioned above, such as acetylation, 
sumoylation and S-nitrosation (reviewed by Brahimi-Horn et al., 2005). 
1.1.3. Targets of HIF Transactivation 
HIF binds directly to a DNA sequence known as the Hypoxia Response Element (HRE), 
with a consensus sequence of RCGTG (Pescador et al., 2005; Wang and Semenza, 1995; 
Wenger et al., 2005), where R can be an adenine or guanine. There is also some evidence 
for a secondary cis-acting element named the HIF Ancillary Sequence (HAS), which is 
separated from the HRE core sequence by 8bp and improves transactivation by HIF 
(Kimura et al., 2001). As mentioned previously, there are over 100 known genomic HIF 
binding sites (Wenger et al., 2005), with novel sites still being discovered. As DNA 
binding specificity is apparently indistinguishable between HIF-1 and HIF-2 at a 
consensus HRE, many genes under the control of a HRE are responsive to both forms of 
HIF. One example of a non-specific HRE is located upstream of Vegf (Vascular 
Endothelial Growth Factor) (Levy et al., 1995; Liu et al., 1995), a gene which was 
originally identified as a target of HIF-1 transactivation (Forsythe et al., 1996), but was 
later found to activatable by HIF-2 (Flamme et al., 1997; Flamme et al., 1998; Wiesener et 
al., 1998). This HRE is located about 975bp upstream of the human Vegf transcription 
start site. Similarly, hypoxic response of Dec1 in human neuroblastoma cells was found to 
be mediated through HIF-1 binding at a HRE 145bp upstream of its transcription start site 
(Miyazaki et al., 2002), yet further analysis using chromatin immunoprecipitation (ChIP) 
and siRNA techniques has shown that both HIF-1 and HIF-2 are capable of binding at this 
HRE and activating Dec1 transcription (Holmquist-Mengelbier et al., 2006). Phd3 
(encoding the HIF Proline Hydroxylase Domain protein 3) is another example of a gene 
which is sensitive to both HIF forms, although it is more sensitive to ectopic expression of 
HIF-2 than HIF-1 (Aprelikova et al., 2004; Lau et al., 2007). 15   
There are also examples of target gene specificity between HIF-1 and HIF-2. Hypoxic 
response of genes such as Ca9 (encoding Carbonic Anhydrase IX, a pH regulator) and 
Slc2a1 (also known as Glut-1, encoding a glucose transporter) occurs only through HIF-1, 
as knockdown of HIF-1 alone in breast cancer cells results in loss of the response of these 
genes to hypoxia, despite the presence of HIF-2 (Sowter et al., 2003). Glycolytic enzyme 
genes such as Ldha (encoding Lactate Dehydrogenase) or Pgk1 (encoding 
Phosphoglycerate Kinase 1) respond to HIF-1 but not HIF-2 (Hu et al., 2003; Semenza et 
al., 1994). The predominance of HIF-1 target genes compared to HIF-2 was initially not 
surprising, given that most of the initial studies were specifically designed to identify HIF-
1 responsive genes, with relatively few studies aimed at identifying target genes of HIF-2. 
However, subsequent microarray experiments comparing hypoxic activation of genes in 
breast cancer cells to HIF- siRNA-treated cells have since shown that the majority of 
hypoxia responsive genes are dependent on the presence of HIF-1 alone (Aprelikova et al., 
2006; Elvidge et al., 2006). When compared with the essentially ubiquitous expression 
pattern of HIF-1, this implies that HIF-1 is the most important isoform for the general 
hypoxic response, as the response of few genes is affected by loss of HIF-2.  
As fewer genes which display specificity towards HIF-2 transactivation are known, HIF-2 
activity is thought to provide a more specific set of cellular responses. The Epo gene 
(which encodes Erythropoietin) is currently considered to be the best characterised in vivo 
HIF-2 specific target gene. Knockout or knockdown of HIF-1 in mouse astrocytes results 
in a significant reduction in the hypoxic response of Vegf and Ldha, while no change in 
Epo response is observed at all (Chavez et al., 2006). Conversely, the same authors 
observed significant decrease in Epo response after infection with lentivirus encoding 
HIF-2-directed siRNA, and that HIF-2 rather than HIF-1 was predominantly 
detectable bound at the Epo HRE by ChIP. Importantly, similar results have subsequently 
been observed for the hepatic Epo response to hypoxia or anaemia in mice (Rankin et al., 
2007). Similarly, Flk1, Cited2 (Aprelikova et al., 2006; Elvert et al., 2003) and Col10a1 
(Saito et al., 2010) are regulated by HIF-2 alone in specific environments. The exact 
mechanism for this specificity is unclear, but may relate to the profile of other 
transcription factors bound in the vicinity. 
Selection between HIF forms at enhancers regulating Flk1 and Cited2 appear to be related 
to specific interaction between HIF-2 and ETS family transcription factors. ELK1 (ETS-
LiKe protein 1) binds DNA proximal to the HRE at Cited2 and is required for its hypoxic 16   
activation (Aprelikova et al., 2006), while ETS1 performs a similar role at the Flk1 HRE 
(Elvert et al., 2003). Although bioinformatic analysis suggests a role for ETS factor 
binding at other HIF-2 preferred sites, these have not been experimentally verified and so 
the extent to which ETS factors affect HIF binding specificity at other loci or in various 
cell types is not known.  
Experiments using HIF-1/HIF-2 over-expressed chimeric protein also imply that 
selection of target genes by either HIF-1 or HIF-2 is not dependent on the DNA-binding 
domain of the HIF- protein, using Ca9 as an example of a HIF-1 specific target gene, 
and Phd3 as an example of a gene which is more sensitive to HIF-2 than HIF-1 
overexpression. Hypoxic activation of Ca9 transcription requires the presence of HIF-1 
PAS, ODDD and N-TAD domains in a chimeric HIF- protein, but these can be ligated to 
the DNA binding domain of either HIF-1 or HIF-2 for equal effect. Meanwhile, strong 
activation of Phd3, achieved by over-expression of HIF-2, requires only the presence of 
the HIF-2 C-TAD ligated to other domains from either HIF- subunit (Lau et al., 2007). 
Extrapolated, these experiments suggest that a protein consisting of the HIF-1 bHLH, 
PAS, ODDD and N-TAD domains ligated to the HIF-2 C-TAD domain would be 
capable of activating all known HIF targets, unless target specificity at genes other than 
Ca9 and Phd3 is regulated in a different way. Another group has published similar data 
indicating that the N-TAD of HIF-1 or HIF-2 is required for target specificity, while 
the C-TAD confers activation of shared transcriptional targets (Hu et al., 2007). 
Furthermore, there are sites known where both HIF-1 and HIF-2 binding can be detected 
by ChIP, but one or the other HIF form cannot activate gene transcription (Mole et al., 
2009). This evidence taken together suggests that target genes specificity is due primarily 
to post-DNA-binding events and genomic context, rather than primary DNA sequence 
recognition alone.  
HIF-1 is also involved in activation of Notch-1 pathway gene targets. Hypoxia was first 
noted to decrease expression of differentiation markers in neuroblastoma cells, resulting in 
a more undifferentiated gene expression profile (Jogi et al., 2002). Notably, the expression 
of Notch-1 was increased upon hypoxic exposure. Further experiments show that hypoxia 
increases Notch-1 activation of its target genes, and that HIF-1 binds directly to the 
Notch-1 Intracellular Domain (ICD), rather than the DNA, to produce this effect 
(Gustafsson et al., 2005). Therefore, alternative arrangements of HIF-1 at responsive 
genes are possible, and HIF-responsive genes may not require a RCGTG motif for HIF 17   
recruitment. The Notch-1 ICD is also hydroxylated at two asparagines by FIH (Coleman 
et al., 2007; Zheng et al., 2008), and although functional effects of this modification are 
yet to be found, this does further connect the HIF and Notch transcriptional regulation 
pathways. 
1.1.4. Complex Patterns of HIF Hypoxic 
Regulation 
The differing physiological functions of HIF-1 and HIF-2 are due to more than simple 
differences in target gene selection. Although the response of the HIFs to hypoxia is 
broadly similar due to regulation of both by the oxygen sensing HIF hydroxylases outlined 
previously (Chapter 1.1.2), there is additional modulation using this pathway and others 
for each HIF-1 and HIF-2. These intricacies indicate that the response to hypoxia is not 
equivalent between different cell types, in terms of both regulation of the HIF pathway 
and the downstream effects. Research has shown that exposure to different concentrations 
of oxygen and different periods of hypoxia can invoke different levels and types of HIF 
activation between cell types. One example is observed during cycles of hypoxia and 
normoxia, known as intermittent hypoxia. Rat pheochromocytoma PC12 cells show no 
change in HIF signalling after 10 cycles of 30 seconds hypoxia followed by 4 minutes of 
normoxia, but HIF-1 protein levels are increased after 30 cycles and HIF-dependent 
transcription is observed after 60 cycles (Yuan et al., 2005). This demonstrates that the 
response of a cell to hypoxia is not only affected by its current conditions, but also the 
preconditioning of the cell. Intermittent hypoxia is commonly a result of sleep apnea, 
therefore HIF signalling in response to this stimulus is likely to be medically relevant. 
The atmospheric oxygen concentration which results in stabilisation and activation of 
HIF- differs between cell types, and in some cell types one subunit can be activated 
while the other is not. Figure 1.2a describes the difference in HIF-1 stabilisation in 
moderate hypoxia between CACO2 and 293T cells, where an oxygen concentration of 
between 2% and 5% gives different levels of detectable HIF-1 protein between the two 
cell lines (Bracken et al., 2006). Another example has been described in the human 
neuroblastoma SK-N-BE(2)C cell line, which stabilise only HIF-2 at moderate hypoxia 
(5% O2), while both HIF-1 and HIF-2 are stable and active after exposure of these cells 




Figure 1.2. Examples of differences in HIF- regulation between cell types. (a) HIF-1 protein is 
stabilised at higher oxygen concentrations in 293T cells than CACO2 cells (adapted from Bracken 
et al., 2006). PHD activity compared to FIH activity (measured by HIF-1 protein level and C-
TAD activity respectively, see Figure 1.1) is affected by oxygen concentration differently between 
HepG2 (b) and HeLa (c) cells (adapted from Bracken et al., 2006). (d) SK-N-BE(2)C cells 
demonstrate an alternative HIF-1 and HIF-2 stabilisation pattern over extended hypoxia 
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Differences in PHD (as indicated by HIF-1 protein level) and FIH (by HIF-1 C-TAD 
transactivation) activity in graded hypoxia are observed between hepatocellular carcinoma 
HepG2 and cervical adenocarcinoma HeLa cells, as an example (Figure 1.2b,c). This 
shows that in moderate hypoxia some cell lines have stable yet C-TAD-inactive HIF- at 
moderate hypoxia (Bracken et al., 2006), suggesting that some HIF protein may be able to 
activate transcription of genes using only its N-TAD. This form of HIF may only be able 
to activate a subset of HIF targets compared to HIF with both active TADs. This idea is 
further supported by the work of Dayan et al. (2006), who show that some HIF target 
genes can be classified as FIH sensitive or insensitive. As cell types are adapted to survive 
in different oxygen concentrations depending on the quality of their vascularisation and 
required metabolic rate, it is sensible that there are differences in the conditions required 
for HIF activation between tissues. 
However, despite these differences, in most cell types studied induction of both HIF- 
subunits is consistent over time. HIF-1 and HIF-2 protein are detectable after 30-60 
minutes of hypoxia in HeLa cells, reaching a maximum induction after 2 hours. After this 
point, both HIF- proteins are present and continue to be readily detectable after 48 hours 
of hypoxia (Wiesener et al., 1998). This is consistent with observations from other cell 
types such as the CACO2, monkey kidney fibroblast COS-1 and human kidney 293T lines 
(Bracken et al., 2006). In contrast, some cell types also display differential stabilisation of 
HIF-1 compared to HIF-2 in prolonged hypoxia (Figure 1.2d). Early transient stabilisation 
of HIF-1 followed by HIF-2 stabilisation in prolonged hypoxia has been described for 
the PC12, SK-N-BE(2)C and A549 cell lines (Bracken et al., 2006; Holmquist-Mengelbier 
et al., 2006; Li et al., 2006; Uchida et al., 2004). Therefore, this represents an alternative 
stabilisation pattern in a subset of cell types for HIF- under extended hypoxia. 
Regulation of Hif1a or Epas1 mRNA transcription is likely to play a role, as Holmquist-
Mengelbier and colleagues (2006) describe increased Epas1 message in prolonged 
neuroblastoma hypoxia. Alternatively, message stability or efficiency of translation may 
play some role, as described in the next section, or other unknown post-translational 
modifications on HIF-stability.  
Transcriptional activity of HIF-1 and HIF-2 may also be regulated in extended hypoxia by 
products of the Hif3a gene. Hif3a produces many alternatively spliced isoforms, one of 
which is termed Inhibitory PAS domain protein (IPAS, also known as HIF-32) (Makino 
et al., 2002; Maynard et al., 2003). IPAS acts in a dominant-negative fashion, binding to 20   
HIF- in place of HIF- and preventing DNA binding, which affects vascularisation of 
the cornea in mice (Makino et al., 2001). Another HIF-3 isoform, HIF-34, has been 
observed to work in a similar way (Maynard et al., 2005). Some HIF-3 variants contain 
an ODD domain, and are therefore responsive to hypoxia through proline hydroxylation 
and VHL-mediated degradation by the same pathway as the other HIF- proteins 
(Maynard et al., 2005). The Hif3a gene is also under the direct transcriptional control of 
HIF through a HRE enhancer (Makino et al., 2007; Tanaka et al., 2009). Therefore, this 
pathway provides a mechanism for negative feedback in the HIF pathway. 
1.1.5. Regulation of HIF- mRNA Transcription 
by Hypoxia 
Considering that the post-translational regulation of HIF- by hydroxylation has been 
well-characterised, there has been relatively little research into the regulation of Hif1a or 
Epas1 transcription. Indeed, the cellular response to hypoxia is primarily driven by HIF in 
coordination with the oxygen sensing activity of the PHD and FIH hydroxylases (Elvidge 
et al., 2006). Wenger and colleagues reported no change in levels of Hif1a transcript in 
mouse tissues upon treatment with carbon monoxide (Wenger et al., 1996), nor in mouse 
hepatoma Hepa1 or human astroglioma LN229 cell lines after 4 hours hypoxic treatment, 
although results were inconclusive in HeLa cells (Wenger et al., 1997a). Anoxic treatment 
of cultured rat cardiomyocytes for 2 or 4 hours also fails to alter Hif1a mRNA expression 
(Ladoux and Frelin, 1997). Similarly, no change has been observed for Epas1 mRNA 
levels in human colorectal adenocarcinoma HT-29, human kidney 293, human 
hepatocellular carcinoma Hep3B or HeLa cell lines (Wiesener et al., 1998). 
However, there have been reports of altered expression of HIF transcripts in hypoxia 
treated cells. Wang and colleagues observed hypoxic induction of Hif1a and Arnt mRNA 
in Hep3B cells (Wang et al., 1995), while increased Hif1a message has been detected in 
rat and mouse organs such as the brain and lungs upon systemic hypoxic treatment 
(Wiener et al., 1996). Although the primary mouse and human Hif1a promoters are 
insensitive to hypoxia (Luo et al., 1997; Wenger et al., 1997b; Wenger et al., 1998), there 
is some evidence to suggest that there is an alternate Hif1a promoter for the mouse gene 
which is constitutive in mouse fibroblast L929 cells, but hypoxia-responsive in the Hepa1 
mouse hepatoma cell line (Wenger et al., 1997b; Wenger et al., 1998).  21   
1.1.6. Post-transcriptional Control of HIF- 
Message by Hypoxia 
More recently, experiments with different cell types have shown a negative regulation of 
Hif1a message in response to hypoxia treatment. First noted in immortalised human 
lymphocytes, Hif1a message is also reduced in the A549, PC12, rat neuroblastoma NB104 
and mouse colon adenocarcinoma CT-26 cell lines upon exposure to 4 hours or longer of 
continuous hypoxia (Li et al., 2006; Rossignol et al., 2004; Thrash-Bingham and Tartof, 
1999; Uchida et al., 2004). This response is dependent on protein synthesis and the HIF 
pathway, and appears to act through antisense Hif1a transcription (aHIF), resulting in an 
antisense transcript which overlaps the 3’UTR of the Hif1a message (Rossignol et al., 
2002; Thrash-Bingham and Tartof, 1999; Uchida et al., 2004). Transcription of aHIF is 
controlled by HIF-1 itself at HREs downstream of the Hif1a gene (Uchida et al., 2004). 
The aHIF RNA is thought to bind the Hif1a mRNA 3’UTR and disrupt a hairpin structure, 
revealing an AU rich element which promotes degradation of the message (Rossignol et 
al., 2002). This is supported by evidence the Hif1a message has a considerably shorter 
half-life in hypoxia-mimetic (cobalt chloride) treated A549 cells compared to controls 
(Uchida et al., 2004). aHIF is expressed in many human, mouse and rat tissues, but is not 
hypoxia responsive in all cell types (Rossignol et al., 2004; Rossignol et al., 2002). This 
mechanism of destabilising Hif1a mRNA is likely to be connected to the lowered 
expression of HIF-1 protein described previously (Chapter 1.1.4) during extended 
hypoxia in PC12, SK-N-BE(2)C and A549 cells. However, this does not account for the 
increase in HIF-2 protein levels observed in these cell types after similar periods of 
hypoxic treatment, the cause of which is currently unknown. 
The HIF pathway can also be affected by conditions other than hypoxia. In addition to 
regulation by antisense HIF RNA, the HIF pathway is responsive to many microRNA 
(miRNA) transcripts, which are short RNA duplexes that promote degradation and inhibit 
translation of target mRNAs. The first example of this was described for the miR-17-92 
cluster, expression of which results in lowered HIF-1 and HIF-2 protein levels in 
immortalised lung epithelial cells (Taguchi et al., 2008).  In addition, mouse Hif1a is 
regulated by miR-199a in cardiac myocytes (Rane et al., 2009), while miR-20b can inhibit 
its translation (Cascio et al., 2010; Lei et al., 2009). Both of these miRNAs act using a site 
in the Hif1a 3’UTR. Other messages encoding proteins of the HIF pathway are also under 22   
the control of miRNAs, as VHL is targeted by miR-92-1 (Ghosh et al., 2009), while FIH-1 
levels are affected by miR-31 (Liu et al., 2010). However, the effects of these miRNAs on 
the HIF pathway appear to be restricted to a fine-tuning role, as expression of any one of 
the Hif1a targeted miRNAs reduces hypoxic HIF-1 protein detection, but does not 
completely repress it.  
Epas1 mRNA has been shown to be under the control of the RNA-binding Iron 
Regulatory Proteins IRP1 and IRP2 (Sanchez et al., 2007). In low cellular iron conditions, 
the IRPs bind to hairpin structures in target mRNA sequences known as Iron Responsive 
Elements (IRE), and in the case of Epas1, inhibit translation of the message into protein. 
As iron levels are crucial in erythropoiesis, which in turn has an effect on oxygen delivery 
and occurs in response to hypoxia, regulation of HIF-2 translation directly adds another 
level of control to this system. 
Hypoxia has been shown to downregulate translation of most mRNAs, as the cell 
apparently attempts to conserve ATP by avoiding translation of unnecessary proteins (Liu 
and Simon, 2004), through regulation of the mTOR pathway (Brugarolas et al., 2004; 
Connolly et al., 2006; Liu et al., 2006) in a HIF-independent fashion (Arsham et al., 
2003). However, HIF- escapes this regulation, along with some but not all HIF-
responsive genes (Thomas and Johannes, 2007). This may be related to the RNA-binding 
proteins HuR and PTB, which bind and promote translation of Hif1a message in response 
to the hypoxia mimetic cobalt chloride (Galban et al., 2008). 
Between the effect of RNA-binding proteins, miRNAs, antisense HIF transcripts and 
transcriptional regulation, it is clear that there are several levels of regulation of HIF- 
message working to fine tune the response to cellular hypoxia (see Figure 1.3), in addition 
to hydroxylation-dependent regulation of HIF- described earlier (Chapter 1.1.2). The 
stabilisation and activation of HIF- through activity of the PHD and FIH hydroxylases is 
the most powerful activator of the HIF pathway, yet different cell types in various 
situations could feasibly call on additional regulators to produce more subtle changes, in 
order to effect a more cell-appropriate response. Although not discussed in detail here, 
there are also some mechanisms where HIF can be activated by non-hypoxic means. As an 
example, signalling from growth factors such as IGF-1 has been shown to promote 
translation of Hif1a transcript in normoxia through MAPK and AKT kinase pathways 
(reviewed by Bilton and Booker, 2003).  23   
 
Figure 1.3. Examples of various mechanisms of regulation imposed on the HIF- subunits, with 
processes affected shown in blue and the molecular effector of regulation shown in red. A 
selection of processes affecting either HIF-1 or HIF-2 (or both) are all shown on one diagram 
for simplicity, and not all regulatory mechanisms may be active at the same time or in the same 
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1.1.7. HIF- Physiological Roles in Mice and 
Humans 
The extent of redundancy between the two HIF- subunits has been examined through 
generation of knockout mice. Arnt1
-/- embryos do not survive past 10.5 days after 
fertilisation, due to several defects in angiogenesis which appear to be related to impaired 
HIF pathway function, rather than the other bHLH/PAS transcription factors which 




-/- embryos all display impaired placenta vascularisation and development (Cowden 
Dahl et al., 2005), which would also be expected to impact negatively on the overall 
health of the embryo. In order to elucidate the functions of each HIF- not compensated 
for by the other, mice with homozygous deletions of Hif1a and Epas1 have been studied 
in further detail. 
In wild-type animals Hif1a mRNA is detectable in all organs and is thought to be 
essentially ubiquitous (Wiener et al., 1996). As the majority of currently known HIF target 
genes are activated by HIF-1 in preference to HIF-2 in cell culture models, it is thought 
that HIF-1 is responsible for the general cellular response to hypoxia, while HIF-2 
performs more specific roles. Hif1a
-/- stem cells exhibit poor induction of glycolytic 
pathway encoding genes such as Glut1, lower expression of Vegf and less growth under 
hypoxic conditions (Iyer et al., 1998; Ryan et al., 1998). Generation of mice from these 
stem cells showed that Hif1a
-/- embryos were morphologically abnormal after 8.5-9.5 days 
of development, and no longer viable after 10.5 days due to failed neural tube closure and 
impaired vascularisation, causing reduced oxygenation of tissues (Iyer et al., 1998; Ryan 
et al., 1998). In order to investigate roles of HIF-1 other than embryonic development, 
conditional Hif1a knockout mice have been generated, implicating HIF-1 function in brain 
development (Milosevic et al., 2007; Tomita et al., 2003), normal heart function (Huang 
et al., 2004), active skeletal muscle (Mason et al., 2004), inflammation, efficiency of 
bacteria killing by macrophages (Cramer et al., 2003; Peyssonnaux et al., 2005), 
chondrogenesis in joints (Provot et al., 2007), skin (Boutin et al., 2008) and 
haematopoietic stem cell maintenance (Takubo et al., 2010). Therefore, while HIF-1 
regulates the general response of cells to hypoxia, it also has functions in many specific 
contexts, in roles not limited to systemic or cellular hypoxic response. 25   
Epas1, which encodes for HIF-2, has been the subject of repeated study through use of 
knockout mouse technology. Tian and colleagues (1998) generated Epas1
-/- embryos and 
observed homozygous mutant death from 12.5 days post fertilisation, with a more subtle 
morphological disruption than had been observed for Hif1a
-/- mice. The cause of death 
was attributed to bradycardia arising from insufficient catecholamine synthesis and 
release, as supplementing water with catecholamine precursor DOPS rescued some of the 
embryos to birth (Tian et al., 1998). Curiously, heterozygous transgenic mice originating 
from this stock were able to survive to adulthood after backcrossing heterozygotes with 
another strain of mouse (Scortegagna et al., 2003a; Scortegagna et al., 2003b), allowing 
some study of more subtle adult phenotypes. Of particular note were hematopoietic 
deficiencies (Scortegagna et al., 2003b), reactive oxygen species stress, low body weight, 
hypocellular bone marrow and testes, hypertrophic heart and steatotic liver (Scortegagna 
et al., 2003a), reduced hypoxic erythropoietin production (Scortegagna et al., 2005) and 
retinopathy resulting in blindness (Ding et al., 2005). A second set of Epas1
-/- mice have 
been independently generated by Peng and colleagues (2000), who observed some embryo 
death from 13.5 days post fertilisation, yet survival of some embryos to birth without 
DOPS supplements. The homozygous mutants in these experiments appeared to die from 
vascular remodelling defects, with reduced catecholamine release playing only a small 
role. Generation of a third Epas1
-/- mouse line resulted in embryos which again mostly 
died 13.5 days post fertilisation, while in this case those which survived to birth displayed 
respiratory distress due to lowered lung surfactant production (Compernolle et al., 2002).  
Epas1 mRNA was first detected in vascular endothelial and highly vascularised tissues, 
has a more restricted expression profile compared to HIF-1, and is often only expressed 
within subsets of cells in a tissue (Wiesener et al., 2003). Epas1 is expressed at a high 
level in the developing heart, placenta, organ of Zuckerkandl, adrenal glands, carotid 
body, regions of the brain and neonatal lungs (Ema et al., 1997; Tian et al., 1998; Tian et 
al., 1997; Trollmann et al., 2008). As the organ of Zuckerkandl, adrenal glands and carotid 
body all produce catecholamines, expression of Epas1 in these areas may relate to the 
originally discovered catecholamine-deficiency phenotype of Epas1
-/- mice, while the 
expression of Epas1 in the heart, placenta and lungs is matched by developmental 
phenotypes in these organs in the subsequent knockout mouse studies as described above. 
The differences between the survival and phenotypes of Epas1
-/- mice between different 
experiments are confounding, but appears to be related to differences in genetic 
backgrounds of the mice. Nonetheless, the presence of HIF-2 clearly has several 26   
functions during development which align with its normal expression pattern, and HIF-2 
is at least partially non-redundant with respect to the more ubiquitous HIF-1. 
As with Hif1a, Conditional Epas1 knockout mice have been generated to examine roles 
for HIF-2 later in development. Deletion of Epas1 only in VE-Cadherin-expressing 
endothelial cells results in blood vessels with increased permeability (Skuli et al., 2009), 
which may be related to the vascular remodelling defects observed previously in Epas1
-/- 
mice (Peng et al., 2000). Gruber and colleagues generated mice with Epas1 deletion in all 
cells after birth by tamoxifen-inducible Cre recombinase, which caused anaemia and loss 
of stress-induced erythropoiesis in the immature and adult mice (Gruber et al., 2007). 
Interestingly, the previously mentioned HIF target gene Epo was found to be unresponsive 
to erythropoietic signals resulting from haemolysis in the Epas1
-/- mice, whereas Epo 
response was not adversely affected by loss of Hif1a. This, along with further studies with 
Epas1 deletion in either mouse hepatocytes (Rankin et al., 2007) or astrocytes 
(Weidemann et al., 2009), indicates that adaptive erythropoiesis due to induction of the 
Epo gene is predominantly regulated by HIF-2 in vivo, despite responding to either HIF 
homolog in vitro. In addition, deletion of Epas1 in the duodenum indicates that HIF-2 but 
not HIF-1 is involved in regulation of iron absorption through activation of genes such as 
DMT1-1A (Mastrogiannaki et al., 2009). In support, cases of familial erythrocytosis in 
humans have been genetically linked to dysfunction of the HIF pathway, and in particular 
HIF-2. Two separate loss-of-function mutations at the gene encoding HIF--regulator 
PHD2 have been detected which are linked to this disease (Al-Sheikh et al., 2008; Percy et 
al., 2006), while in other families with the disease at least five different polymorphisms 
have been found within the Epas1 gene (Percy, 2008; Percy et al., 2008a; Percy et al., 
2008b; van Wijk et al., 2010). These mutations have either been shown to or are expected 
to give rise to gain-of-function HIF-2protein by disrupting interaction with negative 
regulators such as PHD2. This provides supporting evidence to the controlled transgenic 
mouse experiments in describing the central role of HIF-2 in regulating erythropoiesis, 
as well as the supply of nutrients involved in erythropoiesis. 
Transgenic mouse models have recently connected aberrant HIF-2 function to the onset of 
osteoarthritis. Mice which overexpress Epas1 in specifically in chondrocytes exhibit  
spontaneous cartilage destruction, while Epas1
+/- mice were resistant to cartilage insult 
from collagenase treatment or destabilisation of the medial meniscus (Yang et al., 2010). 27   
In support, proinflammatory cytokines potently upregulate HIF-2 at both the protein and 
message level in mouse articular chondrocytes (Yang et al., 2010). 
Finally, transgenic mice have been generated in order to address the issue of redundancy 
between HIF-1 and HIF-2. Since HIF-1 is expressed nearly ubiquitously while HIF-
2 has a more restricted expression pattern, it is likely that the phenotypes observed in 
Hif1a
-/- mice are not compensated for by HIF-2 due in part to the lack of expression of 
Epas1 in some cell types. An allele of Hif1a was constructed with the Epas1 gene inserted 
in place of the Hif1a coding sequence (Hif1a
Epas1KI) (Covello et al., 2006). A mouse 
heterozygous for this allele expresses HIF-2 in place of HIF-1, in an effective Hif1a
-/- 
background. This means that any compensation for the loss of HIF-1 by HIF-2 will 
result in a Hif1a
Epas1KI/Epas1KI mouse phenotype which is less severe than the Hif1a
-/- 
phenotype. However, Hif1a
Epas1KI/Epas1KI embryos were detected in a significantly smaller 
numbers than expected 7 days post-fertilisation (Covello et al., 2006), compared to Hif1a
-/- 
embryos which show normal percentages of homozygotes until  9 days post-fertilisation 
(Iyer et al., 1998). Further experiments on this knock-in line show that ectopic HIF-2 
expression has a dominant effect which results in a more severe phenotype than the   
Hif1a
-/- background alone would be expected to produce. Therefore, HIF-2 must have 
functions which are not shared by HIF-1. The converse experiment of a Hif1a knock-in 
at the Epas1 locus has not been published, as HIF-1 is ubiquitous. This means that 
phenotypes observed in Epas1
-/- mice already indicate functions of HIF-2 which are not 
compensated for by HIF-1. 
1.1.8. Effects of the HIF Pathway on Cancer 
As potent regulators of angiogenic, metabolic and apoptotic pathways, HIF-1 and HIF-2 
are increasingly being studied with relation to their oncogenic properties. Dysregulation of 
the HIF pathway can drive cancer progression as a result of accumulated inherited or 
somatic mutations, or from the environmental hypoxia found within a solid tumour. 
The von Hippel-Lindau (VHL) disease is a well characterised familial cancer caused by 
various mutations of the Vhl gene, which encodes the E3 ubiquitin ligase pVHL. Increased 
susceptibility to kidney and other forms of cancer are dominantly transmitted in families 
with Vhl loss of function mutations, resulting in highly vascularised solid tumours (Kaelin 
and Maher, 1998). The previously described model of HIF- normoxic degradation 28   
through the pVHL mediated ubiquitin-proteasome pathway was originally discovered 
when Vhl
-/- renal carcinoma cells were observed to have constitutive HIF activity 
(Cockman et al., 2000; Krieg et al., 2000; Maxwell et al., 1999). VHL patients are 
heterozygous for functional Vhl and are therefore susceptible to somatic genetic loss of 
VHL protein. This results in constitutive activation of the HIF pathway and rapid 
development of tumours such as renal cell carcinoma (Kondo et al., 2002; Maranchie et 
al., 2002). Interestingly, it appears that HIF-2 is a more potent oncogene than HIF-1 
when constitutively activated in cultured cells of this type (Kondo et al., 2002; Maranchie 
et al., 2002). However, it is interesting that patients heterozygous for Vhl are only 
susceptible to specific forms of cancer, rather than all types of cancer. 
The oncogenic properties of the HIF pathway have been tested in other broader contexts, 
and show that these effects of aberrant HIF activity are not confined to the VHL disease 
state. Maxwell and colleagues employed a technique using xenografts of hepatoma cells, 
including experiments where the cells contained mutant HIF-1. Using this model, tumour 
angiogenesis and overall growth of solid tumours were observed to be dependent on HIF 
in vivo (Maxwell et al., 1997). In support of this role for HIF in cancer, increased presence 
of nuclear HIF-1 and HIF-2 has been detected by immunohistochemistry of primary 
and metastatic tumour sections of widely varying origins, relative to normal tissue (Talks 
et al., 2000; Zhong et al., 1999).  
Further insights into the specific functions of HIF-1 and HIF-2 in tumour development 
can be gained from transgenic embryonic stem (ES) cell models, which form solid 
teratocarcinoma tumours when injected into nude mice. Hif1a
-/- ES cells form significantly 
smaller teratocarcinomas with fewer blood vessels compared to wildtype ES tumours 
(Ryan et al., 1998). Similarly, injecting Hif1a
-/- mouse embryonic fibroblast (mEF) cells 
results in the formation of smaller fibrosarcomas than wildtype mEFs (Ryan et al., 2000). 
The fibrosarcoma Hif1a
-/- model exhibits lowered expression of Vegf, yet unlike the 
teratocarcinoma model no difference in blood vessel density was observed. In another set 
of experiments designed to study breast cancer development and metastasis, Liao and 
colleagues generated mice with a mammary epithelial conditional knockout Hif1a locus in 
a breast-cancer susceptible genetic background (Liao et al., 2007). In accordance with the 
other models, tumour growth was slowed by the lack of HIF-1, and HIF target genes were 
expressed at lower levels than for the control. In this case, however, metastatic growths in 
the lungs were also quantified, showing significantly fewer resulting from the Hif1a
-/- 29   
tumours, demonstrating that HIF-1 can also promote metastasis. These experiments imply 
that HIF-1 dependent progression of cancer occurs through multiple downstream 
pathways, and the effect of each is context dependent. 
However, HIF-2 is increasingly thought to provide an even more potent stimulus than 
HIF-1 for advancement of cancer. Teratocarcinomas formed from mouse ES cells with 
replacement of the Hif1a gene with Epas1 (Hif1a
Epas1KI/Epas1KI) form faster growing, more 
vascularised tumours with higher expression of target genes such as Vegf, when compared 
to teratocarcinomas formed from wildtype ES cells (Covello et al., 2005). High expression 
of HIF-2 in clinical neuroblastoma cases correlates with a poor prognosis (Holmquist-
Mengelbier et al., 2006), while aberrant expression of HIF-2 results in high expression 
of progenitor markers and low expression of markers of differentiation (Pietras et al., 
2008; Pietras et al., 2009). As HIF-2 has separately been found to bind and activate 
transcription of Pou5f1, which encodes the pluripotency marker Oct-4 (Covello et al., 
2006), it seems that activity of HIF-2 is linked to increased pluripotency, a trait which 
allows for increased tumour adaptivity. Curiously, in the context of neuroblastomas, HIF-
1 expression is correlated with a positive outcome (Noguera et al., 2009). In addition, 
forced expression of stabilised HIF-2 in a mouse strain susceptible to lung tumours 
results in larger, more invasive tumours than in control mice (Kim et al., 2009). 
Furthermore, conditional endothelial Epas1 knockout mice display reduced 
vascularisation of lung carcinoma xenografts compared to wildtype mice (Skuli et al., 
2009), highlighting an important HIF-2 function in not only the tumour itself, but also the 
supporting endothelial cells. 
1.1.9. Summary and Preliminary Approach 
Clearly, the HIF pathway is more than a simple hypoxia response pathway, as it is under 
the control of a complex regulation system which allows for differential activation of 
different HIF- subunits or even different domains within each HIF- protein, depending 
on the type of activating stimulus and cellular context. In particular, many facets of the 
regulation of HIF are highly dependent on the experimental cell type used, as described in 
Chapters 1.1.4, 1.1.5 and 1.1.6. Therefore, we reasoned that selection of an appropriate set 
of cell lines and conditions was critical for continuing research in the HIF field, given that 
the contrasting functions of this pathway are most pronounced when comparing different 
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There are aspects of the HIF transactivational pathway which are not explained by its 
currently known components, in particular when comparing HIF-1 function to HIF-2. In 
transgenic mouse models HIF-1 and HIF-2 are non-redundant, and while the two 
proteins are regulated in a similar way, differences in regulation and target gene specificity 
have been observed. Most of the research published in the field to date has focussed on 
HIF-1, while the specifics of HIF-2 function are still poorly understood. Therefore, in 
order to further study the differences between the two HIF- subunits, two approaches are 
possible. On one hand, different regulation and activation conditions can be studied, with 
the aim of elucidating differences in pathways upstream of HIF activation. Alternatively, 
the different downstream effects of HIF-1 and HIF-2 activity can be examined directly by 
testing for changes in target genes. We decided to use the second approach, as at the time 
this project commenced HIF-2 had been poorly studied and consequently relatively few 
target genes were known for HIF-2, and none of these displayed preference for HIF-2 over 
HIF-1. Therefore, we postulated that there were more HIF-2 responsive genes which had 
not yet been discovered, which may be preferred or even specific for HIF-2 activity with 
respect to HIF-1. The identification and characterisation of unknown HIF-2 target genes 
would help to explain with more clarity the physiological function of HIF-2, with 
particular reference to the multiple phenotypes of Epas1
-/- mice. Novel target genes may 
also help to shed light on the mechanisms of HIF binding site selection, or be used as a 
readout when studying regulation of the two HIF forms. As such, the long term aim of this 
research was to identify novel HIF-2 target genes, and this Ph.D project was a 
continuation of that research. 
1.2. Preliminary Experiments 
1.2.1. Novel HIF Target Genes 
For the reasons outlined in the previous chapter, a microarray experiment was designed 
and performed by Anthony Fedele as part of his Ph.D project to search for novel HIF 
target genes (Fedele, 2004). At the time, few microarray experiments had been published 
concerning the HIF pathway, but since this time a number of microarray experiments have 
been used to search for HIF responsive genes. These published microarrays used 
conditions of hypoxia alone (Aravindan et al., 2005; Burke et al., 2003; Elvidge et al., 
2006; Greijer et al., 2005; Jin et al., 2002; Jogi et al., 2004; Leonard et al., 2003; Mense et 31   
al., 2006; Robins et al., 2005; Warabi et al., 2004; Zhang and Hill, 2004), overexpression 
of HIF-1 or HIF-2 (Takeda et al., 2004; Wang et al., 2005), and knock-down of HIF-
1 or HIF-2 (Aprelikova et al., 2006; Hu et al., 2003), and used cell types derived from 
the kidney, endothelium, breast and cervical cancers. However, the function of the HIF 
pathway can be altered by cellular context, therefore these multiple microarray 
experiments are not redundant, and alternative target genes of HIF may still be found 
which are silenced in certain cell types. Given the known defects of the Epas1
-/- mouse 
models in catecholamine synthesis (Tian et al., 1998), we decided to use a cell line which 
can synthesise and release catecholamines. This was hoped to make the microarray data 
relate to possible HIF-2 functions, such that HIF targets could be found which may not be 
hypoxia-regulated in other cell types. At this time, erythropoiesis was thought to be 
regulated by either HIF form, rather than HIF-2 preferentially (as discussed in Chapter 
1.1.7), so erythrocyte-related cell lines were not considered. Our group used the PC-12 rat 
pheochromocytoma cell line, as it has a well characterised ability to produce 
catecholamines in response to hypoxia and expresses relatively high, inducible levels of 
HIF-2 (Kumar et al., 1998; Taylor and Peers, 1998). 
1.2.2. The PC12/TetON System 
To identify the genes regulated by HIF-1 or HIF-2 individually, a Tet-ON doxycycline-
inducible expression system was incorporated into the PC12 cells by sequential stable 
transfections. The Tet-ON system consists of one expression cassette which provides 
constitutive expression of the Reverse Tetracycline Transactivator (rtTA), while a second 
provides the coding sequence for protein to be overexpressed downstream of a 
Tetracycline Responsive Element (TRE). In the presence of tetracycline, or its derivative 
doxycycline, rtTA is able to bind at the TRE and activate transcription. Three monoclonal 
cell lines were generated using this system, differing only in the coding sequence under 
the control of the TRE: one encoding mouse HIF-2; one encoding human HIF-1 with 
an activating N803A mutation; and one control PC12 TetON cell line with an empty 
expression cassette. Transcription of the HIF- cDNA leads to stabilised protein at 
normoxia by overloading the regulatory hydroxylases, while the N803A mutation was 
required to achieve robust HIF-1 activity by preventing FIH-mediated asparagine 
hydroxylation of the HIF-1, leading to activation in normoxia. The differences in species 
and incorporated mutations of HIF-1 and HIF-2 in the Tet-ON cell lines are a result of 32   
optimisation for maximum doxycycline-responsive HIF activity. Microarrays were then 
performed comparing cDNA from doxycycline-treated TetON-HIF-2 and TetON-HIF-
1
N803A cells (Fedele, 2004). Cell lines were treated with doxycycline for 16 hours before 
lysis in order to match previous data indicating that PC-12 cells express both endogenous 
HIF-1 and HIF-2 this timepoint (Bracken et al., 2006). The data from the first 
microarray were not reproducible by replicate semi-quantitative PCR experiments.  
1.2.3. Verification of Microarray Data 
After the inconsistent results of the first experiment, a subsequent microarray was 
performed to identify HIF-2 targets alone, comparing cDNA from doxycycline-treated 
TetON-HIF-2 cells to the TetON-Control cell line. Verification of the results of this 
second microarray was performed as part of my research towards my Honours thesis. The 
twelve genes most consistently upregulated by HIF-2 overexpression were selected for 
further analysis (Table 1.1). Two of these genes were previously characterised HIF targets: 
Vegf and Bnip3. These twelve genes were retested by northern blot for response to HIF- 
in the TetON overexpression PC12 cell lines, and also for response to hypoxia in 
unmodified PC12 cells. Vegf and Bnip3 were consistently upregulated by HIF-1, HIF-2 
and hypoxia, although the effect of HIF-1 was greater than that of HIF-2. Other genes 
such as INrf2, Spr, Scn3b and Cacna2d1 were not reproducibly regulated by either HIF-1 
or HIF-2 overexpression, and were therefore likely false positives. However, two genes 
not previously known as HIF targets were consistently detected by northern blot as a 
higher level in both hypoxic and HIF- overexpressing PC12 cells: Slc16a1 and Rgs4 
(Olechnowicz, 2005). 33   
 
 
Table 1.1. The twelve most consistently upregulated genes in the doxycycline treated PC12-
TetON-HIF2 cell line, compared to the TetON control line (Fedele, 2004). Genes are ranked by 
B value, which depends on both the fold change and P value. Note the presence of HIF-2a is an 
artefact of the cDNA-mediated HIF-2 overexpression used in this cell line, and Bnip3 and Vegf 
are previously characterised HIF target genes. The response of these genes to doxycycline and 
hypoxia was verified by northern blot (Adapted from Olechnowicz, 2005).   
Gene ID Gene Name P.Value B
AF304364 INrf2; cytosolic inhibitor of Nrf2 4.30 Up 6.98E-05 8.42
AJ277828 HIF-2a; Hypoxia Inducible Factor 2a, Rattus norvegicus 8.04 Up 8.33E-04 6.74
U44845 Vitronectin; S-protein; epibolin; adhesion protein. 3.23 Up 8.33E-04 6.64
NM_017214 Rgs4; Regulator of G-protein Signaling 4 2.12 Up 2.60E-03 5.36
M36410 Sepiapterin Reductase  1.80 Up 6.01E-03 4.61
L03556 Hox1.3 protein 3' end (clone RAHB2 8/10)  4.04 Up 1.09E-02 3.72
AF243515 Bnip3; BCL2/adenovirus E1B 19 kDa-interacting protein 3 1.69 Up 1.10E-02 3.64
M31178 Calbindin D28 1.51 Up 1.80E-02 3.04
AF215726
VEGF; vascular endothelial growth factor-A120 (alternatively 
spliced)
1.97 Up 2.07E-02 2.77
NM_012716 Slc16a1; Solute carrier 16 member 1; MCT1 1.61 Up 2.51E-02 2.42
U04933 NACA7; Sprague-Dawley (CD-1) Na-Ca exchanger isoform NACA7 1.59 Up 2.55E-02 2.21
AJ243395 Na+b3; Voltage-gated sodium channel b3 subunit 1.62 Up 4.08E-02 1.18
AF286488 Ca+a2d1; Voltage-gated calcium channel a2/d-1 subunit 1.55 Up 4.08E-02 1.15
Fold 
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Slc16a1 encodes a solute carrier which transports monocarboxylic acids across the plasma 
membrane. Over three independent northern blot experiments, Slc16a1 mRNA was 
detected at 3.1 ±0.7 fold higher levels in 16-hour hypoxia treated PC12 cells than in 
normoxia (Standard Error of the Mean given for n=2). The response to doxycycline 
treatment of the TetON-HIF-1, TetON-HIF-2 and TetON-Control cell lines was 
consistent with HIF dependent regulation, but less dramatic changes of 2.5 ±1.7, 1.6 ±0.4 
and 0.7 ±0.5 respectively (with Standard Deviation for n=3) were observed. Therefore, 
while Slc16a1 may represent a novel hypoxia regulated gene, the response to 
overexpression was only subtle, and stronger for HIF-1 than HIF-2. Many HIF-1 
target genes are already well characterised, while novel HIF-2 target genes are more rare, 
so this gene was deemed to be a low priority for further testing. 
Rgs4 encodes Regulator of G-Protein Signalling 4 (RGS4), one of a family of proteins 
which contain an RGS domain. Rgs4 was upregulated by hypoxia (2.8 ±1.3 fold, SEM for 
n=2) and HIF-2 overexpression (2.8 ±1.3 fold, SD for n=3), but was unresponsive to 
HIF-1 overexpression (1.2 ±0.1, SD for n=3) or the TetON control (1.2 ±0.2, SD for 
n=3) (Figure 1.4). Although the regulation of Rgs4 observed was moderate, the apparent 
preference for HIF-2 over HIF-1 in regulation made this putative target gene worthy of 
further investigation. Furthermore, the known role of the Rgs4 gene product in modulating 
G-protein function provided a putative link of considerable interest between hypoxic 
signalling and G-Protein coupled receptor signalling. Therefore, this research for this 
thesis focuses on the hypothesis that transcription of Rgs4 is regulated by hypoxia through 
the HIF pathway. 
1.3. Regulator of G-Protein Signalling 4 
1.3.1. G-Protein Coupled Receptors and the 
RGS Family of Proteins 
G-Protein Coupled Receptors (GPCRs) are seven transmembrane domain proteins which 
are found at the plasma membrane in eukaryotes, with an extracellular ligand receptor 
domain and a cytosolic G-protein interaction domain. In its inactive state, a GDP-bound 




Figure 1.4. Representative northern blots of unmodified PC12 cells with or without 16 hours of 
hypoxic treatment, and the TetON-Control, TetON-HIF1 and TetON-HIF-2 PC12 cell lines 
with or without 16 hours of doxycycline treatment (adapted from Olechnowicz, 2005). Total RNA 
was extracted and separated by 1% agarose/formamide/MOPS gel electrophoresis, northern 
blotted, then probed with 
32P-labelled Rgs4, Vegf (positive control) or actin (loading control) 
coding sequence clones. Blots are representative of either three (Rgs4 with doxycycline 
treatments), two (Rgs4 with hypoxia, Vegf with doxycycline) or one (Vegf with hypoxia) 
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ligand binding, the G subunit exchanges GDP for GTP, and the G-protein trimer 
dissociates to a GTP-bound G monomer and a G dimer. These subunits then move away 
from the receptor to signal to secondary effectors. G has intrinsic GTPase activity, and 
will eventually hydrolyse its bound GTP to GDP. At this point, the G subunit will 
recondense with the G dimer at the GPCR to await reactivation by the receptor. RGS 
family proteins contain a RGS domain, which binds to GTP-bound G and increases the 
rate of GTP hydrolysis, resulting in reduced signal transduction (Berman et al., 1996b; 
Watson et al., 1996). This interaction occurs at the switch regions of G, rather than the 
GTPase catalysis site (Tesmer et al., 1997). A bound RGS domain therefore lowers the 
transition state energy of GTP hydrolysis allosterically, rather than contributing directly to 
the reaction. This role of the RGS domain can itself be allosterically inhibited by 
phosphatidylinositol 3,4,5-trisphosphate (PIP3), an effect which is relieved by Ca
2+-bound-
Calmodulin binding (reviewed by Ishii and Kurachi, 2003). RGS4 is also subject to N-
terminal palmitoylation, which inhibits its effect as a GTPase activator (Tu et al., 1999). 
The family of proteins which contain Regulator of G-Protein Signalling (RGS) domains 
includes the products from at least 37 different genes (Siderovski and Willard, 2005). 
These proteins are classed by homology of RGS domains and presence of other domains 
into 8 subfamilies: RZ, R4, R7, R12, RA, GRK, GEF and SNX. While many of these 
families include proteins which also contain other recognisable domains, the R4 sub-
family comprises relatively short proteins with no known domains other than the RGS 
domain (reviewed by Willars, 2006). Rgs4 encodes RGS4, which was amongst the first of 
the RGS proteins to be discovered (Druey et al., 1996) and encodes the prototypical 
member of the R4 subfamily. There are numerous forms of RGS4 (see Chapter 1.3.2), but 
the most prominent form of RGS4 has 205 amino acids, of which 120 form the RGS 
domain (Popov et al., 1997). Other R4 subfamily members such as RGS5 and RGS16 are 
of a similar size and composition. 
1.3.2. Expression Pattern of RGS4 
Rgs4 mRNA is detected at high levels in adult brain and heart in rats and mice, with lower 
expression detectable in lung, liver and skeletal muscle (Nomoto et al., 1997; Zhang et al., 
1998). However, the specific regions of Rgs4 expression within the brain are less clear, as 
in-situ hybridisation and qPCR studies of the developing or adult brain often give 
conflicting results (Erdely et al., 2004; Gold et al., 1997; Grillet et al., 2003; Grillet et al., 37   
2005; Ingi and Aoki, 2002; Larminie et al., 2004). The cause of these differences is 
unclear, but nonetheless it appears that Rgs4 expression within the brain is very specific 
between regions and possibly dynamic. Notably, expression of Rgs4 overlaps to some 
extent with expression of other R4 subfamily members. Rgs5 is strongly expressed in the 
heart, vasculature and skeletal muscle (Seki et al., 1998), but is restricted in the brain to 
regions such as the amygdala and hypothalamus (Gold et al., 1997). Rgs16 also has a 
specific expression pattern within the brain, highest in the thalamus (Grafstein-Dunn et al., 
2001).  
Human Rgs4 produces at least 5 different transcripts through either alternative splicing or 
alternative promoters, of which two encode the previously mentioned 205 amino acid (aa) 
protein, one encodes a 302aa protein (extended at the N-terminus) and two produce 
truncated RGS4 forms (187aa and 93aa) (Ding et al., 2007). The relative expression of 
each of these variants in vivo is not clear, although the transcript designated as Rgs4-1 by 
Ding et al. (2007) is identical to the originally discovered 205aa form. Different variants 
of mouse Rgs4 transcript all give rise to the same open reading frame, which is equivalent 
to the coding sequence of human splice variant Rgs4-1 (Ding et al., 2007), implying that 
this is the prototypical Rgs4 form. 
1.3.3. Regulation of RGS Genes and Proteins by 
Hypoxia 
Regulation of Rgs4 and its protein product by hypoxia is not unprecedented in the 
literature. Rgs4 has appeared in the results of one published hypoxia-related microarray. 
Treatment of SK-N-BE(2)C human neuroblastoma cells with hypoxia for 72 hours led to 
increased hybridisation to a transcript listed as FLJ38885 by between 5 and 8.2 fold (Jogi 
et al., 2004). Upon further investigation, this sequence aligns as a partially-processed form 
of Rgs4 mRNA, which is likely to also detect fully processed Rgs4 transcript. Rgs5 was 
also consistently detected at 2.2 to 2.6 fold increased levels. However, the authors did not 
verify these positive responses with further experiments (Jogi et al., 2004). The other 
published microarray experiments described earlier (Chapter 1.2.1) used either arrays 
which did not feature an Rgs4 probe, or reported no significant change in Rgs4 levels to 
either hypoxia or change in HIF- expression. As these studies used cell types which are 
not known to express Rgs4, it is likely that the hypoxic response of Rgs4 is restricted to 38   
cell types which express basal Rgs4 before treatment, such as neuroblastoma or 
pheochromocytoma cells. It is interesting to note that other bHLH/PAS family members 
have also been linked to regulation of Rgs4 expression levels. Rgs4 transcript levels are 
decreased by 3 fold in the anterior hypothalamus of Sim1
-/- embryonic mice (Caqueret et 
al., 2006), and also decreased in cultured mouse hippocampal neurons after RNAi-
mediated knockdown of Npas4 (Lin et al., 2008). As the DNA binding specificities of 
HIF, SIM-1 and NPAS4 are similar, it is possible that these is some crosstalk between 
these factors at an enhancer which regulates Rgs4 expression. 
It has been reported that exposing Human Umbilical Vein Endothelial Cells (HUVECs) to 
hypoxia causes a rapid yet modest induction of Rgs5 message, which encodes an R4 
subfamily member closely related to Rgs4 (Jin et al., 2009). Levels remain increased for at 
least 12 hours of treatment before returning to control levels by 24 hours. Curiously, while 
this report showed western blot data indicating similarly increased levels of RGS5 protein, 
no change in RGS4 protein level was detected (Jin et al., 2009). Although no experimental 
test for Rgs4 message levels was presented, this indicates that the response of Rgs4 to 
hypoxia may be replaced in some contexts by other RGS family members. It is interesting 
to note that Rgs4 and Rgs5 are adjacent in the human genome, separated by about 50kb of 
intervening sequence, and as such may feasibly share some transcriptional enhancers. 
At the posttranslational level of control, protein stability of RGS4, RGS5 and RGS16 is 
regulated by the N-end rule pathway (Davydov and Varshavsky, 2000; Lee et al., 2005), 
where the N-terminal residue of a protein affects its degradation. N-terminal residues other 
than Met, Gly, Val, Ile or Pro signal for protein degradation through the ubiquitin-
proteasome pathway (Gonda et al., 1989). These residues can be exposed by proteolysis or 
activity of methionine aminopeptidases (MetAPs), which remove the N-terminal 
methionine of a target protein (Davydov and Varshavsky, 2000). MetAP acts on RGS4 to 
reveal its second amino acid, Cys. This residue is oxidised, leading to recognition by 
ATE1, an enzyme which ligates an arginine to the N-terminus of RGS4 (Lee et al., 2005). 
This arginine is then recognised directly by E3 ubiquitin ligases UBR1 and UBR2 
resulting in ubiquitylation of RGS4 and subsequent proteasomal degradation (Lee et al., 
2005). Curiously, the cysteine oxidation step is sensitive to hypoxia, such that RGS4 (Hu 
et al., 2005) and RGS5 (Lee et al., 2005) exhibit hypoxic protein stabilisation and 
accumulation. It is unknown whether there is a hypoxia-sensitive enzyme responsible for 
this oxidation step, in a role similar to that of FIH and the PHD enzymes in the HIF 39   
pathway, or if cysteine oxidation occurs spontaneously in the presence of oxygen. The 
phenotypes of mice defective for ATE1, UBR1 and UBR2 imply that the N-end rule 
pathway has physiological roles in neural development (An et al., 2006), cardiovascular 
development and remodelling (An et al., 2006; Kwon et al., 2002), pancreas function 
(Zenker et al., 2005) and meiosis in spermatocytes (Kwon et al., 2003). It is unclear 
whether the pathway is in effect throughout the body or only in a subset of tissues as there 
are other poorly characterised components (Tasaki et al., 2005). However, while the effect 
of hypoxia on RGS4 has been characterised in terms of the N-end rule pathway, no 
experiments were presented in these papers addressing Rgs4 mRNA levels. Altered Rgs4 
mRNA may augment the effect of N-end rule mediated protein stability, or may produce a 
similar hypoxia-responsive outcome in cell types which lack the N-end rule pathway 
components. Furthermore, as we theorise that the N-end rule pathway and the now the HIF 
pathway are both involved in a hypoxic increase of RGS4, it is interesting to note that the 
impaired vascular remodelling phenotype of Ate1
-/- (Kwon et al., 2002) and Ubr1
-/-Ubr2
-/- 
(An et al., 2006) mice overlaps with the phenotype of Epas1
-/- mice (Peng et al., 2000). 
1.3.4. G-selectivity of RGS4 Function 
There are at least sixteen known genes which encode G subunits, which can be divided 
into four subfamilies by sequence and function: s; 12; i; and q (reviewed by 
Hildebrandt, 1997; Neves et al., 2002; and Simon et al., 1991). There are also multiple 
different G and G subunits, and alternative splicing occurs on some subunits, so defining 
roles for a specific G is complicated. RGS4 exhibits some specificity in G selection, 
determined by both biochemical interaction and functional assays. Signalling through i 
subfamily members i1, i2, i3, o and z (Berman et al., 1996b), as well as t and q 
(Berman et al., 1996a; Hepler et al., 1997) is dampened by RGS4 presence, while RGS4 
can be immunoprecipitated with members of the i subfamily (Watson et al., 1996). 
However, RGS4 exerts no effect on s (Berman et al., 1996b) or 12 (Berman et al., 
1996a). Other RGS proteins also display similar selectivity between subfamilies of G 
(reviewed by De Vries et al., 2000). The secondary effectors for members of different G 
subfamilies are diverse: s subunits activate adenylyl cyclase, while i subunits generally 
inhibit adenylyl cyclase. Signalling by q triggers production of inositol triphosphate by 
Phospholipase C, while effectors for the 12 are still unclear. Also, some specific ion 
channels can be regulated through the effect of the partner G dimer (reviewed by Neves 40   
et al., 2002). Novel secondary effectors are still being discovered for each of these G 
proteins, and each subfamily of G-proteins can be used by a variety of different GPCRs, 
so the scope for effects of RGS4 function is wide. In this way, the molecular basis for 
RGS4-regulated physiological roles is poorly understood. 
1.3.5. RGS4 Function in the Brain 
In keeping with its observed expression pattern, many proposed functions of RGS4 relate 
to the brain, as described on the right-hand side of Figure 1.5. In particular, alterations at 
the Rgs4 gene locus are thought to be a contributing factor for schizophrenia, a psychosis 
which has a heritability component of up to 80% (Merikangas and Risch, 2003). This link 
was first established by microarray analysis of matched schizophrenic and control 
postmortem prefrontal cortices (Mirnics et al., 2001), an area which becomes 
dysfunctional in affected individuals (Goldman-Rakic and Selemon, 1997). Mirnics and 
colleagues (2001) report that out of 6 matched microarray studies, expression of only one 
gene was found to be significantly altered in all experiments: Rgs4, which exhibited 
increased expression in affected individuals. In support, the human Rgs4 locus (at 1q23) is 
located near to a previously discovered genomic region with strong linkage to familial 
schizophrenia at 1q21-22 (Brzustowicz et al., 2000). Since then, multiple studies have 
included Rgs4-linked single nucleotide polymorphisms to determine whether this locus is 
associated with schizophrenia susceptibility. The Schizophrenia Research Forum collate 
these results, showing that of 31 studies, 15 present data supporting a link between the 
Rgs4 locus and schizophrenia, while 18 present negative results (Heimer, 2010). This 
indicates that while polymorphisms of the Rgs4 locus may be related to heritable 
schizophrenia in some cases, the disease is also likely to involve other loci as well as 
environmental factors, such that Rgs4 represents one of many possible susceptibility loci. 
Indeed, there are other susceptibility genes known, such as Nrg1, Comt and Notch4 
(reviewed by Schmidt-Kastner et al., 2006). 
One of the several theories for the molecular cause of schizophrenia is the dopamine 
hypothesis, which states that excess dopamine signalling in the central nervous system is a 
major factor in the disease (reviewed by Murray et al., 2008). This theory originates from 
the eventual discovery that antipsychotic drugs such as haloperidol used in the treatment 
of schizophrenia target the D2 dopamine receptor (D2R), one of a family of dopamine 




Figure 1.5. Flowchart of possible functions of RGS4 in the cardiovascular (left) and nervous 
(right) systems. Also pictured are the influences of hypoxia on these systems, and on the regulation 
of RGS4, in many cases through the HIF transcriptional pathway. The connector labelled “HIF?” 
question mark denotes the novel mechanism of RGS4 regulation by the HIF pathway under 
investigation in this thesis, which may describe the molecular mechanism behind some of the 
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cyclase (reviewed by Seeman, 2006). Interestingly, as the D2R is a Gi-linked GPCR, 
RGS4 can inhibit its downstream signalling. RGS4 has been shown to directly promote 
the GTPase activity of Gi after activation by the D2R, causing a decrease in not only Gi 
but also G signalling (Ho et al., 2007; Yan et al., 1997). In this way, RGS4 regulates a 
signalling system thought to be central to the molecular pathogenesis of schizophrenia. 
Furthermore, there is some suggestion of a link between obstetric complications involving 
hypoxia and schizophrenic risk later in life (Cannon et al., 2000).  
RGS4 can negatively regulate Gi-mediated signalling from the m-opioid (morphine) 
and/or d-opioid receptors depending on context (Garnier et al., 2003; Leontiadis et al., 
2009; Wang et al., 2009). As opiates such as morphine are used widely in the treatment of 
pain, it is intriguing that Rgs4 mRNA is upregulated in rat spinal cord following 
neuropathic pain (Garnier et al., 2003), possibly to act in a negative feedback loop on the 
opioid receptors. Rgs4 message also increases in the locus coeruleus during morphine 
withdrawal (Gold et al., 2003). Rgs4
-/- mice have been generated which display only 
subtle phenotypes, as they develop without gross morphological abnormalities, possibly 
due to compensation by other RGS family members. Knockout mice are smaller than 
wildtype, fall from a rotating rod more quickly, and are more resistant to some pain 
treatments (Grillet et al., 2005), while later studies indicate these mice have some 
disruption to metabolic homeostasis pathways (Iankova et al., 2008). They display mostly 
normal responses to morphine withdrawal, the sole difference being the lack of a 
characteristic sniffing response (Grillet et al., 2005). However, Grillet and colleagues note 
that this relates to the phenotype of D2R
-/- mice, where withdrawal symptoms are also 
identical to wildtype save for an enhanced sniffing response (Maldonado et al., 1997). 
Furthermore, more detailed studies using conditional and total Rgs4 knockout and knock-
in mice indicate significant roles of Rgs4 in different regions of the brain in dampening the 
effect of opiate signalling (Han et al., 2010). 
1.3.6. RGS4 Function in the Cardiovascular and 
Other Systems 
Although expressed at a relatively lower level than in the brain, Rgs4 is thought to also 
have roles in the heart and vascular system, as described on the left-hand side of Figure 
1.5. Both in vitro and in vivo models of heart hypertrophy result in increased levels of 43   
Rgs4 mRNA (Zhang et al., 1998), while conversely, overexpression of Rgs4 inhibits the 
hypertrophic response in cell culture models (Tamirisa et al., 1999) and in vivo (Rogers et 
al., 1999). Therefore, regulation of Rgs4 transcription appears to give rise to a negative 
feedback loop. In support, increased expression of Rgs4 has been shown to inhibit GPCR 
signalling from ligands such as endothelin and phenylephrine, which normally invoke 
hypertrophy in cultured cardiomyocytes (Schaub et al., 1997; Snabaitis et al., 2005; 
Tamirisa et al., 1999). Additionally, endothelin signalling has also been shown to activate 
HIF through downregulation of Phd2 expression in melanoma, so HIF may be included in 
this negative feedback loop (Spinella et al., 2010). Heart hypertrophy has been described 
in Epas1
-/- mice (Scortegagna et al., 2003a), which may therefore be related to the 
proposed transcriptional activation of Rgs4 by HIF, as lack of HIF-2 may allow 
hypertrophy to occur in an unregulated manner. 
While no heart disorders were originally noted in Rgs4
-/- mice (Grillet et al., 2005), more 
detailed studies have since noted that knockout mice display an increased sensitivity to the 
muscarinic M2 acetylcholine receptor (M2R) agonist carbachol (Cifelli et al., 2008). 
Activation of M2R signalling in cardiomyocytes results in bradycardia, while RGS4 
modulates M2R signalling in vitro by inhibiting G-mediated activation of G-Protein-
regulated Inward Rectifying K
+ channels (GIRK) (Doupnik et al., 1997; Fujita et al., 
2000; Inanobe et al., 2001). Once again, this may relate to the bradycardic phenotype 
observed in Epas1
-/- mice (Tian et al., 1998), as lack of HIF-2 may prevent upregulation of 
RGS4 resulting in excess bradycardic signalling. 
There may also be a role for Rgs4 in the development of tubules in the vascular and 
respiratory system. In vitro assays show increased Rgs4 in MB114 endothelial and Mv1Lu 
lung epithelial cells during tubulogenesis, yet viral expression of Rgs4 in the same cells 
inhibits tubulogenesis (Albig and Schiemann, 2005). This implies another regulatory role 
for RGS4 in a negative feedback loop. However, similar effects are observed for Rgs5, 
indicating that there may be some degree of redundancy between these RGS proteins in 
the regulation of vascular development (Albig and Schiemann, 2005; Manzur and Ganss, 
2009). This would explain the lack of major cardiovascular developmental defects in 
Rgs4
-/- mice (Grillet et al., 2005). Overexpression of Rgs4 inhibits signalling by VEGF in 
endothelial cells, despite this signal occurring through a receptor tyrosine kinase (Albig 
and Schiemann, 2005), while the HIF pathway is well characterised in its activation of 
Vegf transcription, so a connection between these pathways would be of interest. 44   
Rgs4 may also have a role in cancer progression, as it is a negative regulator of tumour 
size, lamellipodia formation and subsequent cell motility in breast cancer (Xie et al., 
2009). This may be a cell type specific effect, as previous work has instead correlated 
Rgs4 overexpression with a decrease in glioma cell motility (Tatenhorst et al., 2004). As 
described previously (Chapter 1.1.8), the HIF pathway is also known to be highly 
involved in oncogenesis. 
1.4. Summary and Approach 
1.4.1. Summary 
Mammalian cellular hypoxia sensing and response is a vital function for survival and 
adaptation of cells individually, as well as for development and adaptation of the entire 
organism, as the HIF pathway is strongly conserved through mammalian evolution, while 
disruption of this pathway causes severe deleterious phenotypes. Although previous 
research has identified numerous hypoxia responsive genes, it appears that the hypoxic 
response is not uniform between different cell types and contexts. Furthermore, current 
knowledge of HIF-responsive genes does not fully explain the range of phenotypes 
observed in HIF knockout mice. As such, we reasoned that there were more hypoxia 
responsive genes yet to be found, and that the careful selection of cell types used may be 
critical in their identification. In this way, novel genes may be found which are responsive 
to hypoxia in a subset of cell types, but do not respond in others and have therefore been 
overlooked in previous studies. Preliminary studies in our lab using microarray technology 
indicated that Rgs4, encoding RGS4 protein, may in fact be a novel HIF-responsive gene 
in the PC12 rat pheochromocytoma cell line. 
Curiously, RGS4 has proposed roles in development and regulation of signalling in both 
the nervous and cardiovascular systems, as well as pathophysiological roles in 
psychological disorders, heart disease and cancer. Several of these processes have links to 
hypoxia, but molecular mechanisms have not yet been found. The hypothesis 
investigated in this thesis is that hypoxic regulation of Rgs4 is mediated by HIF. My 
aim is to elucidate the molecular mechanism of transcriptional regulation of Rgs4 in 
response to hypoxia, and to define the contexts in which it occurs. This interaction 
may then provide explanations for some of the uncharacterised effects of HIF pathway 45   
disruption, and provide a more complete understanding of the physiological mammalian 
response to hypoxia. 
1.4.2. Approach 
To address this aim, I designed experiments around two related approaches. The first of 
these aimed to clarify the types of cells in which Rgs4 is responsive to hypoxia, by testing 
for increased relative Rgs4 mRNA levels in neural and endothelial related cell lines using 
qRT-PCR and northern blotting. In these experiments, hypoxia, hypoxia mimetics and 
siRNA knockdown were all used to implicate the HIF transcription factors in this 
regulation. 
Secondly, I aimed to test whether Rgs4 is regulated in a similar fashion to other known 
HIF-responsive genes. If this is the case, it would be expected that the HIF transcription 
factors bind at a genomic site proximal to the Rgs4 transcription start site, known as a 
HRE. To eliminate other possibilities, the effect of transcription-independent regulation, 
3’UTR mRNA elements and the hypoxia-response time were tested. Finally, enhancer 
reporter assays were used alongside bioinformatics to search for a putative direct HIF 
binding site at the human and rat genomic Rgs4 loci.  46   
2. Methods 47   
2.1. Reagents 
2.1.1. Commercially Sourced Reagents 
Standard solutions supplied by Technical 
Services Unit (TSU) unless otherwise 
described, and used at 1x concentration 
unless otherwise specified. 
All water used is Milli-Q purified 
(Millipore).  
All chemicals from Sigma-Aldrich, 
unless otherwise stated. 
All restriction enzymes, related buffers 
and BSA from New England 
Biosciences. 
1kb+ DNA marker: Invitrogen 
32P-dATP: Perkin Elmer 
AnaeroGen sachets: Oxoid 
Betaine: Sigma 
Big Dye Terminator Ver.3: Amersham 
DMEM, MEM and RPMI1640: Gibco 
dNTPs: Finnzymes 
Dual Luciferase Reporter Assay Kit: 
Promega 
FCS: JRH 
Gel Purification Kit: Qiagen 
Horse Serum: Sigma 
Klenow fragment: NEB 
Lipofectamine2000: Invitrogen 
Nytran Membrane: Schleicher and 
Schuell 
Oligo(15)-dTs: Geneworks 
pGEM-T Easy Kit: Promega 
PfuTurbo: Stratagene 
ProbeQuant G-50 Microcolumns: 
Amersham 
Proteinase K: Roche 
qPCR Fast SYBR Green Mastermix: 
Applied Biosystems 
Random dNTP hexamer: Geneworks 
RNaseIN: Ambion 
Superscript III: Invitrogen 
Taq Polymerase: NEB 
TRI Reagent: Sigma 
X-gal: Biovectra48   
2.1.2. PCR Primer Sequences 
Oligonucleotides for use as PCR primers were designed with the aid of UCSC Genome 
Browser (Kent et al., 2002) and Primer3 (Rozen and Skaletsky, 2000), and synthesised by 
Geneworks (Thebarton, South Australia) at 40nmole synthesis scale and sequencing/PCR 
purity grade. Primers were resuspended in H2O to 100mM, diluted to a 10mM working 
stock in H2O, and stored at -20ºC. 
The following primers were used to clone probes for use in northern blot probing: 
rat Rgs4 - 618 bp PCR product  
Rgs4 upper (110)   ATG TGC AAA GGA CTC GCT GGT  
Rgs4 lower (727)   TTA GGC ACA CTG AGG GAC TAG 
rat Vegf - 477 bp PCR product  
hVEGF upper (37)   GCC TTG CTG CTC TAC CTC CAC  
hVEGF lower (513)   CAA ATG CTT TCT CCG CTC TGA 
 
The following primers were used to sequence plasmids as indicated: 
pGEM-T Easy 
BS M13-20     GTA AAA CGA CGG CCA GT  
BS Reverse    AAC AGC TAT GAC CAT G 
pGL3basic, pGL3promoter 
RVPrimer3    CTA GCA AAA TAG GCT GTC CC 
GLPrimer2    CTT TAT GTT TTT GGC GTC TTC CA 
  RVPrimer4    GAC GAT AGT CAT GCC CCG CGC 49   
The following primers were used for amplification of target gene cDNA in qRT-PCR. 
Primers were designed using Primer3 (Rozen and Skaletsky, 2000), set to anneal at a 
predicted temperature of 60ºC and amplify a target sequence of 75-150bp in length, 
crossing at least one intron boundary to minimise amplification from genomic DNA 
contamination. 
human Rgs4 – 106bp PCR product from cDNA 
hRgs4_qPCR_F  TTGCGAATTCCAAGCTGTTA 
hRgs4_qPCR_R  AGCAGGAAACCTAGCCGATG 
human Vegf – 119bp PCR product from cDNA 
VEGF_qPCR_F  CCTTGCTGCTCTACCTCCAC 
VEGF_qPCR1_R  GCAGTAGCTGCGCTGATAGA 
human Polr2a – 67bp PCR product from cDNA 
Polr2a_qPCR1_F  ACCCTCCGTCACAGACATTC 
Polr2a_qPCR1_R  CCATCAAGAGAGTCCAGTTCG 
human Actb – 75bp PCR product from cDNA 
hActb_qPCR_F  ACAGAGCCTCGCCTTTGC 
hActb_qPCR_R  GCGGCGATATCATCATCC 
mouse/rat Polr2a – 85bp PCR product from cDNA 
mrPolr2a_qPCR1_F   GCA CCA TCA AGA GAG TGC AG 
mrPolr2a_qPCR1_R  GGG TAT TTG ATA CCA CCC TCT G 
mouse Rgs4 – 100bp PCR product from cDNA 
mRgs4_qPCR1_F  TCC TCG CTA AGA ATC CCT CAG 
mRgs4_qPCR1_R   CCA GCC GAT GTT TGA TGT C 50   
mouse Vegf – 101bp PCR product from cDNA 
mVegfa_qPCR1_F   CTG CTG TAC CTC CAC CAT GC 
mVegfa_qPCR1_R   CGC TGG TAG ACA TCC ATG AAC 
rat Rgs4 – 74bp PCR product from cDNA 
rRgs4_qPCR1_F   CAA GAT GTG CAA AGG ACT CG 
rRgs4_qPCR1_R   CCA GCC GAT GTT TCA TAT CC 
rat Vegf – 116bp PCR product from cDNA 
rVegfa_qPCR1_F   GGC TTT ACT GCT GTA CCT CCA C 
rVegfa_qPCR1_R   AAT AGC TGC GCT GGT AGA CG 
human Hif1a – 89bp PCR product from cDNA 
hHIF1A_qPCR2_F   CATGTGACCATGAGGAAATGAG 
hHIF1A_qPCR2_R  AAAGCTTCGCTGTGTGTTTTG 
human Epas1 – 98bp PCR product from cDNA 
hEPAS_qPCR2_F   CTGCGACCATGAGGAGATTC 
hEPAS_qPCR2_R   TGAAGAAGTCCCGCTCTGTG 
mouse/rat Hif1a – 125bp PCR product from cDNA 
mrHif1a_qPCR_F   CGG CGA GAA CGA GA GA 
mrHif1a_qPCR_R  GAA GTG GCA ACT GAT GAG CA 
mouse/rat Epas1 – 104bp PCR product from cDNA 
mrHif2a_qPCR_F  GGT TAA GGA ACC CAG GTG  
mrHif2a_qPCR_R   GGG ATT TCT CCT TCC TCA GC 
human Dec1 – 97bp PCR product from cDNA 51   
hDec1_qPCR1_F  GAC CGG ATT AAC GAG TGC AT  
hDec1_qPCR1_R   CAA GAA CCA CTG CTT TTT CCA 
human/mouse/rat Rgs5 – 181bp PCR product from cDNA 
hmrRgs5_qPCR1_F  TCAGTGAGGAAAACCTTGAGTTC 
hmrRgs5_qPCR1_R  AGGTTCCACCAGGTTCTTCAT 
human Mlh1 – 88bp PCR product from cDNA 
hMLH1_qPCR1_F   AGC CTA TTT GCC CAA AAA CA 
hMLH1_qPCR2_R   TGT GGG GTG CAC ATT AAC AT 
The following primers were used to amplify parts of the human Rgs4 genomic locus as 
described in Figure 4.6a for ligation to pGEM-T Easy and subcloning to pGL3 or 
pCI_FL. Note that some primers incorporate 5’ restriction enzyme sites, and therefore may 
not align perfectly to genomic sequence. Some primer sequences are duplicated. 
Sequence A 
hRgs4_-15kb_F    ACCTGGAAAATCCTGCCTCT   
hRgs4_-11.3kb_R_XhoI  CTCGAGCTCCATCCTTCACTGCCCTA   
Sequence B 
hRgs4_-11.5kb_F    GGAATGGAAAACTCCCCTTG   
hRgs4_-8.4kb_R_XhoI  CTCGAGTGGTGCTCTAAAATGTTCTATCCA   
Sequence C 
hRgs4_-8.6kb_F_MluI-  AAGAAAACGCGTAAGCCAGAAGTGATGGAGGA 
hRgs4_-6.7kb_R_XhoI-  GCTAATCTCGAGAATCAAGGGGCATTCTACCC   
Sequence D 
hRgs4_-2.2kb_R_XhoI  CTCGAGTAACAGAGCTGGGTCCAGATACA   52   
hRgs4_5'FS_-6.5kb_F   GGCACAGAACAGGGGAAATA   
Sequence E 
hRgs4_5'FS_-6.5kb_F   GGCACAGAACAGGGGAAATA   
hRgs4_TSSsv_R     TCCAAGATCTGATCCTCACGA   
Sequence F 
hRgs4_5'FS_-2.2kb_F   GATGGGATAGCATGGTGGAC   
hRgs4_TSSsv_R    TCCAAGATCTGATCCTCACGA   
Sequence G 
hRgs4_5'FS_-2.2kb_F     GATGGGATAGCATGGTGGAC   
hRgs4_5'FS_0.05kb_R  CTTCGGCTTTGAGCGTACTT   
Sequence H 
hRgs4_5'FS_-2.2kb_F   GATGGGATAGCATGGTGGAC   
2kbRgs4_NheI    GCTAGCGAAAGCAGTAGCGGCAAAAG   
Sequence I 
hRgs4_qPCR_F    TTGCGAATTCCAAGCTGTTA   
2kbRgs4_NheI    GCTAGCGAAAGCAGTAGCGGCAAAAG   
Sequence J 
hRgs4_3.3kb_F_KpnI   GGTACCCGAGGTGCTTCTACAGTT 
hRgs4_6kb_R_XhoI     CTCGAGTATTTGGCCTCAGGTTTTCC 
Sequence K       
hRgs43UTRpA_XbaI_F  TCTAGATTCTCACCTGAAGGCAGAGG  
hRgs43UTRpA_XhoXba_R  CTCGAGTCTAGACACTGGCACAGGAGGGATTA   53   
Sequence L 
hRgs4_8.2kb_F_MluI   ACGCGTAAACATCAGGGTGTAGGGTGA   
hRgs4_12.9kb_R_XhoI  CTCGAGTTCCTTCCTTGTGTCATATTTCC   
Sequence M 
hRgs4_8.2kb_F_MluI    ACGCGTAAACATCAGGGTGTAGGGTGA   
hRgs4_17.9kb_R_XhoI  CTCGAGTTGCCAGTGGGGAAACTAAC  
Sequence N 
hRgs4_12.8kb_F_MluI  ACGCGTCTGCTTAGGCCATTAAACCA  
hRgs4_17.9kb_R_XhoI  CTCGAGTTGCCAGTGGGGAAACTAAC    
   
2.1.3. siRNA Duplexes 
siHIF1A_1541  Sense    r(CUG AUG ACC AGC AAC UUG A) dTdT 
Antisense  r(UCA AGU UGC UGG UCA UCA G) dTdT 
siHIF2A_1599  Sense    r(CAG CAU CUU UGA UAG CAG U) dTdT 
      Antisense  r(ACU GCU AUC AAA GAU GCU G) dTdT 
siHIF1A_1530  Sense    r(CGA CAC AGA AAC UGA UGA C) dTdT 
      Antisense  r(GUC AUC AGU UUC UGU GUC G) dTdT 
siHIF2A_668    Sense    r(UCA GCU UCC UGC GAA CAC A) dTdT 
      Antisense  r(UGU GUU CGC AGG AAG CUG A) dTdT 
siRNA sequences target the sites of Hif1a and Epas1 mRNA as described originally by 
Sowter et al. (2003), and were synthesised by Qiagen. RNA/DNA oligonucleotides were 
resuspended in siRNA Suspension Buffer at 20mM concentration, heated at 90ºC for 1 
minute then 37ºC for 60 minutes to anneal duplexes, then stored at -20ºC. 54   
2.1.4. Plasmids 
pGEM-T Easy:  Promega  
pGL3basic:     Promega  
pGL3promoter:   Promega  
pHRE4 (pHRE4GL3, containing 4 repeats of the Epo HRE in pGL3promoter):    
      Ema et al. (1997) 
pCI_FL:    Peter McCarthy (Adelaide University) 
pRLTK:     Promega 
phRLCMV:    Promega 
2.2. Experimental Procedures 
2.2.1. Tissue Culture 
PC12 rat pheochromocytoma cells were grown in Dulbecco’s Modified Eagle Medium 
(DMEM) supplemented with 10% Horse Serum and 5% Fetal Calf Serum (FCS). Neuro-
2A mouse neuroblastoma and SK-N-SH human neuroblastoma cells were grown in 
Minimal Essential Medium (MEM) supplemented with 10% FCS. SK-N-BE(2)C human 
neuroblastoma cells were grown in RPMI-1640 supplemented with 10% FCS. Mouse 
embryonic fibroblasts (mEFs) were grown in DMEM supplemented with 10% FCS. 
Human Umbilical Vein Endothelial Cells (HUVECs) were a kind gift from Dr Claudine 
Bonder (Institute of Medical and Veterinary Science, South Australia), while mouse 
embryonic stem cell maintenance and differentiation in N2B27 medium was performed by 
Tom Klarić (Adelaide University), following previously established protocols for neural 
differentiation (Ying et al., 2003). All media contained both L-glutamine and phenol red, 
and cells were grown on standard tissue culture plasticware. 
Cells were maintained at 37ºC and 5% CO2, and passaged with trypsinisation when near-
confluent. Stocks of each cell-line were frozen in cryotubes in FCS supplemented with 
10% DMSO, using a “Mr. Frosty” (Nalgene) container to provide slow cooling to -80ºC. 55   
Cryotubes were then stored at -80ºC for a period of 6-12 months, or archived in liquid 
nitrogen storage.  
Hypoxic conditions were achieved by sealing the culture vessel inside an airtight container 
along with an AnaeroGen sachet (Oxoid). Testing of this procedure with an oxygen meter 
indicated that oxygen levels are depleted over the course of the first hour to less than 0.1% 
oxygen. Treatment times are given as the time from sealing the container. 
Dimethyloxalylglycine (DMOG) stocks were prepared at 1M in DMSO, while 2,2’-
Dipyridyl (DP) stocks were prepared at 100mM in DMSO, such that both chemicals were 
used at a dilution factor of 1000x in tissue culture medium. An equivalent amount of 
DMSO (0.1%) was used as a negative (vehicle) control. 
2.2.2. Total RNA Extraction and Northern 
Transfer 
Subconfluent PC12 and Neuro-2A cells were treated with normoxia, hypoxia, DMSO, 
DMOG or DP for 16 hours as described above. Total RNA for this and other methods was 
harvested by lysing cells in 1mL TriReagent (Sigma) as per the Sigma protocol 
(substituting 200mL chloroform for 100mL BCP at the biphase formation step), or by lysis 
in RLT/-mercaptoethanol (Qiagen) buffer and extraction using the Qiagen RNeasy Mini 
column kit. All manipulation of RNA or preparation of materials which come into contact 
with RNA was performed with either designated RNase-free reagents or cleaned with a 
solution consisting of 200 mM NaOH and 1% SDS. Extracted total RNA was dissolved in 
30-50mL H2O, 1ml of which was diluted in 99ml H2O for concentration quantification by 
spectrophotometry at 260nm using an Eppendorf BioPhotometer. RNA was also tested for 
purity by the measured A260/A280 ratio, and integrity of RNA was assessed by running 
1mL on a 1% agarose/TBE gel and visualising rRNA bands by ethidium bromide staining. 
10x MOPS buffer was prepared in H2O: 200 mM MOPS, 50 mM NH4Ac, 10 mM EDTA, 
to pH 7 with NaOH. To set a formamide/MOPS/1% agarose gel, 1.5 g of agarose was 
dissolved by boiling in 108 mL H2O, then cooled to around 65
ºC. At this point, 15 mL of 
10x MOPS buffer and 27 mL of formaldehyde was added and mixed in. The gel was then 
poured into a moulding apparatus and allowed to cool in a fumehood. 20 μg of each total 
RNA sample was diluted to a final concentration of 10 μL in H2O. 3μL MOPS buffer 56   
(10x), 10 μL formamide and 3.5 μL formaldehyde was added to each sample, mixed and 
heated at 65
oC for 10 minutes to denature RNA. The samples were then transferred to ice, 
and 0.5 μL ethidium bromide and 7 μL loading buffer added to each sample. The samples 
were loaded to the gel immediately after mixing, then the gel was run at 70V for 2 hours 
in 1x MOPS buffer, or until the loading dye had migrated to ¾ the length of the gel. After 
running, the gel was soaked twice for 15 minutes in H2O, then photographed under 70% 
UV-light. 
A transfer stack was constructed as follows, in order from the base to the top: dish 
containing 20x SSC buffer; gel support (upturned moulding apparatus); long piece of 
Whatmann paper as a wick, covering the support and extending into the 20x SSC; the gel 
containing the electrophoresed RNA (face down); slices of parafilm around the edge of the 
gel to prevent contact between the above paper and the wick; the Nytran membrane; three 
wet pieces of Whatmann paper, cut to membrane size; a 5-10 cm stack of paper towel, cut 
to the size of the membrane; a weight. Transfer occurred for around 24 hours at room 
temperature, after which the stack was disassembled and the membrane rinsed briefly in 
H2O. The RNA was then auto-UV-crosslinked (Stratagene Stratalinker) to the membrane 
and sealed in plastic for storage at 4
ºC until use. 
2.2.3. Generation of Radiolabelled Probes 
Due to high homology between sequences, cDNA probes for rat target sequences were 
used for probing both mouse and rat cell line extracts. Probes were excised from their 
corresponding pGEM-T Easy plasmid by digestion with EcoRI, then separated by 1% 
agarose gel electrophoresis. Bands of expected length were recovered by gel purification 
(Qiagen), and recovered DNA concentration was estimated by running a small amount on 
a second 1% agarose gel in comparison to the 1kb+ DNA ladder standard. 
200ng of DNA probe was used per 20mL of pre-hybridisation buffer in hybridisation 
flask. This DNA was added to 1μL of random dNTP hexamer (100 μM), and made up to 
14 μL with H2O. The DNA was denatured at 95ºC for 5 minutes, then cooled on ice. Next, 
2.5 μL of dNTPs(-dATP) (5 mM) and 2.5 μL of TM buffer (10x), then 5 μL of 
32P-dATP 
(10 μCi/μL) and 1μL of Klenow fragment (10U/μL) were added, mixed and incubated at 
37ºC for 1 hour. 25 μL of TE was added, and the labelled DNA fragments retrieved using 
ProbeQuant G-50 microcolumns. The reaction product was applied to the top of a 
prepared G-50 column, and centrifuged for 2 minutes at 3 kRPM into a fresh 57   
microcentrifuge tube. The eluant was diluted by addition of 150-350 μL 1xTE and stored 
at -20ºC until use. 
2.2.4. Hybridisation of Northern Transfer 
Membrane 
The membranes were blocked in 20mL of prehybridisation buffer, or 40mL if multiple 
membranes were being prehybridised simultaneously, overnight at 42ºC with slow 
rotation. Prehybridisation buffer: 50% formamide, 5x SSC, 50 mM NaPO4 (pH 6.5), 5x 
Denhardt’s solution, 0.1% SDS, 0.3 mg/mL sheared salmon sperm DNA in H2O. Labelled 
probes were heated at 95ºC for 5 minutes to denature the DNA, then cooled on ice for 5 
minutes before application to the membranes. All 400 μL of the labelled probe was 
transferred to the membrane in prehybridisation buffer, and was allowed to hybridise 
overnight at 42ºC with slow rotation.  
After hybridisation, the hybridisation buffer was replaced with 2x SSPE/0.1% SDS and 
washed for 15 minutes at 42ºC with rotation. This was repeated once with 2x SSPE/0.1% 
SDS at the same conditions, then finally the wash buffer was replaced with 0.1x 
SSPE/0.1% SDS and washed for 45 minutes at 65ºC. The membranes were then removed 
from the hybridisation flasks and sealed in plastic, then exposed to a phosphorimager 
screen for 48-72 hours. The phosphorimager screen was scanned to computer using a 
Typhoon Trio (Amersham Biosciences), and images were manipulated using QuantityOne 
(Bio-Rad) and Adobe Photoshop software.  
Probes were stripped from membranes with stripping buffer (10 mM Tris pH 7.5/0.1% 
SDS) and boiled in a microwave for at least 5 minutes. The membrane was then rinsed 
three times in RO water and sealed in plastic for storage at 4ºC until needed. 
2.2.5. Reverse Transcription of mRNA 
2mg of total RNA (generated as described in Chapter 2.2.2) was mixed with 1mL of 
300ng/mL random oligonucleotide hexamer and 1mL of 500ng/mL oligo(15)dT in a 
volume made up to 19mL with H2O, and annealed by heating to 70ºC for 10 minutes in a 
theromocycler, followed by 5 minutes on ice. These tubes were set up in duplicate for 58   
each RNA sample. Mastermixes are then prepared, resulting in each tube receiving 6mL 5x 
First Strand Buffer (Invitrogen), 2mL 0.1M DTT, 1mL 10mM dNTPs and 1mL SUPERase-
In RNase inhibitor (Ambion). To one tube (“cDNA”) 1mL Superscript III Reverse 
Transcriptase (RT) (Invitrogen) was added, while the other received 1mL H2O (“noRT”). 
Reactions progressed in a thermocycler set at 50ºC for 150 minutes, then 70ºC for 15 
minutes to inactivate the reverse transcriptase. cDNA was stored at -20ºC until use. 
2.2.6. Quantitative PCR 
Quantitative PCR was performed in triplicate on cDNA samples (qRT-PCR), while one 
reaction per no RT sample was also set up as a negative control. Reactions were set up on 
ice using 2x Fast SYBR Green Mastermix (Applied Biosystems) according to the 
manufacturer’s protocol: per reaction, 10mL 2x Fast SYBR Green Mastermix, 1.0mL 
cDNA or noRT sample (template), 0.4mL of left primer and 0.4mL of right primer (each at 
10mM), and 8.2mL H2O. Mastermixes of SYBR Green Mastermix and template were set 
up, mixed and added to wells of a 96well (BIOPlastics Cat#AB19809) tray first, followed 
by a mastermix of primer pairs and water. Trays were sealed with an Opti-Seal 
(BIOPlastics), then vortexed at low power to mix contents gently. Thermal cycling and 
detection was performed using the StepOne Plus (Applied Biosystems), using the 
following cycling parameters: 95ºC for 10 minutes, 95ºC for 15 seconds, 60ºC for 1 
minute and read tray, cycle to step two 39 additional times, then for melting curve analysis 
95ºC for 15 seconds, 60ºC for 1 minute, then ramping temperature by 0.3ºC increments, 
reading tray at each temperature. Primary amplification curves were analysed using the 
StepOne v2.1 (Applied Biosystems) software. Briefly, thresholds were set at the same 
point for an entire tray, at a level which aligned to the most reproducible detection of 
amplification yet below the end of the logarithmic amplification period. Resulting target 
Cycle(threshold) values (C(t)) were converted to arbitrary relative quantities with Polr2a 
or Actb as a reference gene using either StepOne or Q-Gene software (Muller et al., 2002), 
both of which use modified versions of the 2
-C(t) method (Livak and Schmittgen, 2001). 
These arbitrary values were then normalised to a control sample set at 1, to allow for 
comparison of fold change as a mean with standard deviation across n independent 
experiments and statistical analysis. For a new primer set, qRT-PCR products were run on 
a 3% agarose/TBE gel to confirm product size compared to expected size, then melt curve 
analysis was used in subsequent experiments to ensure specificity of amplification. 59   
To determine statistical significance of target gene fold change in expression, the mean 
and standard deviation of the independent normalised relative expression values were 
transferred to Excel (Microsoft). As the control to which comparison was being made is 
set at 1 (with no resulting standard deviation between independent experiments), Student’s 
t-test cannot be used, as this calculation can only compare two values each with error 
values. Therefore, 99% confidence intervals (p=0.01) for the experimental value were 
calculated using standard deviation and n. Significance was assigned (indicated by an 
asterisk) when the value 1 (control value) was outside of the 99% confidence interval of 
the experimental value. 
PCR efficiency of each primer pair was calculated by performing qPCR in triplicate on a 
set of serial dilutions of species-appropriate cDNA. This data was plotted to a log10/linear 
graph, and a line of best fit was calculated by Excel. The slope of this line was converted 
to an efficiency value (where 1 equals perfect amplification) using the equations below, 
with the aid of Q-Gene software. Primer pairs were accepted if E was greater than 0.9 and 
less than 1.1. 
        (     )   
Equation 2.1. Amplification of target DNA by PCR. Nc: Template amount after cycle C; No: 
Original template amount; E: PCR efficiency, between 0 and 1 (Adapted from Rutledge and Cote, 
2003). 
       (     )  
    
Equation 2.2. PCR efficiency calculation from log10[cDNA] vs C(t) standard curve, as depicted in 
Figure 6.1 (Adapted from Rutledge and Cote, 2003). 
2.2.7. Transfection of siRNA Duplexes 
SK-N-BE(2)C cells were plated at a confluency of around 40% in 6 well trays, in normal 
growth media. siRNA duplex sequences targeted towards Hif1a or Epas1 mRNA were 
ordered, as described by Sowter et al. (2003) and Chapter 2.1.3. For Figure 3.5a, cells 
were transfected the day after plating with 50nM of each siRNA and 5mL 
Lipofectamine2000 (Invitrogen), diluted in RPMI 1640 without serum as directed by the 
Invitrogen protocol. 12-24 hours later, media was replaced with normal growth media, 
before a repeat transfection using the same method. 12-24 hours later, media was once 60   
again replaced with normal growth media, supplemented with either 100mM DP or 0.1% 
DMSO (vehicle). After 8 hours treatment, media was removed and cells were lysed for 
total RNA extraction or western blot as described in other chapters. Cells for Figure 3.5b 
were treated in the same way, but volumes were scaled up to 6cm
2 dish scale. 
For Figure 3.6, a similar protocol was followed, with the following exceptions. Cells were 
transfected with 50nM siRNA and 5mL siLentFect (Bio-Rad) per well instead of 
Lipofectamine2000. Growth media was replaced 24 hours after the second transfection, 
and cells were grown for an additional 12-24 hours before treatment. Cells were treated 
with normoxia or hypoxia for 8 hours as described in Chapter 2.2.1, followed by lysis for 
total RNA extraction or western blot. 
2.2.8. Western Transfer 
Growth media was aspirated from cells, then cells were rinsed with cold 1x PBS and lysed 
in 80mL 1x Laemmli buffer with Protease Inhibitor Cocktail (2mg/mL aprotinin, 4mg/mL 
bestatin, 5mg/mL leupeptin and 1mg/mL pepstatin at final concentration) and 40mM DTT. 
2x Laemmli buffer consists of: 125mM tris-HCl pH 6.8, 20% Glycerol, and 5% SDS in 
H2O. 40mL of this whole cell extract mixed with was loaded with 13.3mL 4x SDS Gel 
Running Buffer: 50% glycerol, 0.05% bromophenol blue, 0.1mM EDTA pH 8 in H2O. 
This mixture was heated for 5 minutes at 95ºC, briefly centrifuged, then loaded to a 7.5% 
SDS/polyacrylamide gel. 5-10mL of Precision Plus Protein Dual Color Standard (Bio-
Rad) was also loaded in a separate lane. 7.5% Separating (lower) gel: 2.5mL Lower 
buffer, 1.875mL 40% 29:1 Bis-Acrylamide, 5.625mL H2O, 8mL TEMED and 80mL 10% 
ammonium persulphate; 4.5% Stacking (upper) gel: 2.5mL 4x Upper buffer, 1.13mL 40% 
29:1 Bis-Acrylamide, 6.37mL H2O, 8mL TEMED and 80mL 10% ammonium persulphate. 
Lower buffer: 181.1g tris and 40mL 10% SDS, made up to 1L with H2O, with pH adjusted 
to 8.8 with HCl. Upper buffer: 60.5g tris and 40mL 10%SDS, made up to 1L with H2O, 
with pH adjusted to 6.8 with HCl. The gel was run at 140V in 1x GTS until adequate 
separation between high molecular weight bands could be observed. 10x GTS solution: 
30.3g Tris base, 144g Glycine, 10g SDS, made up to 1L with H2O. 
Protein was transferred to nitrocellulose membrane (Pall) by wet transfer. Transfer 
apparatus was set up in transfer buffer from negative to positive as follows: mesh sponge, 
Whatmann paper, polyacrylamide gel (facing the negative side), nitrocellulose membrane, 61   
Whatmann paper, mesh sponge. 1x Transfer buffer: 10mL 10% SDS, 100mL methanol, 3g 
tris and 14.4g glycine, made up to 1L with H2O. Western transfer then progressed at 
250mA for 1½ hours in transfer buffer at 4ºC. After transfer, nitrocellulose membrane was 
stained briefly with 0.1% Ponceau in 5% acetic acid for visualisation of transfer 
effectiveness, and to facilitate cutting the membrane between the 75 and 50kDa size 
markers. Membranes were then blocked in 7.5% skim milk in 1x PBS for at least 1 hour. 
The high molecular weight portion of the membrane was probed for HIF-2 with anti-
HIF-2 rabbit antibody Cat# NB100-122 (Novus) diluted at 1:1000 in 1x PBS with 1% 
skim milk. Following detection, membrane was rinsed in 1x PBS and HIF-1 was 
detected with anti-HIF-1 mouse antibody Cat# 610959 (BD Biosciences) at 1:500 
dilution in 1x PBS with 1% skim milk. The low molecular weight portion of the 
membrane was probed for -Tubulin with anti--Tubulin rat antibody (Novus), diluted at 
1:10000 in 1x PBS with 1% skim milk. Primary antibody binding occurred overnight with 
rocking at 4ºC. Antibody solutions were poured off and stored at 4ºC with 0.02% sodium 
azide, while membranes were washed 3 times with rocking for 5 minutes in 1x PBS at 
room temperature. Horseradish Peroxidase (HRP)-conjugated secondary antibodies 
against rabbit, mouse or rat primary antibodies were then applied at 1:10000 dilution in 1x 
PBS for 1 hour at room temperature with rocking. Following this, antibody solutions were 
aspirated and membranes were washed 3 times in 1x PBS as previously. Membranes were 
then dried by blotting, and enhanced chemiluminescence reagents (Pierce and Millipore) 
were used to detect HRP by 1-10 minute exposure of X-ray film to membranes. 
2.2.9. Actinomycin D Treatment and mRNA 
Decay Calculation 
SK-N-SH or SK-N-BE(2)C cells were grown subconfluency in 8x 10cm
2 dishes 
containing 10mL growth media. Cells were treated by adding either 20mL of 2mg/mL 
actinomycin D (in DMSO, resulting in 4mg/mL final concentration), or an equivalent 
amount of DMSO as a negative control. Media was gently mixed in the dish by swirling, 
left for 10 minutes, then cells were treated with normoxia or hypoxia as described in 
Chapter 2.2.1 for 4, 8 or 12 hours, while a negative control sample was lysed immediately 
to determine starting relative expression levels. After treatment, cells were lysed and total 
RNA was extracted and expression levels quantified with qRT-PCR as described above. 62   
qRT-PCR results were analysed as described above to give Rgs4 mRNA levels relative to 
Polr2a for each time point, presented as a representative experiment in Figure 4.1a and d. 
As cDNA samples are normalised for total RNA amounts used in reverse transcription 
reaction, C(t) values without normalisation to reference gene levels were used to compute 
target gene mRNA half-life, to remove the effect of reference gene degradation. C(t) 
values were converted to values relative to basal expression levels using Equation 2.1 by 
setting N0 = 1 for normoxic control expression, giving an arbitrary common threshold 
value Nc. Values from two independent experiments were entered into Prism (GraphPad) 
and graphed as an x,y scatter plot with one phase decay line fitted, constraining the plateau 
to 0 as mRNA was assumed to become eventually undetectable as time approaches ∞. 
Calculated half-life ranges at 99% confidence were then computed by Prism software. 
2.2.10. Mammalian Luciferase Reporter Assays 
PC12 or SK-N-BE(2)C cells were plated in 24 well trays at 20-30% confluency in 2mL 
normal growth media per well. Cells were transfected twice (at 24 and 48 hours), each 
time by adding 1mL Lipofectamine2000 (Invitrogen), 100ng of pGL3 or 25ng of pHRE4 
firefly luciferase reporter and 25ng of phRLCMV renilla luciferase reporter in 0.5mL 
serum-free media per well. Reporter plasmids are described in Chapter 2.1.3. 100ng of 
pGFP was transfected in separate wells to assess transfection efficiency. Growth media 
was replaced before the second transfection, and before treatment. On the third day, cells 
were treated with 16 hours of normoxia or hypoxia as described in Chapter 2.2.1, 
following which media was aspirated and cells were lysed  in 100mL 1x Passive Lysis 
Buffer (Promega) per well, shaking for at least 20 minutes at room temperature. 10mL of 
lysate from each well was then measured using the Dual Luciferase System (Promega) 
reagents and Glomax luminometer (Promega). Luminometer plate read settings: Injection 
1 (Luciferase Assay Reagent II) 75mL, wait 3 seconds, integrate 10 seconds, injection 2 
(Stop and Glo reagent) 75mL, wait 3 seconds, integrate 10 seconds. Data was then 
processed with Excel (Microsoft) and Prism (GraphPad), and presented as a representative 
of three independent experiments. 63   
2.2.11. Published ChIP-seq Data Alignment and 
Analysis 
Chromatin immunoprecipitation with deep sequencing DNA detection (ChIP-seq) data for 
NPAS4, CBP, and PolII in mouse cortical neurons treated with either 2 hours KCl-induced 
membrane depolarisation or control culture conditions was retrieved from bigWig files 
provided in the supplementary figures of reference (Kim et al., 2010). These files were 
applied to the mm9 mouse genome assembly using the Genomes tab of the UCSC Genome 
Browser (Kent et al., 2002), and regions covering genes Drebrin (Chromosome 13, bases 
55450000-55700000) and Rgs4 (Chromosome 1, bases 171580000-171830000) were 
viewed (Figure 4.7). HRE-like sequences were searched for using the MBCS plug-in for 
Microsoft Word (Muller et al., 2001), and located in the UCSC Genome Browser using 
the each site’s flanking 20 bases.  64   
3. Rgs4 is Responsive to Hypoxia 
and the HIF Pathway 65   
3.1. Results 
3.1.1. Preamble 
The preliminary data described in Chapter 1.2 and background literature described in 
Chapter 1.3 suggest that the Rgs4 gene and its product are under the control of hypoxia-
sensitive pathways. In particular, the data described in Figure 1.4 show that exogenous 
expression of HIF-2 or hypoxic treatment of the rat pheochromocytoma PC12 cell line 
both result in increased expression of Rgs4 mRNA. However, it is not clear whether these 
responses are conserved in other species or even different cell types. It is also unclear 
whether this hypoxic response is dependent on the endogenous HIF pathway, as ectopic 
expression of HIF- factors could feasibly lead to activation of genes not normally 
affected by HIF. Finally, if the hypoxic response of Rgs4 is controlled by HIF, it is unclear 
whether this response is solely due to activity of HIF-2 or whether both HIF forms are 
involved, as overexpression of these proteins may distort their natural specificity between 
DNA binding target sequences.  
Therefore, the work described in this chapter aims to further explore the conditions in 
which Rgs4 mRNA is regulated by hypoxia, and to investigate whether the regulation of 
Rgs4 levels by hypoxia utilises the HIF pathway. 
3.1.2. Northern Blot Analysis of Rgs4 Response 
to Hypoxia and Mimetics 
The preliminary experiments of Figure 1.4 were initially extended by testing for a 
response of Rgs4 message to hypoxia in other cell lines, taken from different species and 
cell type origins. In the first instance, this selection included human embryonal kidney 
293T cells, mouse neuroblastoma Neuro-2A cells, and mouse P19 embryonal carcinoma 
cells in either undifferentiated, neural or muscle differentiation states. These were tested 
alongside the PC12 cell line that was originally used, as a positive control. These cells 
were treated with or without hypoxia for 16 hours before total RNA harvest and analysis 
by northern blotting. Rgs4 mRNA was not detectable in normoxic or hypoxic 293T cells, 
nor in any of the P19 cell treatments (data not shown). Rgs4 transcript was readily 66   
detectable at a higher level in hypoxic PC12 cells than in normoxic control cells as 
observed previously, but was also weakly detected in hypoxic but not normoxic Neuro-2A 
cells (Figure 3.1). Housekeeping gene -Actin was probed for as a loading and transfer 
control. Average fold change for Rgs4 in PC12 cells relative to -Actin was similar to the 
measurements in the preliminary data (Figure 1.4), while in the Neuro-2A cells fold 
change in message was not able to be calculated due to the lack of detection at normoxia. 
Vegf and Ldha were also probed for as a positive control for hypoxic gene activation in 
each cell line tested, as they are well characterised target genes of HIF, and were detected 
in all cases at elevated levels in response to hypoxia regardless of the detection of Rgs4. 
Weaker secondary bands were commonly seen after probing, most notably with -Actin 
and Ldha probes, and may relate to lowly expressed splice variants or non-specific 
hybridisation. In the case of the loading control, alignment of the coding sequences of 
actin family members -actin and -actin in rat result in over 80% identity, so multiple 
similar members from the actin family may be detected with one probe.  
The experiment was also extended to include treatment with dimethyloxalylglycine 
(DMOG) and 2,2’-dipyridyl (DP) for 16 hours, compared to vehicle (DMSO) controls. 
DMOG is an analogue of 2-oxoglutarate (2-OG), while DP chelates Fe-II. As the PHD 
and FIH regulatory enzymes require 2-OG and Fe-II to hydroxylate HIF-, treatment with 
these chemicals is known to stabilise and activate both HIF- subunits (Jaakkola et al., 
2001). Therefore, these hypoxia mimetic chemicals may be expected to provide a stimulus 
for activating the HIF pathway without activation of other hypoxia-responsive pathways. 
PC12 cells increased Rgs4 message in response to 16 hour treatment with either DMOG or 
DP relative to vehicle treatment, while Rgs4 was responsive to DMOG but not DP in 
Neuro-2A cells (Figure 3.1). Positive control Vegf and Ldha were upregulated in this cell 
line by both treatments, as expected. In all cases the fold change of Rgs4 mRNA in 
hypoxia-mimetic treated cells was slightly greater than that observed for hypoxia 
treatment, with the curious exception of DP treatment of Neuro-2A cells. 
In order to link these findings to human disease and other genetic information, and given 
the consistent hypoxic induction of Rgs4 in the neuroblastoma cell line, human 
neuroblastoma cell lines were selected for use in subsequent experiments. Initial 
experiments were performed using northern blotting (data not shown), but quantitative 
RT-PCR (qRT-PCR) used for subsequent analyses presented in the next chapter. 67   
 
 
Figure 3.1. Cultured rat pheochromocytoma PC-12 and mouse neuroblastoma Neuro-2A 
cells were treated for 16 hours with normoxia, hypoxia or hypoxia mimetics. 1mM 
dimethyloxalylglycine (DMOG) or 100mM 2,2’-dipyridyl (DP) was added to normal 
growth medium, while vehicle (0.1% DMSO) was used as a negative control. Following 
treatment, total RNA was analysed by northern transfer and detection of the indicated 
target mRNAs by 
32P-labelled cDNA probes and exposure to a phosphorimaging screen. 
Representative scans of at least two independent experiments are shown. 
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3.1.3. Response of Rgs4 in Human 
Neuroblastoma to Hypoxia and Mimetics 
The response of Rgs4 to hypoxia was next examined in human neuroblastoma cell lines. 
Quantitative RT-PCR was optimised in order to enable accurate quantification of changes 
in expression levels, increased sensitivity and a higher throughput of experiments. The 
results of optimisation and verification of this technique are presented in the appendix 
(Chapter 6.1.1). The SK-N-SH and SK-N-BE(2)C  are independent human cell lines 
derived from neuroblastoma biopsies, and therefore were expected to display a similar 
response to that observed in the mouse neuroblastoma cell line (Chapter 3.1.2). 
Neuroblastoma and pheochromocytoma are both cancers of the sympathetic nervous 
system, with pheochromocytoma arising from the chromaffin cells of the adrenal medulla, 
and neuroblastoma from primitive neuroblast cells of the developing sympathetic nervous 
system (reviewed by Fung et al., 2008). These human neuroblastoma lines were tested for 
Rgs4 response to a 16 hour treatment with hypoxia, DMOG or DP by qRT-PCR (Figure 
3.2). Neuro-2A (data not shown) and PC12 samples were retested by this method to 
compare the qRT-PCR detection method with the previously presented northern blots 
(Figure 1.4 and Figure 3.1). For PC12 cells, quantification by qRT-PCR gave a 4-fold 
response of Rgs4 to hypoxia, and a 3-fold response to either DMOG or DP treatment, 
which is consistent with the data obtained by northern blot. 
Three independent experiments were performed with the SK-N-SH cell line, with relative 
Rgs4 levels showing a statistically significant mean change of 4.8 fold in hypoxia, 4.3 fold 
in DMOG and 3.3 fold in DP, when comparing each treatment to appropriate negative 
controls (Figure 3.2a). Statistical analyses across the three independent experiments were 
performed using 99% confidence intervals for the treated samples compared to untreated 
samples as described in Chapter 2.2.6. Known HIF target gene also displayed significant 
responses to the treatments, albeit at a higher fold change than observed for Rgs4. Similar 
results were observed for the SK-N-BE(2)C (Figure 3.2b) and previously tested PC12 
(Figure 3.2c) cell lines, which are presented as representative qRT-PCR experiments of 
n=2 relative to Polr2a prior to normalisation to calibrator (negative control) sample. 
Therefore, the two human neuroblastoma lines are good models for investigating the 
hypoxic response of Rgs4, and show that this response is conserved over evolution 




Figure 3.2. (a) SK-N-SH cells were treated with normoxia, hypoxia, 0.1% DMSO (vehicle), 1mM 
DMOG or 100mM DP for 16 hours before target gene analysis by qRT-PCR. Mean fold change 
with standard deviation between three independent experiments is shown, with asterisks indicating 
that normoxic control lies outside of the 99% confidence interval of relative target gene 
expression. (b) SK-N-BE(2)C and (c) PC12 cell lines were tested in two independent experiments 
in the same manner, representative experiments are shown with standard deviation between three 
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Using the qRT-PCR technique, we also tested other cell lines for Rgs4 expression. cDNA 
samples of mouse embryonic stem cells undergoing neural differentiation generated by 
Tom Klarić were tested, (Figure 3.3a) and although Rgs4 could not be detected by qRT-
PCR in cultured undifferentiated mouse embryonic stem cells, after 3 days of neural 
differentiation triggered by growth in N2B27 medium Rgs4 was readily detectable. Rgs4 
was then further upregulated in continued neural differentiation until a maximum 
expression relative to Polr2a after 10 days of treatment. However, as only one set of 
differentiated cells were tested, and reference gene Polr2a expression was not stable 
across these samples, these results can be taken as preliminary only. Differentiated stem 
cells may therefore provide a non-cancerous model for testing the hypoxic regulation of 
Rgs4, however this was not attempted due to time constraints. Mouse embryonic 
fibroblasts (mEFs) were also tested by 16 hour normoxic or hypoxic treatment, showing 
strong upregulation of Vegf, while Rgs4 was detectable but not positively regulated by 
hypoxia (Figure 3.3b).  
3.1.4. Hypoxic Response is Specific for Rgs4 in 
Neural-like Cells 
As outlined in Chapter 1.3.3, it has previously been suggested that Rgs5 but not Rgs4 
message levels are responsive to hypoxia in Human Umbilical Vein Endothelial Cells 
(HUVECs) (Jin et al., 2009). Rgs4 and Rgs5 both encode members of the R4 subfamily of 
RGS domain proteins, and are both located in the human genome on Chromosome 1 
q23.3, separated by 50kb of intervening sequence. Experiments were designed to test for 
Rgs4 and Rgs5 hypoxic response in the SK-N-BE(2)C cell line in comparison to primary 
HUVECs. As Jin and colleagues report a maximum increase in Rgs5 after 3 hours hypoxic 
treatment, but a return to control levels after 24 hours of treatment, we treated cells for 0, 3 
or 16 hours with hypoxia. We then tested by qRT-PCR for Rgs4, Rgs5 and positive control 
Vegf expression relative to Polr2a (Figure 3.4). Across three independent experiments, 
Rgs4 and Vegf were significantly upregulated in SK-N-BE(2)C cells after hypoxic 
treatment, yet Rgs5 was not significantly responsive. Interestingly, no increase in Rgs4 or 
Rgs5 levels could be detected in hypoxic HUVECs, despite significant upregulation of 
positive control Vegf. Furthermore, small yet significant decreases in Rgs4 and Rgs5 (0.51 
and 0.69 fold change respectively) could be detected after the longer treatment with 




Figure 3.3. (a) cDNA samples from undifferentiated (day 0) and neural differentiated (N2B27 
medium treated) mouse embryonic stem cells were analysed for Rgs4 relative to Polr2a. (b) 
Mouse embryonic fibroblasts (mEF) were exposed to normoxia or hypoxia for 16 hours before 
cDNA preparation. In both figures, target genes were quantified relative to Polr2a in three 
replicate qRT-PCR reactions, on one set of experimental cDNA.   
Mouse Embryonic Stem Cells
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Figure 3.4. SK-N-BE(2)C and HUVEC cell cultures were treated with 0 (normoxia), 3 and 16 
hours of hypoxia before lysis and RNA extraction. Quantification of Rgs4, Rgs5 and Vegf mRNA 
levels relative to Polr2a was performed using qRT-PCR, then normalised to normoxic levels to 
give fold change. Mean fold change with standard deviation between three independent 
experiments is shown, with asterisks indicating that normoxic control lies outside of the 99% 
confidence interval of relative target gene expression.    
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response is detected, and further indicate that the hypoxic responses of Rgs4 in 
neuroblastoma and pheochromocytoma cells are observed in neural-like cell types only. 
3.1.5. Loss of HIF-1 or HIF-2 Impairs the 
Response of Rgs4 to 2,2’Dipyridyl 
The response of Rgs4 to hypoxia, the hypoxia-mimetic chemicals DMOG and DP, and to 
overexpressed HIF-2 in the PC-12 cell line strongly suggests that the HIF pathway is 
responsible for regulation of Rgs4. However, in order to directly test the involvement of 
HIF in this regulation, and the contribution of endogenous HIF-1 compared to HIF-2, 
experiments involving knockdown of Hif1a (encoding HIF-1) or Epas1 (encoding HIF-
2) were designed. RNA interference (RNAi) has been successfully used previously to 
knockdown Hif1a and Epas1 by transfection of small interfering RNA (siRNA) molecules 
to human cell lines (Sowter et al., 2003), so we applied the same technique with 
optimisation to the SK-N-BE(2)C cell line. A standard negative control siRNA tagged 
with AlexaFluor-546 was also used to control for non-specific RNAi and transfection 
effects, as well as allowing optimisation of transfection efficiency by microscopy (data not 
shown). 
After optimisation, siRNA-mediated knockdown of HIF-1 and HIF-2 in SK-N-BE(2)C 
cells was found to be most efficient after two rounds of transfection, and 8 hours of 
hypoxia or DP treatment. Both HIF-1 and HIF-2 are induced after 8 hours of treatment 
in these cells (Holmquist-Mengelbier et al., 2006), so it would be expected that at this 
timepoint both are functional and knockdown would cause a negative effect on target gene 
response. As a larger target gene response was observed in SK-N-BE(2)C cells following 
DP treatment compared to hypoxia (Figure 3.2c), we reasoned that this diminished 
response of HIF target genes due to siRNA-mediated knockdown would be most 
detectable following DP treatment. 
Sub-confluent SK-N-BE(2)C were plated, then transfected twice with 50nM of negative 
non-specific control siRNA, siHIF1A_1541 (targeted to Hif1a), siHIF2A_1599 (targeted 
to Epas1) or a combination of siHIF1A_1541 and siHIF2A_1599 (siHIF1 + siHIF2) 
before treatment with 100mM DP (or 0.1% DMSO vehicle control). Three independently 
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Figure 3.5. (a) SK-N-BE(2)C cells were transfected twice with 50nM siRNA using 
Lipofectamine2000 reagent, before 8 hours 0.1% DMSO vehicle (V) or 100mM DP treatment. 
Western blot was then performed for HIF-1, HIF-2 and Tubulin as indicated, with asterisks to 
indicate non-specific bands. (b) Following identical treatment, SK-N-BE(2)C cells were analysed 
for Rgs4, Vegf, Dec1, Hif1a and Epas1 expression levels relative to Polr2a by qRT-PCR. Mean 
fold change with standard deviation between three independent experiments, each normalised to 
the DP-treated level of expression of each gene after negative control siRNA transfection, is 
shown with asterisks indicating that normoxic control lies outside of the 99% confidence interval 
of relative target gene expression. (c) Representative experiment set up identically to (b), but using 
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Tubulin protein levels (Figure 3.5a), and by qRT-PCR for Rgs4, Vegf, Dec1, Hif1a and 
Epas1 transcript expression relative to Polr2a (Figure 3.5b). Expression was normalised 
to the DP-treated Control siRNA sample for each replicate, then mean and standard 
deviation was calculated across the three independent experiments for statistical analysis. 
Western blot analysis of identically-treated SK-N-BE(2)C cell cultures detected HIF-1 
and HIF-2 at decreased levels in the relevant siRNA transfected cultures, although 
reliable detection of HIF-2 was problematic despite repeated optimisation (Figure 3.5a). 
Similarly, partial knockdown of the HIF- subunits was observed by qRT-PCR, as Hif1a 
and Epas1 mRNA levels are decreased but still detectable upon relevant siRNA 
transfection. Unexpectedly, levels of both HIF encoding mRNAs were also found to 
change upon DP treatment alone, with Hif1a decreasing while Epas1 levels increased. 
Regulation of HIF- encoding mRNAs by hypoxia or hypoxia mimetics is not commonly 
observed in other cell types, therefore this result was investigated further in later 
experiments (Chapter 4.1.5). 
Induction by DP compared to vehicle was observed for known HIF target genes Vegf and 
Dec1, as well as Rgs4, in accordance with previous results (Figure 3.2b). Knockdown of 
HIF-1 but not HIF-2 significantly repressed induction of Vegf and Dec1 by DP 
treatment, yet knockdown of HIF-2a gave no significant effect on these target genes. Rgs4 
induction was significantly repressed by knockdown of either HIF-1 or HIF-2, but 
maximum repression of response required a combination of both HIF-1 and HIF-2 
knockdown.  
Unfortunately, the effectiveness of siRNA-mediated knockdown of HIF-1 and HIF-2 
was not consistent with repeated experiments. An identical protocol was used to transfect 
SK-N-BE(2)C cells with a secondary set of siRNA sequences targeted to the HIF- 
encoding transcripts: siHIF1A_1530 and siHIF2A_668. However, as shown by a 
representative experiment (Figure 3.5c), knockdown efficiency of HIF-1 was poor, as 
indicated by both Hif1a transcript knockdown and knock target gene (Vegf, Dec1) 
knockdown. Nonetheless, a small reduction in Rgs4 response can be observed with siRNA 
treatment against HIF-2. 77   
3.1.6. HIF- Knockdown has a Small Effect on 
Rgs4 Hypoxic Response 
To further test the requirement of the HIF pathway in Rgs4 regulation, siRNA-treated SK-
N-BE(2)C cells were also tested under hypoxic conditions, rather than with a hypoxia 
mimetic. SK-N-BE(2)C cells were transfected with the secondary set of duplex siRNAs in 
a similar fashion to the experiments of Chapter 3.1.5, following which cells were exposed 
to hypoxia for 8 hours before lysis for analysis by qRT-PCR (Figure 3.6). Due to ongoing 
optimisation, siLentFect transfection reagent was used, which resulted in more effective 
knockdown than previous experiments which used Lipofectamine2000. 
Hif1a and Epas1 message levels were significantly decreased in the appropriate siRNA-
transfected cells, and Hif1a and Epas1 responses to hypoxia were similar to the trends 
observed following DP treatment (Figure 3.5), as treatment results in a relative decrease in 
Hif1a levels and an increase in Epas1. Knockdown of either HIF- subunit caused 
significant decreases in the hypoxic response of known HIF target genes Vegf and Dec1, 
although knockdown of both HIF- subunits did not improve repression of the hypoxic 
responses of either target gene. Notably, knockdown of HIF-2 alone inhibited Vegf and 
Dec1 hypoxic response, where HIF-2 knockdown previously had little effect on the 
response of either of these genes to DP (Figure 3.5). 
In this experiment, knockdown of the HIF- subunits had a subtle negative effect on Rgs4 
upregulation. However, this effect was not consistent between the four independent 
experiments, resulting in a large standard deviation when taken together as displayed in 
Figure 3.6. As a result the effects of these siRNAs on Rgs4 hypoxic regulation were not 
statistically significant. This implies that the DP-induced activation of Rgs4 is somewhat 
different to hypoxia, and that Rgs4 is different in its response to both stimuli than Vegf and 
Dec1. 78   
 
Figure 3.6. SK-N-BE(2)C cells were transfected twice sequentially with 50nM siRNA using 
siLentFect reagent, before 8 hours normoxic (N) or hypoxic treatment. Total RNA was then 
prepared for analysis of Rgs4, Vegf, Dec1, Hif1a and Epas1 levels relative to Polr2a by qRT-PCR. 
Mean fold change with standard deviation between four independent experiments, normalised to 
the hypoxia-treated level of expression of each gene after negative control siRNA transfection, is 
shown with asterisks indicating that normoxic control lies outside of the 99% confidence interval 
of relative target gene expression. 
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3.2. Discussion 
3.2.1. Hypoxic Response of Rgs4 is Conserved, 
but Cell Type Specific 
The work presented in the previous chapters shows that Rgs4 is regulated by hypoxia in a 
cell type specific manner, and that the HIF pathway plays a role in this regulation. Rgs4 
mRNA is detected at increased levels after 16 hour hypoxic treatment of rat 
pheochromocytoma PC-12 and mouse neuroblastoma Neuro-2A cells by northern blot 
(Chapter 3.1.2), and subsequently in these cell lines along with human neuroblastoma SK-
N-SH and SK-N-BE(2)C cells by qRT-PCR (Chapter 3.1.3). The PC-12 samples also 
demonstrate the accuracy of the qRT-PCR method in comparison to northern blot, as a 
similar fold induction was obtained for quantification from both detection methods. The 
detection of a hypoxic response of Rgs4 between cells of rat, mouse and human species 
indicates that this response predates the divergence of humans and rodents in the 
Euarchontoglires clade of mammals. Conservation of such a response implies that 
upregulation of Rgs4 mRNA by hypoxia has an important physiological role. 
Rgs4, like other HIF targets such as Vegf, is upregulated by hypoxia-mimetic chemicals 
DMOG and DP, which are potent inducers of the HIF pathway. These chemicals inhibit 
the activity of 2-OG dependent hydroxylases, which includes the enzymes which 
hydroxylate key residues of HIF- in normoxia to inhibit HIF function (Chapter 1.1.2). 
Some off-target cellular effects would be expected from treatment with each of these 
chemicals or hypoxic treatment, yet the response of Rgs4 to both of these chemicals and 
hypoxia strongly implicates HIF in the regulation of this gene. One exception was 
observed, in which Rgs4 is responsive to hypoxia and DMOG treatment, but not DP in the 
mouse Neuro-2A cell line (Figure 3.1). This result is perplexing, as other HIF responsive 
genes Ldha and Vegf are upregulated by DP treatment in the same samples tested, 
therefore the treatment is activating the HIF pathway as expected. This observation was 
confirmed by qRT-PCR detection on the same RNA samples (n=3, data not shown). 
Therefore, the regulation of Rgs4 or the HIF pathway may be more complex in the Neuro-
2A cell line than in the PC12, SK-N-SH or SK-N-BE(2)C cell lines, so for simplicity 
Neuro-2A cells were not used for further analysis (Chapter 4). 80   
Rgs4 is known to be expressed in the cardiovascular system (Chapter 1.3.6), and Jin et al. 
(2009) describe detection of both RGS4 and RGS5 protein in Human Umbilical Vein 
Endothelial Cells (HUVECs). Furthermore, experiments presented in that publication 
show increased Rgs5 mRNA and protein levels in hypoxia-treated HUVECs, yet RGS4 
protein levels did not change and Rgs4 mRNA levels were not tested. In the experiments 
presented in this thesis, HUVECs were compared to a neuroblastoma cell line, using both 
3 and 16 hour hypoxia treatments, as the published Rgs5 response in HUVECs was 
observed to be maximal at the 3 hour timepoint (Jin et al., 2009). The results in this thesis 
disagree with the published data for Rgs5, as Figure 3.4 shows a hypoxic response at both 
timepoints for Vegf in HUVECs, but no positive change in either Rgs4 or Rgs5 mRNA, 
and actually a modest but statistically significant decrease in levels of both after 16 hours 
of treatment relative to Pol2a. However, the lack of hypoxic regulation of RGS4 in 
HUVECs presented by Jin et al. (2009) is supported by these results. Additionally, Rgs4 
and Vegf respond to hypoxia in SK-N-BE(2)C neuroblastoma cells, but Rgs5 levels are not 
significantly responsive at either treatment timepoint. This shows that the response of 
Rgs4 to hypoxia is not a general property of RGS encoding genes, and also that Rgs4 
responds to hypoxia only in a subset of cell types in which it is expressed. 
The differences between the results presented in this thesis and those published by Jin et 
al. (2009) are difficult to reconcile, but the published results show only a modest 2-fold 
change in Rgs5 mRNA, normalised to 28S RNA levels detected before northern transfer, 
which do not account for slight errors in transfer or probing. Jin et al. (2009) also present 
Rgs5 promoter reporter studies showing a maximum 2 fold change in relative luciferase 
activity, so even if this transcriptional response is real it may be difficult to reproducibly 
detect. The published experiments use an oxygen-regulated chamber to achieve 1% 
atmospheric oxygen, whereas the experiments presented in this thesis use AnaeroGen 
sachets in sealed containers, which achieve a final oxygen concentration of below 0.1%, 
so different hypoxic treatment conditions may also explain the differences in results. 
Furthermore, Jin et al. (2009) do not present positive controls for hypoxic gene response, 
so the efficiency of hypoxic treatment and HIF pathway induction in these published 
experiments is not clear. Nonetheless, our experiments show that the hypoxic response of 
Rgs4 in neuroblastoma is of a greater magnitude than that of Rgs5, which is not 
upregulated in either cell type at 0.1% oxygen.  81   
Rgs4 was not detected in many of the other cell types tested in either normoxia or hypoxia, 
suggesting that the Rgs4 gene is silenced in these cell types. However, as Rgs4 transcript 
is readily detectable in both neuroblastoma and HUVEC samples, but responsive to 
hypoxia in neuroblastoma and not the endothelial cells, HIF activity on the Rgs4 gene 
does not appear to be the only requirement for hypoxic induction for the gene. Vegf is 
responsive to HIF in both cell types, so Rgs4 may have a more complex mechanism of 
regulation than other HIF target genes. As Rgs4 is not silenced in HUVECs, there may be 
factors which prevent HIF activity on Rgs4 transcription in a HUVEC context, or 
alternatively factors which allow HIF activity on Rgs4 in neuroblastoma cells. 
These experiments suggest that the hypoxic response of Rgs4 is limited to certain cell 
types. Although a thorough set of Rgs4-expressing cells has not yet been tested, the only 
cell types discovered with a positive Rgs4 hypoxic response have been derived from 
neuroblastoma or pheochromocytoma. These are both cancers of the sympathetic nervous 
system (SNS), and these derived cells are both able to be differentiated to neural cells with 
Nerve Growth Factor (NGF) treatment, so Rgs4 hypoxic response may be limited to 
neural-like cells or even restricted to only cells of the SNS. Alternatively, there may be 
other types of cells which respond to hypoxia with upregulation of Rgs4 transcript that 
have not yet been tested. To test these alternatives, a more comprehensive approach would 
involve in situ hybridisation for Rgs4 using mice treated with systemic hypoxia, to test for 
tissues which exhibit Rgs4 hypoxic response. In situ hybridisation could also be used to 
compare Epas1
-/- and wildtype mice, as Epas1
-/- mice can develop to birth in certain 
genetic backgrounds (Scortegagna et al., 2003a). In this case, impaired HIF signalling may 
affect normal Rgs4 expression in some tissues.  
To test whether the Rgs4 response is specific to cancerous cells, the sympathetic nervous 
system or a general phenomenon for neural-like cells, mouse embryonic stem (mES) cells 
in different states of differentiation can also be tested. Figure 3.3a shows that Rgs4 is 
readily detectable in mES cells after 3 days of neural differentiation in N2B27 medium, so 
cells at representative stages of this process could be treated with normoxia or hypoxia and 
tested for Rgs4 expression. Finally, elucidation of the molecular mechanisms behind HIF 
activation of Rgs4 in neuroblastoma may determine whether additional factors are 
required for this response, which may in turn aid in prediction of cell types express 
increased levels of Rgs4 in hypoxia. Experiments on this approach are described in 
Chapter 4.  82   
3.2.2. Rgs4 is Regulated by Both HIF Forms  
To directly test the role of endogenous HIF in the regulation of Rgs4, siRNA duplexes 
antisense to HIF-1 or HIF-2 were transfected to human neuroblastoma cells. Two 
siRNA sequences against Hif1a and Epas1 were used to control for off-target effects, but 
as these sequences have been used before in several publications (Chen et al., 2009; Lau et 
al., 2007; Raval et al., 2005; originally by Sowter et al., 2003), specificity to the 
respective HIF- transcripts was not expected to be problematic. Despite problems 
visualising HIF-2 knockdown by western blot due to poor antibody specificity, 
knockdown of both proteins after DP treatment was detected and transcripts of both HIF- 
encoding genes were observed to be significantly lower when targeted with either primary 
siRNA sequences (Figure 3.5a,b). Only partial knockdown of Hif1a or Epas1 transcripts 
were observed by qRT-PCR, although some additional knockdown effect may be expected 
through inhibition of message translation, as protein knockdown of HIF-1 appears to be 
greater than that observed at the message level.  
Known HIF target genes Vegf and Dec1 both exhibit a smaller response to hypoxia when 
siRNA against both HIF- subunits is employed, showing that the HIF- knockdown is 
functional but still incomplete. However, considerable variation between experiments 
occurred in terms of knockdown efficiency, despite repeated attempts at optimisation. In 
the case of experiments using the secondary siRNA sequences and DP treatment (Figure 
3.5c), inconsistent knockdown was observed which could possibly be attributed to varying 
transfection efficiencies resulting from differences between frozen stocks of the same cell 
lines. The same sequences acted at a greater efficiency on cells treated with hypoxia in a 
later experiment, although a modified protocol using a different transfection reagent was 
used. These problems may be remedied by viral transfer of short hairpin-encoding genes, 
or possibly use of conditional Hif1a or Epas1 mouse ES cells differentiated to neural 
precursor cells, if such cells behave in a similar fashion to these neuroblastoma cell lines 
in terms of hypoxic Rgs4 regulation 
Cells transfected with siRNA were exposed to 8 hours of treatment with either DP (Figure 
3.5) or hypoxia (Figure 3.6), a treatment period at which protein levels of both HIF-1 
and HIF-2 are expected to be strong (Holmquist-Mengelbier et al., 2006). At this 
timepoint, knockdown of either HIF-1 or HIF-2 during DP treatment resulted in a 
modest yet significant reduction in the response to either treatment of Rgs4, while 83   
knockdown of both HIF- subunits resulted in a larger reduction. Positive controls Vegf 
and Dec1 were affected only by siRNA directed against HIF-1. Therefore, in terms of 
DP response, Rgs4 is regulated by both HIF-1 and HIF-2, such that only loss of both 
forms effectively prevents hypoxic gene induction, while Vegf and Dec1 act as HIF-1 
targets alone.  
This result is somewhat contrary to the preliminary results observed in the inducible HIF-
 TetON PC-12 cell lines, where overexpression of HIF-2 resulted in increased Rgs4 
mRNA, while overexpressed HIF-1 did not (Figure 1.4). However, knockdown of 
endogenous proteins is a more biologically relevant experiment to determine the effect of 
each subunit than overexpression of a cDNA, as overexpressed proteins can overload 
other endogenous regulatory pathways or bind DNA with lowered specificity and 
therefore act in a non-physiological manner. Therefore, the most logical conclusion is that 
both HIF forms are capable of transactivating Rgs4 expression in neuroblastoma. There is, 
however, a possibility that there are differences in HIF selection between cell types or 
even species, as these siRNA experiments have only been performed in human 
neuroblastoma and not the rat pheochromocytoma cells. 
However, inconsistent results were observed when the HIF- subunits are targeted by 
siRNA in hypoxic rather than DP treatment. Knockdown of either HIF- subunit 
successfully inhibited the hypoxic regulation of Vegf and Dec1, yet only a small and 
inconsistent decrease in Rgs4 regulation was observed. The reason for this difference 
between hypoxic and DP treatments is not clear. Different HIF target genes may not have 
the same sensitivity to a partial loss of HIF- protein by siRNA, such that a more efficient 
knockdown of HIF is required to significantly inhibit the response of Rgs4. This would be 
supported by the variability observed, as in some independent experiments good inhibition 
of Rgs4 hypoxic response was observed, while in other cases no change could be detected 
at all. Alternatively, there may be other hypoxia-responsive but not DP-responsive 
pathways that can compensate for the loss of HIF in regulation of Rgs4 in hypoxia only. 
One of the few transcription factors to have been shown to directly upregulate Rgs4 is NF-
. Treatment of rabbit smooth muscle cells with interleukin-1 (IL-1) causes 
phosphorylation of IKK2 and degradation of I, two events which form part of the 
canonical NF- activation pathway, resulting in modestly increased Rgs4 mRNA and 
protein levels (Hu et al., 2008). An NF- binding site was discovered in the rabbit Rgs4 84   
5’ proximal promoter 179bp upstream of the transcription start site, where NF- subunit 
p65 binding could be detected by chromatin immunoprecipitation (Li et al., 2010b). 
Although this site is not completely conserved between rabbit and human sequences, 
luciferase reporter assays indicate that IL-1 treatment is able to activate transcription 
from both the rabbit and human Rgs4 promoters (Li et al., 2010b). NF- signalling is 
also known to be activated by hypoxic treatment in some cellular contexts, apparently 
through a tyrosine kinase pathway (Koong et al., 1994a; Koong et al., 1994b). However, 
the reporter assays described in Chapter 4.1.6 do not detect any hypoxic response in an 
area of the Rgs4 promoter which would cover the equivalent NF- binding site from the 
rabbit genome (Li et al., 2010b). Therefore, hypoxic response compensation by NF- in 
this context is unlikely. 
HIF-1 and HIF-2 are known to be stabilised differentially in these neuroblastoma cell 
lines. HIF-1 is the predominant form in acute hypoxia, rapidly reaching maximal protein 
levels within 2 hours of exposure to hypoxia, then gradually decreasing after 8 hours, 
while HIF-2 accumulates to a maximum after 24 or more hours of hypoxic treatment 
(Holmquist-Mengelbier et al., 2006). Therefore, genes under preferential control of either 
HIF form may be expected to show a related pattern of induction across a hypoxia 
timecourse. Experiments performed in the next chapter give results which imply that Rgs4, 
Vegf and Dec1 are all target genes of both HIF-1 and HIF-2, as these target genes are 
upregulated in both acute (1-4 hours) and chronic (8-16 hours) hypoxic treatments (Figure 
4.3). 
The hypoxic regulation of HIF- encoding mRNAs Hif1a and Epas1 is an interesting 
result, as it may shed some light on the mechanisms behind the aforementioned 
differences in HIF-1 and HIF-2 protein levels over hypoxic treatment time. Hif1a 
message was detected at a decreased level after 8 hours treatment with hypoxia (Figure 
3.6) or DP (Figure 3.5), while Epas1 message was increased in the same treatments. As 
inhibition of the HIF-regulatory PHD and FIH enzymes is the intended cellular effect of 
DP treatment, the response of Hif1a and Epas1 mRNA to DP implies that this regulation 
may be downstream of post-translational HIF activation by the PHD and FIH enzymes. In 
this way, a negative (Hif1a) or positive (Epas1) feedback loop may be affecting the 
changes in HIF-a protein observed in chronic hypoxia. Such regulation of the HIF- 
encoding genes is not commonly reported for most cell lines, however Holmquist-
Mengelbier et al. (2006) report similar positive changes for Epas1 mRNA in SK-N-85   
BE(2)C cells at 5% and 1% hypoxia, yet more modest negative changes in Hif1a. The 
exact nature of this regulation is expanded upon in Figure 4.4a and discussed in greater 
detail in Chapter 4.2.3. 
Chromatin immunoprecipitation could help to further define the role of HIF-1 and HIF-2 
in Rgs4 regulation, however it has been difficult to determine a HIF binding site at the 
Rgs4 locus (see Chapter 4.2.2), and more importantly, presence of HIF at a locus is not 
sufficient for activation of transcription, as target gene selection appears to act after DNA 
binding (Hu et al., 2007; Lau et al., 2007; Mole et al., 2009). As previously described, 
mouse knockout models could be used to further pursue the in vivo specificity between 
HIF-1 and HIF-2 in transactivation of Rgs4. 
Taken together, the data presented within this Chapter implicate both HIF-1 and HIF-2 
in the regulation of Rgs4 by hypoxia. Furthermore, the hypoxic regulation of Rgs4 is cell 
type specific, unlike other known HIF target genes such as Vegf. HIF is likely to play a 
major role in hypoxic regulation of Rgs4, however the contribution of other unknown 
hypoxia-responsive pathways cannot be determined without a more complete 
experimental protein knockdown system.  
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4. The Molecular Mechanism of 
Rgs4 Response to Hypoxia 87   
4.1. Results 
4.1.1. Preamble 
As Rgs4 is regulated in some cell types by hypoxia and the HIF pathway, and the HIF 
transcription factors can directly bind and activate transcription of promoters, the simplest 
hypothesis is that HIF directly activates transcription of Rgs4 in hypoxia. However, HIF is 
also known to activate transcription of other transcription factors such as DEC1, and 
specific micro RNA (miRNAs) transcripts, and could feasibly activate expression of RNA 
stabilising proteins, all of which could in turn regulate Rgs4 mRNA levels as secondary 
effectors. There are also examples of RNA-binding proteins which can alter stability or 
translation of target mRNAs in response to hypoxia independent of the HIFs, such as HuR 
(reviewed by Masuda et al., 2009).Therefore, in order to implicate direct activity of HIF or 
other transcription factors on Rgs4 transcription, experiments were designed to test 
whether Rgs4 is regulated in hypoxia by transcriptional or post-transcriptional 
mechanisms, whether the response of Rgs4 occurs in a similar timeframe to other direct 
HIF targets, and whether a hypoxia responsive enhancer element could be found at the 
Rgs4 locus. 
4.1.2. Rgs4 Hypoxic Response is Dependent on 
Transcription 
To test whether hypoxic Rgs4 mRNA accumulation was dependent on transcription, RNA 
degradation assays were performed in both SK-N-BE(2)C and SK-N-SH cells. Cells were 
plated and treated with 4mg/ml of actinomycin D to block transcription, then subjected to a 
timecourse of hypoxic or normoxic treatment. Rgs4 mRNA was quantified by qRT-PCR 
relative to an untreated normoxic control. Untreated cells were also included in the 8 hour 
hypoxia treatment as a positive control for normal Rgs4 regulation. No difference in Rgs4 
levels was observed between the actinomycin D treated or untreated cells at any of the 
normoxic or hypoxic timepoints in SK-N-BE(2)C (n=2) or SK-N-SH (n=2) cells (Figure 
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Figure 4.1. (a) SK-N-BE(2)C cells were treated with 4mg/ml actinomycin D prior to treatment for  
4, 8 or 12 hours with normoxia or hypoxia. Actinomycin D-untreated cells were also used to 
determine control normoxic (0 hours) and hypoxic (8
# hours) Rgs4 levels. Rgs4 mRNA levels 
were quantified using qRT-PCR relative to Polr2a, then normalised to normoxic levels. One 
representative of n=2 is shown. (b) Experiments from (a) were replicated using SK-N-SH cells, a 
representative of n=2 is shown. For SK-N-BE(2)C data from (a), Rgs4 (c) and Polr2a (d) mRNA 
levels relative to total RNA were also calculated from C(t) values without normalisation to 
reference gene relative to normoxia. The mean detection with standard error (n=2) is plotted to 
give a one-phase decay using GraphPad Prism 5. Estimated mRNA half-lives are described in the 
text. 
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The mean detected levels of Rgs4 and Polr2a without normalisation to reference gene for 
SK-N-BE(2)C cells were also plotted against time for normoxic and hypoxic treatments, 
in order to calculate the rate of mRNA degradation by fitting the these points to a one 
phase exponential decay curve (Figure 4.1c,d). For this graph, raw C(t) values for Rgs4 
and Polr2a were converted to relative amounts by setting the normoxic level of transcript 
in each experiment to 1 (such that for normoxic samples, N0 = 1 giving an aribitrary 
threshold value Nc, see Equation 2.1, Chapter 2.2.6). Given that the same amount of total 
RNA was used in cDNA generation, and the same amount of cDNA was used in each 
qRT-PCR reaction, the half-life of Rgs4 and Polr2a mRNA can be estimated for each 
curve. Polr2a is unresponsive to hypoxia, so no difference is expected in its degradation in 
either condition, while any differences in Rgs4 half-life would be due to transcription-
independent regulation of Rgs4 message stability. The one-phase decay curve for Rgs4 
(Figure 4.1c) gave 99% confidence intervals for message half-life of 3.53 - 4.03 hours in 
normoxia, and 3.96 – 4.55 hours in hypoxia. For comparison, the calculated half-lives for 
Polr2a message were 6.57 – 10.72 in normoxia, and 8.22 – 15.39 hours in hypoxia 
(Figure 4.1d). Similar half-lives were determined by applying the same calculations to the 
SK-N-SH cell line data (not shown).  
These data demonstrate that there is no substantial change in Rgs4 mRNA stability in 
response to hypoxia, and the small change that is observed is similar to that observed with 
Polr2a. Given the previously demonstrated robust induction of Rgs4 (Figure 3.2), it is 
clear from the results presented here that the hypoxic accumulation of Rgs4 mRNA 
requires active transcription. 
4.1.3. The Rgs4 3’UTR does not Confer Hypoxic 
Regulation 
The 3’ Untranslated Region (3’UTR) of Rgs4 has regions of high conservation through 
mammalian evolution according to the UCSC genome alignment browser (Kent et al., 
2002). This indicates that there may be functional elements within the 3’UTR which could 
regulate the stability of Rgs4 mRNA. Although the previous experiments show 
transcription is required for hypoxic induction, there is a possibility that hypoxia activates 
transcription of a miRNA or RNA-binding protein. 91   
In order to test for hypoxia-responsive RNA elements in the human Rgs4 3’UTR, the 
entire 3’UTR  was cloned to the XbaI site downstream of the firefly luciferase (luc
+) 
coding sequence in the pCI_FL plasmid, upstream of the SV40 late polyadenylation 
signal. This plasmid has a CMV promoter driving expression of luciferase, as well as a 
chimeric intron in the 5’UTR of luc
+ in order to ensure processing by post-transcriptional 
machinery. The pCI_FL(hRgs4-3’UTR) construct was transfected to SK-N-BE(2)C cells 
and tested for hypoxic luciferase response in comparison to pCI_FL which contains no 
3’UTR, relative to a constitutive renilla luciferase expressing plasmid using the Dual 
Luciferase system (Figure 4.2). Over three independent experiments a small change in 
relative luciferase levels was observed between normoxia and hypoxia treatments, but this 
was observed with or without the presence of the Rgs4 3’UTR. Furthermore, the change 
observed is too small to account for the level of Rgs4 mRNA induction observed in SK-N-
BE(2)C cells by qRT-PCR (Figure 3.2), indicating that the Rgs4 3’UTR is unlikely to 
make a substantial contribution to the hypoxic induction of Rgs4 mRNA or RGS4 protein. 
Notably, presence of the Rgs4 3’UTR did lower relative luciferase readings by around 2-
fold in both conditions compared to the control plasmid, which suggests the presence of an 
inhibitory element within this 3’UTR.  
4.1.4. Rgs4 is Co-regulated with Other Known 
HIF Targets 
The above experiments show that hypoxic regulation of Rgs4 mRNA is dependent on 
transcription (Chapter 4.1.2) and not dependent on the Rgs4 3’UTR (Chapter 4.1.3), and 
that Rgs4 is not only responsive to hypoxia but also hypoxia mimetics that activate the 
HIF pathway (Chapter 3.2.2). Therefore, the simplest and most likely hypothesis is that 
Rgs4 is regulated at the transcriptional level as either a direct HIF target, or as a secondary 
response through other transcription factors under the direct transcriptional control of HIF. 
To ascertain which of these mechanisms is more likely to be occurring, a series of 
timecourse experiments were performed.  92   
 
Figure 4.2. SK-N-BE(2)C cells were plated in triplicate in 24-well trays and transfected twice 
sequentially with 100ng of pCI_FL or pCI_FL incorporating the 3’UTR of human Rgs4 between 
the luc
+ coding sequence and polyadenylation sequence (pCI_FL(hRgs4_3’UTR)), along with 
25ng of phRLCMV as control for transfection efficiency and survival. Separate wells were also 
transfected with pHRE4 as a positive control for hypoxia treatment (see Figure 4.6d, as both 
experiments were performed concurrently). Cells were treated with hypoxia for 16 hours, then 
lysed in Passive Lysis Buffer for analysis using the Dual Luciferase System (Promega). Mean 
Relative Luficerase Units with standard deviation from 3 replicate wells of one experiment are 
shown as a representative of n=3. 
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Other direct HIF target genes such as Vegf and Dec1 are well characterised in terms of 
their response to HIF, as both have defined HREs in their promoters which have been 
verified by chromatin immunoprecipitation (Gray et al., 2005; Holmquist-Mengelbier et 
al., 2006), reporter assays and electrophoretic mobility shift assays (Liu et al., 1995; 
Miyazaki et al., 2002). Dec1 encodes DEC1 (also known as BHLHB2), a direct negative 
regulator of Mlh1 transcription (Nakamura et al., 2008), making Mlh1 repression an 
example of a secondary HIF responsive gene. Therefore, if Rgs4 is a direct HIF target 
gene, the time between hypoxic treatment and response should be similar to that of Vegf 
and Dec1, whereas if Rgs4 is regulated by a secondary HIF-responsive transcription 
factor, it will respond in a similar time to Mlh1.  
Three independent timecourse experiments were performed, where SK-N-BE(2)C cells 
were exposed to increasing periods of DP treatment before RNA harvest and qRT-PCR 
(Figure 4.3). Rgs4 mRNA was detected at significantly increased levels after only 1 hour 
of DP treatment, as were Vegf and Dec1. The levels of these transcripts continued to 
increase until a maximum at 4 hours, after which they remained effectively constant. 
However, levels of secondary response gene Mlh1 (indirectly repressed by HIF) were not 
significantly altered until 4 hours of hypoxic treatment, when levels were significantly 
lowered, reaching a minimum after 8 hours. Therefore, Rgs4 response time to DP is 
consistent with it being a direct HIF target gene.  
4.1.5. Hif1a and Epas1 are Co-regulated with 
Secondary HIF Targets 
SK-N-BE(2)C cells are known to display an alternative pattern of HIF- stabilisation to 
most cell types during prolonged hypoxia. As described previously (Chapter 1.1.4, Figure 
1.2d), in short-term hypoxia these cells stabilise HIF-1 rapidly, yet HIF-2 protein 
stabilisation is delayed. After 8 hours of continuous hypoxia, HIF-1 protein levels 
gradually decrease, while HIF-2 becomes more prominent (Holmquist-Mengelbier et al., 
2006). Altered Epas1 mRNA levels in hypoxia have previously been described for this 
cell line, although no change in Hif1a levels has been reported (Holmquist-Mengelbier et 
al., 2006). To test whether this effect may be related to altered mRNA levels, we subjected 
the three independent SK-N-BE(2)C samples generated for Figure 4.3 to qRT-PCR for 
Hif1a and Epas1 transcripts (Figure 4.4a). Epas1 message was significantly upregulated  94   
 
 
Figure 4.3. SK-N-BE(2)C cells were treated with 100mM DP for 1, 2, 4, 8 or 16 hours in 
comparison to an untreated (0 hours) control. Rgs4, Vegf, Dec1 and Mlh1 message levels were 
quantified by qRT-PCR relative to reference gene Polr2a, then normalised to normoxic levels. 
Data is presented as the mean and standard deviation from three independent experiments. 
Asterisks indicate 99% confidence in difference from normoxic levels.   
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Figure 4.4. (a) SK-N-BE(2)C cDNA samples tested in Figure 4.3 were also analysed for Hif1a 
and Epas1 message levels, relative to Polr2a and negative control levels. Asterisks indicate 99% 
confidence in difference from control levels, n=3. (b) Data from (a) and Figure 4.3 plotted 
together on a proportional x-axis and log2 y-axis. 
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only after 4 hours of hypoxic treatment, to a maximum induction of approximately 6.5 
fold at or after 16 hours. Similarly, Hif1a message did not change until 4 hours of hypoxic 
treatment, where upon levels were significantly decreased to a minimum 3-fold reduction 
at and after 8 hours. Figure 4.4b depicts this data on a proportional x-axis, with a log2 y-
axis to emphasise similarities between message level increases and decreases. Both Hif1a 
and Epas1 mRNA levels respond to hypoxia at a similar time to Mlh1, a gene regulated 
indirectly by HIF, indicating that this regulation is likely to be a secondary response to 
hypoxia. 
4.1.6. Reporter Assays do not Detect an Rgs4 
Proximal Hypoxia Responsive Enhancer 
The evidence presented in Chapters 4.1.2, 4.1.3 and 4.1.4 strongly suggests that Rgs4 
mRNA hypoxic regulation is mediated by direct binding of HIF and activation of 
transcription at the Rgs4 locus, rather than through secondary effectors. As this response is 
conserved between rat, mouse and human cell lines (Chapter 3.1.2 and 3.1.3), a 
bioinformatics search was performed for HIF binding sites (HREs) at the Rgs4 locus in 
both the rat and human genome. HIF is able to bind and induce transcription from cloned 
HREs in transient transfection reporter gene assays, and there are numerous experiments 
in the literature which use this method to determine HRE positions (for examples, see 
Firth et al., 1995; Liu et al., 1995; Miyazaki et al., 2002), many of which have been later 
verified by ChIP experiments. Therefore, we cloned overlapping regions of the rat and 
human Rgs4 loci and tested them for hypoxic response in luciferase reporter assays, in an 
attempt to keep the search as unbiased as possible.  
The minimal HRE consensus sequence has been previously determined from known 
genomic HIF binding sites as RCGTG (Wenger et al., 2005), which can occur in either 
forwards or reverse orientation relative to a Transcription Start Site (TSS). However, due 
to their short length RCGTG sequences occur frequently in the genome, and most of these 
sites do not act as functional HREs. The other factors determining the whether a RCGTG 
sequence can bind HIF functionally are mostly unknown, although other nearby sequences 
and binding factors do have some role (see Chapter 1.1.3). The majority of HREs are 
found within 2kb of the TSS of a regulated gene (Mole et al., 2009), but there are 97   
examples of more distant functional HREs, such as that of the Phd3 gene which is found 
over 10kb from its TSS (Pescador et al., 2005). 
Various fragments of the rat Rgs4 proximal promoter were amplified and cloned from PC-
12 genomic DNA by PCR of sequences 5kb upstream of the TSS (Figure 4.5a). Ten 
RCGTG sequences of either orientation were identified in the 5kb rat Rgs4 promoter 
region. Amplified fragments were cloned to pGem-T Easy for sequencing and comparison 
to expected sequences from the UCSC Genome Browser, then subcloned to the pGL3-
basic luciferase reporter construct. Fragments were cloned into pGL3-basic such that the 
TSS of Rgs4 and a small sequence of the 5’UTR were ligated to the NcoI site at the start 
of the luc
+ (firefly luciferase) coding sequence, in order to replace the entire pGL3 5’ gene 
flanking sequence and provide the most native promoter context possible. 
These pGL3-Rgs4 plasmids were transfected into PC-12 cells in tandem with a renilla 
luciferase constitutive expression vector (pRLTK) and tested for response to 16 hours of 
hypoxic treatment by the Dual Luciferase system (Figure 4.5b). No region of the 5kb 
sequence tested was detectably responsive to hypoxia in two independent experiments, yet 
the shortest A fragment was clearly a stronger promoter for luc
+ than the longer variants. 
A previously constructed plasmid containing 4 tandem copies of the Epo HRE upstream of 
luc
+ was used as a positive control for hypoxic treatment and endogenous HIF activity, 
and displayed strong hypoxic response, while unmodified pGL3-basic served as a negative 
control. 
Considering that no functional hypoxia responsive element could be detected in the 5kb 
promoter of the rat Rgs4 locus, it was decided to widen the search when testing the human 
Rgs4 locus. PCR was used to amplify overlapping genomic fragments from SK-N-BE(2)C 
derived genomic DNA covering 32.9kb of the locus, starting from 15.3kb upstream of the 
Rgs4-1 TSS through to 9.7kb downstream of the transcript poly-adenylation site (Figure 
4.6a). This region was scanned for the minimal HIF-binding RCGTG sequence in either 
orientation, resulting in 27 hits (4 of which relate to 2 palindromic CACGTG sequences). 
Conservation between mammalian species was also analysed using the UCSC genome 
browser, showing some short conserved sequences in the B, D and E regions. However, as 
known HREs for other HIF responsive genes were not necessarily depicted by the 
Genome Browser as being conserved, we decided not to discriminate between genomic 





Figure 4.5. (a) Diagram of the rat Rgs4 locus, with promoter regions selected for analysis shown. 
Regions corresponding to A-D were amplified by genomic PCR and cloned into pGL3basic. (b) 
Reporter gene assay of pGL3-Rgs4 constructs. PC-12 cells were plated in triplicate in 24-well 
trays and transfected with 100ng of pGL3basic, or pGL3basic incorporating the sequences A-D 
depicted in (a), while pHRE4 was transfected separately as a positive control for hypoxic 
induction. 100ng of pRLTK was included in all transfections as control for transfection efficiency 
and survival. Cells were treated with hypoxia for 16 hours, then analysed using the Dual 
Luciferase System (Promega). Mean Relative Luciferase Units for a representative of two 
independent experiments with standard deviation between replicate wells is depicted.   
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Sequences E, F and G contain TSSs, and were therefore subcloned to the NcoI site of 
pGL3-basic, directly upstream of the luc
+ coding sequence, to test for promoter and 
enhancer activity. Sequence G contains three TSS according to the UCSC genome 
browser, which give rise to three different transcripts, one of which results in an extended 
coding sequence. Therefore, transcription from this most distal TSS would result in a 
spurious coding sequence before the luciferase gene coding sequence, while transcription 
for either of the other two TSSs would result in normal luciferase coding sequences. To 
control for this, constructs E and F were generated to include only the most distal TSS, 
and therefore test for transcription at that promoter only. All other fragments do not 
include a TSS, and were therefore subcloned upstream of the SV40 promoter of the pGL3-
promoter plasmid to determine whether they contained enhancers. Sequence H also 
includes the three TSSs described for sequences E, F and G, but places them in the 
enhancer context. As there is a TAA stop codon in frame at the start of the first shared 
intron, the effect of transcription on luc
+ expression from the TSS within sequence H 
should be minimal, leaving only enhancer effects on transcription from the SV40 
promoter.  
Unfortunately, one region between sequences C and D could not be cloned or tested. 
Despite repeated attempts to clone this region, either in isolation or together with 
sequences B or C, ligation of this sequence produced plasmids which inhibited bacterial 
growth, making subcloning and preparation of the plasmid impossible. The 1.16kb 
unclonable sequence between sequences C and D (Figure 4.6a) contains no RCGTG sites, 
and displays no notable sequence homology between mammalian species according to the 
UCSC genome browser. Therefore, it seems unlikely that a HRE or other hypoxia 
responsive enhancer is located within this region. 42% of this sequence is comprised of 
repeats, in particular a TcMar-Tigger element as detected by RepeatMasker software 
(Smit, 1996). These elements may have contributed to the problems in subcloning this 
sequence of DNA. 
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Figure 4.6. (a) Diagram of the human Rgs4 locus, with regions selected for analysis shown. 
Regions corresponding to fragments A-N were amplified by genomic PCR and cloned into 
pGL3basic or pGL3promoter upstream of the luc
+ coding sequence, as described in the text. hRgs4 
splice variants and regions of high conservation within mammals as shown as generated by UCSC 
Genome Browser. HRE-like motifs (RCGTG) locations are also depicted, as detected by MBCS 
software (Muller et al., 2001). (b) SK-N-BE(2)C cells were plated in triplicate in 24-well trays and 
transfected twice sequentially with 100ng of pGL3promoter or pGL3-based reporter plasmids 
incorporating the sequences depicted in (a), while 25ng pHRE4 was transfected separately as a 
positive control for hypoxia treatment. Each transfection included 25ng of phRLCMV as control 
for transfection efficiency and survival. Cells were treated with hypoxia for 16 hours, then 
analysed using the Dual Luciferase System (Promega). Mean Relative Luficerase Units for a 
representative of three independent experiments with standard deviation between replicate wells is 
depicted.   
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Constructs were transfected into SK-N-BE(2)C cells together with the constitutive Renilla 
Luciferase expressing contructs, and treated for 16 hours with hypoxia before analysis by 
the Dual Luciferase system. Results are presented as one representative of three 
independent experiments, and display no change in relative luciferase upon hypoxic 
treatment compared to normoxia (Figure 4.6b, 4.6c and 4.6d). As the constructs were not 
all tested at the same time, positive (pHRE4) and negative (pGL3-promoter) controls were 
performed alongside each set of tested constructs to ensure HIF activation and test for 
non-specific regulation, respectively. As the pHRE4 plasmid contains 4 copies of the Epo 
HRE, a second positive control with only one copy of the Vegf HRE in pGL3 was used to 
confirm that the assay was sensitive enough to detect a single HRE. This reporter was 
activated by hypoxia to a similar extent to the pHRE4 plasmid (data not shown). 
4.1.7. Further Bioinformatic Analyses 
Recently, technological advances have allowed a combination of chromatin 
immunoprecipitation (ChIP) and deep sequencing detection of resulting DNA fragments, 
termed ChIP-seq. This technique is currently being applied to the HIF transcription factors 
in SK-N-BE(2)C cells by a collaborating group, but data is not yet available. There is, 
however, a published set of genomic DNA binding data for RNA PolII, coactivator CBP 
and the transcription factor NPAS4 in cultured mouse cortical neurons after membrane 
depolarisation, an activating condition for NPAS4 (Kim et al., 2010). NPAS4 is a member 
of the bHLH/PAS transcription factor family, heterodimerises with ARNT and binds a 
NCGTG core DNA sequence (Ooe et al., 2004), all of which are traits shared by HIF. 
Nonetheless, NPAS4 is not known to be activated or regulated by hypoxia, and is 
expected to have distinct target genes. However, it is possible that NPAS4 and HIF 
heterodimers bind some of the same genomic sites, given the similarity between their 
consensus DNA binding sequences.  
Rgs4 has previously been detected at decreased levels following Npas4 RNAi-mediated 
knockdown in mouse hippocampal neurons, and as such it is considered to be a candidate 
target gene for NPAS4 (Lin et al., 2008). The ChIP-seq was used to detect not only 
NPAS4, but also coactivator CBP, as it is often found bound at enhancer regions. This 
coactivator also interacts with the C-TAD of HIF- in hypoxia, so the enhancer sites of 
NPAS4 and CBP binding in the Rgs4 locus may also provide some hints as to the 
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The ChIP-seq data from the experiments described above are available in a bigWig format 
in the supplementary section of the Kim et al. (2010) publication, which can be applied to 
the “NCBI37/mm9” assembly of the mouse genome using the UCSC genome browser 
(Kent et al., 2002). Figure 4.7a depicts 250kb of the genomic region surrounding Rgs4 
with this ChIP-seq data aligned, while Figure 4.7b shows the 250kb locus surrounding a 
previously characterised direct NPAS4 target gene, Drebrin (Ooe et al., 2004). While 
Drebrin is located within a relatively gene-rich region, Rgs4 has fewer neighbouring 
genes, the closest of which (Rgs5) is 50kb away. Increased NPAS4, CBP and PolII levels 
were detected in stimulated cells at the promoter and transcription end site for both Rgs4 
and Drebrin. The Drebrin 250kb locus contains several sites which display stimulus-
enhanced binding of these factors, yet these sites localise almost exclusively to the 
promoters or transcription end sites of other known genes. Therefore, there appear to be 
few enhancers present in intervening sequences between genes at the Drebrin locus. The 
250kb Rgs4 locus is quite different however, and displays multiple NPAS4, CBP and PolII 
binding sites in regions where no gene is annotated and no ESTs have been recorded.  
We retrieved the genomic sequences of multiple inducible transcription factor binding 
sites in the 250kb Rgs4 locus (Figure 4.7a, indicated by black bars “1a”–“14”) and 
searched for HRE-like sequences (RCGTG) in either orientation. Of these seventeen 
sequences, eight contained HRE-like motifs, two of which contained multiple motifs. 
These enhancer regions for regulation of Rgs4 by NPAS4 may provide some clues to 
finding enhancers for the regulation by HIF. 
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Figure 4.7. Alignment of NPAS4, CBP and PolII Chromatin IP Deep Sequencing (ChIP-Seq) data 
(Kim et al., 2010) to the UCSC Genome Browser for 250kb-spanning regions centred on the 
mouse Rgs4 gene (a) and mouse Drebrin gene (b). “Un” refers to untreated cells, whereas “KCl” 
are KCl-depolarised cells, a stimulus which activates NPAS4-mediated transcription. “Pol2_4H8” 
antibody detects PolII with either phosphorylated or unphosphorylated C-Terminal Domains 
(CTDs), while “Pol2_8WG16” detects the unphosphorylated form preferentially. Black bars in (a) 
labelled “1a” to “14” indicate regions of interest which appear to act as enhancers. UCSC curated 
genes are depicted in the lower portion of each figure, with arrows indicating direction of 
transcription (and introns), while wide bars indicate exons. Mammalian conservation according to 
UCSC Genome Browser alignment is also depicted at the bottom of each image.   108   
4.2. Discussion 
4.2.1. The Rgs4 Locus is Likely to be a Direct HIF 
Binding Target 
The data presented in Chapter 3 provides evidence for the regulation of Rgs4 levels by the 
HIF transcription factor pathway in mouse, rat and human pheochromocytoma and 
neuroblastoma cells. In this chapter, the possibility of RNA-binding protein involvement 
in Rgs4 hypoxic response was addressed by RNA degradation assays using SK-N-BE(2)C 
and SK-N-SH cells (Figure 4.1). Rgs4 mRNA was shown to not be differentially 
stabilised by normoxic or hypoxic conditions in the absence of transcription, relative to 
Polr2a or relative to total RNA levels. This is evidence against regulation of Rgs4 at the 
level of mRNA stability, and shows Rgs4 mRNA accumulation involves a transcriptional 
response. However, this result in isolation does not exclude the possibility that there is 
hypoxia responsive transcription of RNA-binding proteins or antisense RNAs, which in 
turn affect Rgs4 at the post-transcriptional level.  
Calculations for the half-life of Rgs4 or Polr2a mRNA in these cells were made difficult 
by their high stability, as it becomes difficult to take long timepoints of cells treated with 
actinomycin D as cells become decreasingly viable, introducing variability in detection. 
Also, as total RNA amounts were normalised before cDNA generation, Rgs4 and Polr2a 
detection may be influenced by the stability of ribosomal RNA, which forms the bulk of 
total RNA samples. This variability was observed when testing Rgs4 or Polr2a 
degradation without normalisation to a reference gene (Figure 4.1c,d), but was much less 
notable when Rgs4 was normalised to Polr2a levels (Figure 4.1a,b), reinforcing the 
importance of internal qRT-PCR reference gene normalisation. However, in the 
calculation of the half-life of Rgs4 mRNA, this normalisation step would skew the 
calculations. Nonetheless, it was clear that any differences in the half-life of Rgs4 mRNA 
between normoxia and hypoxia were minimal, and not responsible for the large induction 
of mRNA observed in response to hypoxia in these cells in the absence of actinomycin D. 
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Much post-translational regulation occurs through the 3’UTR of target mRNAs, and the 
Rgs4 3’UTR contains several sites of strong conservation between species. To test for 
hypoxic response conferred through this sequence, we ligated the human Rgs4 3’UTR 
between the firefly luciferase encoding gene (luc
+) and polyadenylation sequence of 
pCI_FL, and tested it in normoxia and hypoxia by luciferase reporter assay (Figure 4.2). A 
small increase in relative luciferase levels was observed in hypoxia, but this was not 
dependent on or increased by the presence of the Rgs4 3’UTR, indicating that this RNA 
sequences is not involved in this regulation.  
However, inclusion of the Rgs4 3’UTR did generally decrease relative luciferase detection 
compared to the control without additional 3’UTR. This indicates that there may be some 
destabilising elements in the human Rgs4 3’UTR which are not regulated by hypoxia. This 
observation is likely to be conferred through one or more of the highly-conserved 3’UTR 
elements as depicted in Figure 4.6a. For example, the largest of the conserved regions 
appears to contain an AU-rich element, as it contains 42.5% uridine and 29.5% adenine 
bases, and two AUUUA core motifs within 200bp, of which only 24 are mismatched or 
inserted bases compared to the mouse sequence. AU-rich elements similar to this cause 
destabilisation of mRNA (reviewed by Chen and Shyu, 1995). Alternatively, the 
conserved elements of the hRgs4 3’UTR may control mRNA translation, or sub-cellular 
localisation of transcript. These sequences could provide Rgs4 response to presently 
unknown signals other than hypoxia, or may simply increase the overall rate of Rgs4 
mRNA turnover to promote a return to normal levels after removal of stimuli, for example 
reoxygenation. In support of this result, AU-rich elements have recently been found within 
the rabbit Rgs4 3’UTR, which negatively regulate Rgs4 expression through association 
with RNA-binding protein HuR (Li et al., 2010a). 
A significant response of Rgs4 was detectable within 1 hour of DP treatment, in a similar 
pattern to that observed for other direct HIF targets Vegf and Dec1 (Figure 4.3). Dec1 
encodes a transcription factor, DEC1, which is known to negatively regulate transcription 
of the Mlh1 gene. Levels of the Mlh1 transcript were not significantly altered until 4 hours 
or more of treatment. Therefore, the timing of Rgs4 response to DP is consistent with the 
hypothesis that it is a direct target of HIF, and the role of intermediary transcription events 
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4.2.2. Rgs4 Transcription May be Regulated by 
a Distant Enhancer 
It seems likely from the discussion above that the HIF pathway directly binds and 
activates transcription of Rgs4. Therefore, a search was undertaken for DNA sequences at 
the rat and human Rgs4 loci which could mediate this response. Functional HIF-1 or HIF-
2 binding sites (HREs) are commonly detected by cloning and testing in mammalian 
reporter assays, although selection between the two HIF forms can become distorted in a 
plasmid context (Lau et al., 2007). However, no functional HRE was detectable in either 
the 5kb upstream sequence of rat Rgs4, nor in any sequence of the 32.9kb human Rgs4 
locus. Fragment H displays a small change upon hypoxic treatment, yet as this fragment is 
overlapped by Fragments E, F, G and I, all of which do not display a similar response, this 
is not likely to represent a real hypoxia-responsive sequence. This is a surprising result, as 
most HIF binding sites in the genome are found by chromatin-IP within 2kb of a TSS 
(Mole et al., 2009).  
Different human Rgs4 promoters were also tested, as this gene has multiple TSSs. The 
originally discovered human Rgs4 promoter (Fragment G) resulted in stronger luciferase 
expression than the alternative promoter (Fragment F), indicating that the former is more 
likely to be the predominant start site of transcription in the SK-N-BE(2)C cell line. The 
different mRNA forms resulting from the alternative transcription start sites are not 
discriminated by the qRT-PCR primers used, nor the northern blot probe used, so previous 
quantification would not indicate the relative presence of these subtly different transcript 
forms.  
Given the unlikelihood of post-transcriptional regulation as discussed in the previous 
chapter, there are two possible explanations for these results: that there is a hypoxia 
responsive element within the regions cloned, but it is not detectable by the conditions 
used in our luciferase reporter assay; or that there is a hypoxia-responsive element outside 
of the regions tested in our assay. In relation to the first alternative, it is possible that the 
Rgs4 HRE is only functional when it is located in the context of native chromatin (as 
distinct from a transfected plasmid), due to interaction between transcription factors, other 
chromatin-bound factors or histone marks. There may also be long-range interaction 
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responsive transcription, which would not be recapitulated by testing each fragment 
individually. However, minimal HIF target sequences discovered to date have all been 
found to be responsive in reporter assays such as those performed for this thesis (for 
examples, see Firth et al., 1995; Liu et al., 1995; Miyazaki et al., 2002), so there is no 
precedence for this explanation. 
The alternative explanation is that there is a HRE located outside of the regions of the 
human Rgs4 locus tested here, either more than 15.3kb upstream of the Rgs4 TSS, or more 
than 9.7kb downstream of its poly-adenylation site. This would make the Rgs4 HRE 
atypical, but as mentioned, not without precedence. Although most HREs are found 
proximal to a TSS, there are exceptions to this observation, such as the HRE for Phd3 
which is found 12.59kb downstream of the TSS (Pescador et al., 2005). In the absence of 
HIF ChIP-seq data, to determine whether Rgs4 transcription could be under the control of 
distant enhancers we analysed ChIP-Seq data for NPAS4 binding, which is a related 
bHLH-PAS family member, as well as for coactivator CBP and RNA PolII (Figure 4.7). 
Both Drebrin and Rgs4 mRNA levels are responsive to NPAS4 (Lin et al., 2008; Ooe et 
al., 2004), and NPAS4, coactivator CBP and RNA PolII are found at the Drebrin locus 
bound to only gene proximal sites. However, at the Rgs4 locus these transcription factors 
are found at several specific loci in distant non-coding regions. Aside from the sites found 
at the Rgs4 proximal promoter and coding sequence, seventeen regions were determined 
where at least two of either NPAS4, CBP and RNA PolII were detected binding in 
response to depolarisation stimulus, in the 250kb flanking the Rgs4 locus (Figure 4.7). 
These binding sites do not coincide with characterised genes, nor do any known expressed 
sequenced tags (ESTs) align to these regions. Ten such sites could be found within the 
same span of the Drebrin locus, all of which are localised to the TSSs of Drebrin or other 
previously characterised genes.  
Therefore, Drebrin appears to be regulated by NPAS4 through enhancers found proximal 
to its promoter, while Rgs4 is appears to be under the control of several enhancers located 
up to 150kb away from its TSS, one or more of which bind NPAS4. These may access the 
Rgs4 promoter through DNA looping, as indicated by the detection of RNA PolII at these 
distal sites. This also indicates that the detection of NPAS4 and CBP at some of these 
distal sites may be due to indirect interactions, such as crosslinking of factors which are in 
proximity to but not bound directly to the DNA at that location. Futhermore, as NPAS4 is 
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ARNT (HIF-), there may be crosstalk between NPAS4 and HIF pathways in Rgs4 
regulation. Crosstalk between NPAS4 and another bHLH/PAS member (SIM-2) has 
already been described (Ooe et al., 2004). The consensus binding sequence for NPAS4 is 
NCGTG, which is similar to that of the HIFs (Ooe et al., 2004), so binding sites for 
NPAS4 could also be binding sites for HIF. Alternatively, at the very least this NPAS4 
enhancer information could be taken as an analogy for the regulation of Rgs4 by HIF, 
which would indicate that Rgs4 is under the control of several distant enhancers, one of 
which may be hypoxia-responsive.  
The sequences of these seventeen Rgs4 locus peaks bound by NPAS4, CBP and/or RNA 
PolII were retrieved and RCGTG motifs (which could theoretically bind both HIF and 
NPAS4) were found in eight of these regions. HRE-like motifs in sequences 3, 5 and 7b 
correlated to peaks of NPAS4 binding from the ChIP-Seq data, while motifs in 6 and 9a 
correlated to CBP binding only (Figure 4.7a). Some of these sites were also found in 
regions of high overall mammalian sequence conservation, yet few of these central 
RCGTG elements were conserved in the corresponding human or rat sequences. If NPAS4 
interacts directly with one of these sites, it may be that the site has moved over 
mammalian evolution. Evolutionary movement of enhancers, either through translocation 
of a locus or generation of a novel superceding enhancer while maintaining the regulation 
of a gene, has been noted as being common for other transcription factors by use of ChIP 
combined with custom microarrays (Odom et al., 2007) and ChIP-Seq technology 
(Schmidt et al., 2010). Hence, the lack of conservation at a candidate binding site should 
not preclude it from analysis as a likely enhancer element.  
Since we do not know whether NPAS4 and HIF commonly bind at the same genomic 
sites, a definitive experiment would need to include ChIP-Seq against HIF-1 and HIF-2 
in normoxic and hypoxic cells. This experiment is currently being performed by 
collaborators using SK-N-BE(2)C cells, and although this data would then align to a 
different species genome than this NPAS4 data, general comparison would still be 
possible. Alternatively, as HIF has been shown to in some cases bind to DNA indirectly 
through the Notch intracellular domain (Gustafsson et al., 2005), consensus HIF binding 
sites may not be found at HIF controlled Rgs4 enhancers. Both direct and indirect HIF 
binding sites may be confirmed by reporter gene assay. 
If the regulation of Rgs4 transcription by hypoxia occurs though distal enhancers 
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explains the previous observation that Rgs4 hypoxic response is limited to a narrow range 
of cell types. Considering that active Rgs4 transcription and HIF activity is not necessarily 
sufficient for its hypoxic regulation, whereas Vegf appears to be regulated by HIF in all 
cell types tested, the alternative enhancer set-up at the Rgs4 locus may allow this 
restriction. In this case, there may be additional neural or neural-precursor specific 
transcription factors which HIF must interact with at this locus in order to promote Rgs4 
transcription. 
4.2.3. Regulation of Hif1a and Epas1 Message 
in Prolonged Hypoxia  
One of the unexpected results of the siRNA knockdown experiment control (Figure 3.5) 
was that Hif1a and Epas1 mRNA levels are regulated during prolonged DP treatment of 
SK-N-BE(2)C cells. This effect is also present during hypoxic treatment, as shown by 
analysis of the timecourse hypoxia samples (Figure 4.4), which were primarily intended to 
quantify the time delay in Rgs4 response to hypoxia (Figure 4.3). Therefore, Hif1a and 
Epas1 message levels are responsive to both hypoxia and a HIF-activating hypoxia 
mimetic chemical, and are likely to be regulated through HIF. Interestingly, while Rgs4 
responds in a similar time to known HIF target genes, Hif1a and Epas1 are only detected 
at altered levels after 4 hours of hypoxia, akin to Mlh1, a secondary responder to the HIF 
pathway. By the 16 hour timepoint, Hif1a mRNA has decreased to close to one-third of its 
normoxic levels (relative to Polr2a), while Epas1 levels have increased by almost 7 fold. 
It is unclear whether these changes are maintained in longer hypoxia treatments, in part 
due to the decreasing health of the cell culture in prolonged hypoxia. However, these 
results do relate to previous observations of HIF- protein levels in SK-N-BE(2)C cells, 
amongst others, during prolonged hypoxic treatment in certain cell types (see Chapter 
1.1.4). 
Holmquist-Mengelbier et al. (2006) present data demonstrating increased HIF-2 and 
decreased HIF-1 protein levels in prolonged severe hypoxia, using the SK-N-BE(2)C 
and KCN-69n human neuroblastoma cell lines, and similar results have also described for 
A549 lung epithelial cells (Uchida et al., 2004). Interestingly, published qRT-PCR 
experiments in neuroblastoma indicate an increase in SK-N-BE(2)C Epas1 mRNA levels 
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here in Figure 4.4 (Holmquist-Mengelbier et al., 2006). Furthermore, no reduction in 
Hif1a message was described for this cell line at any timepoint, disagreeing with the 
results presented in this thesis. Previously published data for the KCN-69n cell line, 
however, fit more closely with the results presented in this thesis, as Epas1 is increased 
while Hif1a levels are decreased by severe hypoxia, after a brief delay of around 4 hours 
(Holmquist-Mengelbier et al., 2006). Subtle changes in reference gene levels are unlikely 
to cause the differences observed in our data, since significant regulation is observed in 
both the positive and negative directions.  
Therefore, the differences between these experiments are likely to result from different 
cell culturing conditions, or different hypoxic conditions. In particular, Holmquist-
Mengelbier and colleagues use an oxygen-regulated chamber to achieve a specific 
environmental oxygen percentage of 1%, whereas our experiments use a less controlled 
system, employing AnaeroGen sachets to absorb oxygen in a sealed container. Although 
the specific oxygen level was not tested concurrently with the experiments in Figure 4.3 
and Figure 4.4, later use of an oxygen meter in the same sealed containers with 
AnaeroGen sachets produces a final oxygen concentration at or below 0.1%. Therefore, it 
is likely that the hypoxia employed in the experiments here is more severe than those 
described by Holmquist-Mengelbier et al. (2006), such that the regulation of Hif1a and 
Epas1 message levels is more pronounced in prolonged conditions of extreme hypoxia, or 
anoxia. HIF-1 and HIF-2 have also been previously shown to be differentially 
regulated by moderate hypoxia (Holmquist-Mengelbier et al., 2006), so it would appear 
that the hypoxic response is significantly affected by the specific oxygen concentration 
available. However, this has not been directly tested here, so future experiments on this 
path would require comparison of hypoxic treatments at 1% and 0.1% oxygen. 
Due to the timing of these responses, regulation of these transcripts by hypoxia is unlikely 
to be due to direct activity of HIF itself on Hif1a or Epas1 transcription, but is likely to 
use an indirect mechanism involving regulation of an intermediate gene. For example, 
negative regulation of Hif1a levels can occur following transcription of aHIF, which is 
under the control of HIF. RNA from aHIF then causes Hif1a mRNA destabilisation (see 
Chapter 1.1.6), so the time taken to transcribe and accumulate aHIF RNA as an 
intermediate may result in the 4 hour delay before response observed here. Alternatively, 
there may be other as-yet unknown miRNA genes which could act in a similar fashion to 
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factors such as Dec1, which in turn may bind at the Hif1a gene and repress its 
transcription. For example, the negative response of Hif1a mRNA occurs in a similar 
timeframe to that of another DEC1 target gene, Mlh1. The effect of either of these 
pathways could be tested by Hif1a 3’UTR reporter assays, promoter reporter assays, or 
ChIP assays to determine whether altered Hif1a levels in this case are due to 
transcriptional or post-transcriptional regulation. This could then be extended to test 
whether this pathway is active at 0.1% oxygen, but not 1% oxygen. 
Similar explanations are possible for the positive regulation of Epas1 message levels. 
There may be an as-yet unknown post-transcriptional pathway regulating Epas1 levels, or 
Epas1 may be regulated by a secondary HIF-responsive transcription factor. Notably, the 
increase in Epas1 to hypoxia was detected in previous studies during prolonged 1% 
oxygen exposure (Holmquist-Mengelbier et al., 2006), whereas the Hif1a response was 
only detected in this thesis which utilised more severe hypoxic conditions, indicating that 
dissimilar oxygen sensing pathways may be in effect for each of these responses. 
This modulation of the two HIF isoforms may enable cell survival and adaptation during 
extended severe hypoxia or anoxia. Increased HIF-2 protein levels have been correlated 
to increased dedifferentiation of clinical neuroblastoma samples and poor prognosis 
(Holmquist-Mengelbier et al., 2006; Pietras et al., 2008), while Epas1 RNAi knockdown 
promotes neuroblastoma differentiation (Pietras et al., 2009). Therefore, the Epas1-
mediated dedifferentiation in non-cancerous cells may enable survival, an effect which 
manifests as an aggressive phenotype in the context of neuroblastoma. It is then likely that 
in some cell types, HIF-1 provides adaptation during short hypoxic insults, but is not 
beneficial during long-term anoxia, while later HIF-2 activates a distinct set of genes to 
adapt the cell for survival in prolonged hypoxia. 116   
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5.1.1. Cell Type Specific Transactivation of Rgs4 
by HIF 
The experiments presented in this thesis indicate that Rgs4 is responsive to hypoxia 
through the HIF pathway, but only in a subset of all Rgs4 expressing cells. Although the 
specific genomic site from which HIF activates transcription of Rgs4 is not clear, it is 
likely that long-range interactions are involved in the transcriptional activation of this 
gene, through DNA-looping. This is in contrast to many, but not all of the known HRE-
containing enhancers that are found proximal to transcription start sites of other HIF target 
genes such as Vegf. Therefore, Rgs4 may have a more complex hypoxia-responsive 
enhancer than most other characterised HIF target genes, raising the question as to why 
the Rgs4 gene would need to be regulated in this fashion. 
One possibility involves the specificity of the Rgs4 hypoxia response to neural-related 
cells. Expression of Rgs4 is not silenced in endothelial cells, as Rgs4 transcript is readily 
detectable, however its expression is not altered by hypoxic treatment, in contrast to 
results using neuroblastoma cells. As a general observation, transcription of other HIF 
target genes such as Vegf is responsive to hypoxia in all cell types, excepting cell types in 
which the gene is silenced. In these cases, presumably the silencing elements outweigh the 
activating properties of HIF, or HIF is not permitted access to the HRE. However, as the 
Rgs4 locus is not silenced in endothelial cells, there must be other elements which 
specifically prevent HIF transactivation of Rgs4 in these cells, or specifically permit HIF 
activation of Rgs4 in neural-like cells, while still allowing the usual HIF transactivation of 
other target genes such as Vegf. This unknown mechanism may be related to the long-
range and complex style of NPAS4-bound enhancer observed at the Rgs4 locus, such that 
if HIF acts in a similar fashion at the Rgs4 locus, other cell-type specific factors or 
conditions may also be required for transactivation. Notably, if HIF transactivates Rgs4 
expression from a distant enhancer, the results presented here show this enhancer interacts 
specifically with the Rgs4 gene and does not act on the nearby Rgs5 gene.  
The idea of a complex enhancer at Rgs4 is supported in part by previous publications 
showing that differential transactivation of target genes by HIF-1 and HIF-2 is controlled 
by post-DNA-binding events, rather than differences in DNA binding (Hu et al., 2007; 
Lau et al., 2007; Mole et al., 2009), indicating generally that the process of transactivation 118   
by the HIFs involves regulatory mechanisms that are not yet fully understood. In other 
contexts, HIF is known to functionally interact with transcription factors such as ETS1 
(Elvert et al., 2003), ELK1 (Aprelikova et al., 2006) and Notch-1 (Gustafsson et al., 
2005). Therefore, HIF regulation of Rgs4 may require interaction with these or other as-
yet unknown transcription factors, resulting in the cell-type specific hypoxic response 
observed in this thesis. There are many examples of other transcription factors which have 
distinct roles in different cell types, such as the RE1-Silencing Transcription factor 
(REST), which binds at distinct genomic sites in embryonic and neural stem cells 
(Johnson et al., 2008), and the T-cell Acute Leukaemia protein-1 (TAL1), which binds 
DNA directly using its bHLH domain during erythrocyte maturation, but binds distinct 
genomic sites during specification of haematopoietic stem cells (Kassouf et al., 2008; 
Kassouf et al., 2010). 
The Rgs4 transcriptional response to hypoxia is affected by loss of either HIF-1 or HIF-
2, but is more sensitive to loss of HIF-2 than some other classical HIF-1 target genes 
(Figure 3.5 and Figure 3.6), indicating that while Rgs4 does not appear to be a target gene 
of HIF-2 alone, regulation of Rgs4 is not identical to these other HIF target genes. A 
recent study using the ChIP-Seq method (Schodel et al., 2011) indicates that long-range 
HIF interactions are more likely to be preferred by HIF-2, while HIF-1 often acts from a 
site proximal to the regulated gene. However, it is unclear whether HIF-2 regulates 
transcription from these enhancers using a different mechanism to HIF-1, and whether the 
difference in enhancer distance from the regulated gene has a functional effect on 
regulation. The use of deep sequencing with ChIP for other transcription factors such as 
p53 has revealed transcription factor binding sites up to 100kb from a regulated gene, and 
other binding site with no detectable direct effect on nearby gene transcription (Wei et al., 
2006). Nonetheless, this finding correlates well with the theory of distant enhancers 
controlling Rgs4 transcription, as results presented here show that HIF-2 has more 
influence on Rgs4 transactivation than it does on target genes such as Vegf or Dec-1, at 
least in the neuroblastoma cell line tested. 
The transcriptional regulation of Rgs4 expression described in this thesis is also interesting 
in the context of previously discovered regulation of RGS4 and RGS5 protein degradation 
by hypoxia through the N-end rule degradation pathway (Chapter 1.3.3). However, while 
HIF transactivation of Rgs4 appears to be restricted to neural-like cells, the N-end rule 
pathway is most likely to be active in cardiovascular cell types (Kwon et al., 2002). 119   
Furthermore, hypoxia regulates Rgs4 transcription but not that of Rgs5, while the N-end 
rule pathway affects both RGS4 and RGS5 proteins. Therefore, the two hypoxia response 
pathways may result in different modes of RGS4 response in vascular and non-vascular 
cell types, in terms of response time or other characteristics. Alternatively, the two 
hypoxia responsive pathways may provide a means of allowing RGS4 response in both 
vascular and neural cell types, while RGS5 is only regulated by hypoxia in vascular cells.  
It is worth making note of the lack of obvious phenotype observed for Rgs4
-/- mice, which 
is curious given the two distinct, conserved levels of hypoxic regulation of RGS4 levels. 
Presumably, the function of RGS4 is favourable in some response to hypoxia, as two 
distinct hypoxia response pathways have been conserved in regulation of RGS4. However, 
although both the HIF and N-end rule pathways are known to have influential roles in 
development, Rgs4
-/- mice have no gross morphological defects (Grillet et al., 2005), 
therefore RGS4 either has little effect in development, or is made redundant by the other 
RGS family proteins. In terms of the HIF-based hypoxic response, Rgs5 does not 
compensate for Rgs4 in neural-like cells, but other members of the family which have not 
yet been tested may be HIF responsive, and therefore compensate for loss of Rgs4, 
considering that many of the RGS family proteins appear to have overlapping specificities 
for G target proteins. Taken together, this might suggest that the physiological role of 
RGS4 hypoxic response is not developmental, but rather used in adaptation to hypoxia. 
Such a role may be too subtle to be observed in Hif1a or Epas1 deficient mice, which have 
severe developmental problems due to disruption of transactivation of other HIF target 
genes. Therefore, it would be of interest to treat Rgs4
-/- mice with systemic hypoxia and 
determine whether these mice have impaired survival or adaptation. Given that the 
experiments in this thesis show specific hypoxic regulation of Rgs4 in cells which express 
catecholamines, and the original aims to find new HIF target genes using catecholamine 
expressing cell types due to the catecholamine-deficient phenotype of Epas1
-/- mice, it 
would be of particular interest to test hypoxic and control Rgs4
-/- mice for perturbations in 
circulating catecholamine levels, or catecholamine signalling within neural cell types. In 
this way, novel physiological roles of Rgs4 may be elucidated using hypoxic conditions 
which could not be found under normal oxygen conditions. 
The observations presented in this thesis can be further related to the putative 
physiological functions of RGS4 protein discussed in Chapter 1.3.5 and 1.3.6. In 
particular, as the HIF transcription factors regulate expression of Rgs4 in neural-like cell 120   
types, hypoxia and HIF may influence the regulation of opiate and/or dopamine signalling 
through Gi proteins, by RGS4 protein activation of Gi-GTP hydrolysis. As mentioned 
previously, foetal hypoxia has been previously linked to risk of schizophrenia (Cannon et 
al., 2000), a mechanism that could possibly involve HIF regulation of Rgs4. Therefore, the 
results of this thesis provide a possible link between several conditions correlated with 
schizophrenia susceptibility. Further experiments would involve testing schizophrenia-
linked Rgs4 SNPs in terms of disruption of gene transcription, which would then act as 
guide to locating novel enhancers of Rgs4. Alternatively, Rgs4, Hif1a or Epas1 mutant 
alleles could be crossed into existing mouse models of schizophrenia to test for 
amplification or reduction of phenotypes. A mouse model for this disease has been 
developed (Hikida et al., 2007), while excessive Rgs4 expression (Mirnics et al., 2001) 
and hypoxia (Cannon et al., 2000) have been linked to the disease state, such that null 
alleles of Rgs4, Hif1a or Epas1 might be expected to weaken the schizophrenic phenotype, 
while overexpression of these genes may cause an increase in deleterious phenotypes.  
As the Rgs4 gene is found to be unresponsive to hypoxia in endothelial cells (Chapter 
3.1.4), it seems less likely that the regulation of Rgs4 by HIF impacts on processes such as 
tubulogenesis, heart hypertrophy or bradycardia. However, the possibility of a role for 
Rgs4 in these processes should not be entirely discounted as Rgs4 may be regulated by 
hypoxia in cardiovascular cell types other than the umbilical endothelial cell type tested 
here. Furthermore, RGS4 protein is regulated by hypoxia in the cardiovascular system, so 
RGS4 may have roles in these processes independent of the HIF pathway. Experiments to 
further test for an Rgs4 hypoxic response would include transcript expression analysis of a 
wider range of primary mouse cell types, and in situ hybridisation towards Rgs4 and other 
relevant genes, using normoxic and hypoxic heart, brain and other tissue samples. In this 
way, the extent to which the transcriptional response of Rgs4 to hypoxia is restricted in 
cardiovascular cell types can be determined.  
Despite numerous published microarray experiments examining the transcriptional 
response to hypoxia (Chapter 1.3.3), Rgs4 has only appeared in one other set of results 
other than those presented in this project. This is clearly due to the restriction of Rgs4 
hypoxic regulation to specific cell types that are not commonly used as models. However, 
these results now imply that there may be other hypoxia and HIF responsive genes which 
have gone hitherto undetected due to experimental cell type selection. While use of cell 
types such as breast cancer has been useful in determining the majority of general HIF 121   
target genes, and in turn the binding profile of HIF throughout the genome (Schodel et al., 
2011), there are likely to be other functional HIF binding sites and responsive genes in cell 
types that have not yet been tested, whether in neural-like cells as tested in this thesis, or 
other unrelated cell types.  
Performing microarrays or ChIP-seq experiments across an exhaustive set of cell types 
would be impractical, so more directed approaches would be required to find these elusive 
target genes. These atypical target genes of HIF would only be expected to represent a 
small subset of total hypoxia and HIF responsive genes, the majority of which have 
already been discovered and have less restricted responsiveness than Rgs4. To discover 
other such novel target genes, physiological functions of HIF which have not yet been 
described by known target genes could direct researchers to use of a specific model cell 
type in microarray or ChIP-seq studies, as the catecholamine-deficient phenotype of 
Epas1
-/- mice did for the experiments presented in this project. However, due to the critical 
role of both HIF-1 and HIF-2 in development, carefully designed conditional knockout 
mouse models would be required to expose the more subtle physiological roles of HIF. 
Various conditional Hif1a
-/- and Epas1
-/- mice have been generated and tested, as 
described in Chapter 1.1.7. Alternatively, atypical HIF target genes such as Rgs4 could be 
used as a model for discovery of other HIF-associated transcription factors, and the 
domains responsible for interaction within HIF-. This would then aid in predicting cell 
types where a restricted hypoxic response might be found, and also would provide a 
method for screening for the genes regulated in this way, either through knockdown of the 
associated transcription factors alongside microarray technology, or through sequential 
ChIP (ReChIP) experiments. Considering that these putative novel protein interactions 
mediate a subset of HIF transactivation targets, some of which like Rgs4 may be involved 
in pathogenesis, an attractive direction of research would be involve small molecule 
inhibitors. Such molecules could be designed to inhibit the formation of transactivation 
complexes involving HIF at specific atypical target genes, while allowing normal HIF-
mediated regulation of classical target genes such as Epo and Vegf, thus minimising 
deleterious side effects.  
In conclusion, the novel discovery presented here that the Rgs4 gene is transcriptionally 
responsive to hypoxia and the HIF pathway in neural-like but not endothelial cells poses 
new questions about the complexity of regulation of HIF activity towards genes such as 
Rgs4, as well as elucidating a novel link between the HIF and G-protein signalling 122   
pathways which could lead to a better understanding of diseases such as schizophrenia. 
These questions can be addressed by further research into Rgs4 transactivation using 
techniques such as ChIP-Seq and model systems such as transgenic mice. The direct 
binding site of HIF at the Rgs4 locus remains elusive, yet its mechanism of HIF action at 
this locus is distinct from that previously discovered at other target genes, and may even 
describe a new subset of as-yet undiscovered HIF target genes. 123   
6. Appendix 124   
6.1.1. Quantitative PCR Optimisation 
Initial experiments were designed to establish the quantitative PCR (qPCR) technique 
prior to the experiments of Chapter 3.1.3, as this had not been performed previously in our 
laboratory. Primers were designed across intron boundaries for human, mouse and rat 
target gene cDNA sequences retrieved from the UCSC Genome Browser (Kent et al., 
2002) using Primer3 software (Rozen and Skaletsky, 2000). Primer sets were designed for 
Rgs4, positive (HIF-regulated) controls Vegf and Dec1, reference (negative) controls 
Polr2a and Actb, as well as Hif1a, Epas1 and Mlh1 in later experiments. cDNA was 
generated from identical amounts of template total RNA, and as total RNA is 
predominantly composed of ribosomal RNA (rRNA), qRT-PCR reactions are already 
normalised to some extent relative to rRNA levels. Although some variability in mRNA 
detection is expected despite this step, Actb (-Actin) was consistently detected in hypoxic 
samples about one PCR cycle later than the normoxic control. Therefore, Actb levels 
appear to be slightly responsive to hypoxia and not suitable for use as a reference. Another 
popular reference gene, Gapdh, is under the direct transcriptional control of HIF, making 
it also unsuitable (Graven et al., 2003). Polr2a (encoding the major subunit of RNA 
Polymerase II), has appeared in several experiments as a more stable reference gene than 
Actb or Gapdh (Brattelid et al., 2010; Radonic et al., 2004; Saviozzi et al., 2006), and was 
also less variable between normoxia and hypoxia that Actb in cDNA samples tested here 
(data not shown). Thus, Polr2a was selected as the most appropriate reference control. 
The quality of each primer set was verified by qRT-PCR using serial dilutions of cDNA 
from an appropriate species. The equation for the progression of PCR is expressed in 
Equation 2.1 (see Chapter 2.2.6), giving E as the efficiency of PCR, or in other words the 
average number of new product molecules produced per cycle per template molecule. E 
can be calculated from the slope of a log10[template] vs C(t) plot (Figure 6.1, Equation 
2.2), where C(t) is the cycle of PCR where the product reaches a threshold amount 
(Rutledge and Cote, 2003). In the case of Figure 6.1, the template concentration used is 
relative to neat cDNA, which is set at 1. This PCR efficiency analysis was performed on 
all primer sets and was determined to be above 90% (0.9) and below 110% (1.1) for C(t) 
less than 30, after which PCR efficiency was less reliable due to the low amount of 
template being detected, impacting on efficiency. Examples for human Rgs4, Vegf and 
Polr2a are provided in Figure 6.1a, with calculations resulting in EhRgs4 = 0.945, EhVegf = 
0.941 and EhPolr2a = 1.035. PCR efficiency over 100% can result from formation of  125   
 
 
Figure 6.1. (a) Representative quantitative PCR efficiency test for hRgs4, hVegf and hPolr2a 
primer sets on serial dilutions of human (SK-N-SH) cDNA. Mean C(t) detection between three 
replicate qPCR reactions is plotted, for  log10 concentrations of cDNA that result in detection of 
target at C(t) < 30. Standard deviations of points are too small to accurately plot, and line slope is 
used to calculate PCR efficiency calculation using Equation 2.2, giving E (hRgs4) = 0.945, E 
(hVegf) = 0.941, and E (hPolr2a) = 2.035. (b) Entire qRT-PCR products from Figure 3.5c were 
run on a 3% agarose/TBE gel, with the DNA size ladder (central lane, from top: 300, 200 and 
100bp markers) to estimate PCR specificity. RT refers to Reverse Transcriptase.   
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non-specific DNA duplexes such as primer-dimers, or from the presence of PCR 
inhibitors. For the purposes of the following experiments, detection of amplified target 
sequences later than 30 cycles was considered to represent levels of target gene expression 
which are at the limit of reliable detection, while C(t) > 35 or no detectable amplification 
within 40 cycles was considered to be effectively ‘undetectable’ target message levels. 
Using more cDNA template per reaction could result in improved detection sensitivity, but 
this was not required for the experiments presented in this thesis. 
Relative amount of target gene mRNA was determined using StepOne (Applied 
Biosystems) and Q-Gene software (Muller et al., 2002), both of which use modified 
versions of the 2
-C(t) method (Livak and Schmittgen, 2001). This method uses the cycle 
number (C(t)) at which the amount of PCR product detection reaches a threshold for both 
target and reference genes, and gives a target expression value in arbitrary units relative to 
the reference gene. To perform statistical analysis, expression was further normalised to 
the calibrator (negative control) cDNA, then the mean and standard deviation across at 
least three independent experiments was taken. After verifying PCR primer set efficiencies 
to be 90% < E < 110%, the programs were set to assume PCR efficiency of 1, as even a 
10% difference in calculated efficiency produces only a small effect. For example, when 
comparing a hypothetical qPCR result of a 2 cycle difference in C(t) of target between two 
samples, which equates to a 4-fold relative difference in target amount, altering the 
theoretical PCR efficiency E from 0.9 to 1.1 gives a 10% range around the expected result, 
4. The effects of imperfect PCR efficiency are more pronounced with higher differences in 
C(t) between samples, and effectively non-existent between samples which give the same 
C(t), so small errors in calculated efficiency are not likely to give false positive results, but 
may slightly affect the fold change observed. In addition, the specific PCR efficiency of 
each subsequent reaction is likely to be slightly variable, so attempting to correct for this 
using a predetermined efficiency value may introduce more error into the calculation than 
it removes. Chapter 3.1.3 describes qRT-PCR experiments using the same samples tested 
previously by northern blot (Figure 3.1), which further demonstrate the comparability of 
the qRT-PCR technique to northern blots. 
In all experiments, qRT-PCR runs were subjected to melting curve analysis to provide 
data on the specificity of amplification (data not shown). This was compared to the 
apparent size of amplified DNA product by electrophoresis in a 3% agarose/TBE gel, with 
reference to the expected size of amplicon (see Chapter 2.1.2). In all cases, single 127   
amplicons were detected, and strong amplification was dependent on reverse transcriptase 
(RT) presence in cDNA generation (Figure 6.1b). 
Replicate cDNA generation using a combination of poly-d(T) and random hexamer 
primers with Superscript III reverse transcriptase was performed to determine the variation 
inherent in reverse transcription (RT), resulting in slightly greater but acceptable standard 
deviation in relative Rgs4 detection between cDNA from triplicate independent RT 
reactions (Figure 6.2b) when compared to triplicate qPCR experiments on the same cDNA 
template (Figure 6.2a). This indicates that bias is not likely to incorporated by generation 
of only one cDNA sample from each RNA sample, followed by triplicate qPCR reactions, 
provided that biological replicates are also performed. Other qRT-PCR parameters such as 
amount of template, PCR reagents, cycling conditions, trays and thermocyclers were also 
optimised to provide the most sensitive and reproducible data possible. 















































































































Figure 6.2. Quantitative PCR analysis of cDNA generated from three Reverse Transcriptase (RT) 
reactions, using the same RNA templates. SK-N-SH cells were treated with 16 hours of normoxia 
or hypoxia, after which total RNA was extracted. Three identical RT reactions were set up using 
this RNA as template, and qPCR was performed in triplicate on each resulting cDNA sample using 
Rgs4 and Actb primers. (a) Rgs4 levels normalised to Actb for each independent cDNA triplicate, 
where each column represents the relative mean of three qPCR reactions on the same cDNA 
template. Error bars indicate standard error of the mean as determined by qGene. (b) Rgs4 levels 
normalised to Actb, where each column represents the relative mean of three qPCR reactions, each 
using a different cDNA template. Error bars indicate standard error of the mean as determined by 




cDNA template: 129   
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 1.1. Addendum 
The following corrections and additions are made in response to the thesis examiners’ 
comments. 
Page 14: The following paragraph should be inserted at the end of Chapter 1.1.2: 
“Acetylation in particular has been shown to modify the activity and stabilisation of HIF-
1 and HIF-2. In mouse cells, acetylation of HIF-1 between the PAS A and PAS B 
domains by a splice variant of ARD1 promotes association with pVHL and proteasomal 
degradation (Jeong et al., 2002), however the relevance of this effect is questionable as 
similar effects are not observed in human cells (Bilton et al., 2005; Fisher et al., 2005; 
Kim et al., 2006). In human cells, acetylation by PCAF activates HIF-1 (Xenaki et al., 
2008), while deacetylation of HIF-1 by Sirtuin1 or HDAC4 prevents HIF-1 
transactivation of many target genes (Geng et al., 2011; Lim et al., 2010). Conversely, 
deacetylation of HIF-2 by Sirtuin1 in human cells can activate transcription of target 
genes (Dioum et al., 2009), so acetylation modifications provide a possible mechanism 
for the differing functions of HIF-1 and HIF-2.” 
Page 15: In contrast to the first paragraph, HIF-2 has also recently been implicated in 
regulation of Glut-1 in colorectal carcinoma cells (Li et al., 2011). The second sentence of 
the second paragraph should read: 
“The Epo gene (which encodes Erythropoietin) is currently considered to be the best 
characterised in vivo HIF-2 specific target gene, as its expression is disrupted in HIF-2 
knockout kidneys (Scortegagna et al., 2005).” 
Page 19: The following sentence and reference should be added to the end of the first 
paragraph: 
“Stabilisation of the HIF- subunits by hypoxia can also be caused by signalling by 
reactive oxygen species produced by the functioning mitochondria, although the effect of 
hydroxylase inhibition is more pronounced at severe hypoxic or anoxic conditions 
(Schroedl et al., 2002).” 
Page 25: On the seventh line, the word “heterozygous” should be replaced with 
“homozygous”. 
Page 26: The following references should be added to the twelfth line: (Gruber et al., 
2007; Scortegagna et al., 2005; Scortegagna et al., 2003). 
Page 28: On the first line of the second paragraph, the word “oncogenic” should be 
replaced with “tumour supportive”. 
 Page 73: The following sentences should be inserted at the end of the first paragraph: 
“After transfection, tagged control siRNA was observed to be colocalised with cells, 
although some fluorescence was detected on unpopulated regions of the growing surface. 
Cellular fluorescence was concentrated in speckles which appeared in all cells observed, 
so optimisation was undertaken to further decrease levels of fluorescence detected on 
unpopulated growth surfaces, in order to increase cell transfection specificity.” 
Page 76: The following sentences should be inserted after the second sentence of the 
second paragraph: 
“Incomplete knockdown of HIF- protein was observed by western blot, while visual 
detection of fluorescently-labelled control siRNA localised to all cells. As these siRNA 
sequences have been used to silence HIF- messages in other cell types previously 
(Sowter et al., 2003), high knockdown efficiency should be possible if transfection 
efficiency is high. Therefore, despite colocalisation of siRNA complexes to cells, it seems 
likely that some siRNA complexes bind to but do not enter SK-N-BE(2)C cells 
effectively, or are being sequestered within cells.” 
Page 80: The following paragraph should be inserted after the third sentence of the 
second paragraph: 
“It has been noted previously that between in moderate hypoxia the HIF- subunits can 
be differently stabilised and activated (Bracken et al., 2006), by not only the PHD and 
FIH hydroxylase enzymes but also mitochondrial activity (Schroedl et al., 2002). To 
ensure complete activation of both HIF-1 and HIF-2, severe hypoxia of less than 1% 
environmental oxygen was used in treatment.” 
Page 80: The first paragraph should be replaced by the following paragraph: 
“Rgs4 is known to be expressed in the cardiovascular system (Chapter 1.3.6), and both 
RGS4 and RGS5 protein are detectable in Human Umbilical Vein Endothelial Cells 
(HUVECs). Jin et al. (2009) describe experiments showing hypoxic induction of RGS5, 
but not RGS4 protein in HUVECs, so I decided to test the hypoxic response of the Rgs4 
and Rgs5 genes in the same cell type by qRT-PCR (Figure 3.4). Both 3 and 16 hour 
hypoxic treatments were tested to allow direct comparison to the previously published 
data (Jin et al., 2009), and also to the other experiments described earlier in this thesis. 
My results disagree with the data of Jin et al. (2009) for Rgs5, as Figure 3.4 shows no 
positive change in either Rgs4 or Rgs5 mRNA, and actually a modest but statistically 
significant decrease in levels of both after 16 hours of treatment relative to Pol2a, in 
contrast to positive control Vegf. However, the lack of hypoxic induction of RGS4 
described previously by Jin et al. (2009) is supported by my experiments on Rgs4 
message levels in HUVECs. This shows that the response of Rgs4 to hypoxia is not a 
general property of RGS encoding genes, and also that Rgs4 responds to hypoxia only in 
a subset of those cell types which express it at a basal level.” 1.2. Addendum References 
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